• Home
  • About Us
  • Health Insurance Companies

Health Plan News

Timely Health Plan News and Commmentary.

Health Plan News
Home Archives for Medical And Healthcare

Support is Replacing Stigma for Many Orphans This World AIDS Day, Save the Children Says

Posted on November 29, 2010 Written by Annalyn Frame

SOURCE: Save the Children

Video Highlights New Hope for Children Affected by HIV and AIDS as U.S. Efforts to Empower African Community Groups Pay Off

WESTPORT, CT–(Marketwire – November 29, 2010) – African community groups are transforming the future for orphans and other children affected by HIV and AIDS thanks to U.S.-funded programs, Save the Children said.

“The United States is doing much more than providing lifesaving drug treatment when it comes to helping people around the world battle the AIDS crisis and it must continue to do so,” said Charles MacCormack, President and CEO of Save the Children. “One of the most remarkable changes is the creation of African community networks dedicated to supporting orphans and other children affected by HIV and AIDS.”

“It’s amazing how care and support can replace stigma and isolation when local groups are empowered to mobilize around children who have been orphaned and left vulnerable by HIV and AIDS,” MacCormack said.

More than 17 million children have lost one or both parents to AIDS. Many millions more children have reduced opportunities in life because HIV and AIDS have struck their families and communities. Most of these children are in Africa.

The United States President’s Emergency Plan for AIDS Relief (PEPFAR) has funded programs offering care and support to more than 3.6 million orphans and vulnerable children in Africa. Save the Children has led several of these large programs in Mozambique, Uganda, and Ethiopia and has put special emphasis on empowering local community groups to care for affected children. The result is sustainable change for children.

For World AIDS Day (Dec. 1), Save the Children has released a new multimedia video highlighting new hope for orphans and other children affected by AIDS in Ethiopia, where 530,000 children have benefited from U.S.-funded programs. 

“One of the most interesting changes involves Ethiopia neighborhood associations that originally formed to help poor families cover funeral expenses,” MacCormack said. “Today these groups have transformed to offer new hope to the living. They are helping children get an education, enough to eat, a place to live, and, perhaps most importantly, a renewed sense of community and loving support that they had lost to AIDS.”

See the video and learn how you can help support children affected by HIV and AIDS here:
www.savethechildren.org/worldAIDSday2010

Save the Children is the leading, independent organization that creates lasting change for children in need in the United States and 120 countries around the world.

Media Contact:
Tanya Weinberg
Email Contact
1-202-640-6647

Colleen Sutton
Email Contact
1-703-203-7843

Filed Under: Medical And Healthcare

MedLink Announces Successful Completion of $2.25 Million Capital Raise

Posted on November 29, 2010 Written by Annalyn Frame

SOURCE: MedLink International, Inc.

NEW YORK, NY–(Marketwire – November 29, 2010) – MedLink (OTCBB: MLKNA), a leading provider of health information technology solutions, today announced that it has closed an aggregate of $2.25 million in financing. Aegis Capital Corp, sole placement agent and exclusive investment banker to MedLink, placed $1.0 million through a private placement, and an additional $1.25 million in capital through the sale of convertible notes sold exclusively to institutional investors. The investment capital proceeds will be used to fund increased sales and marketing, working capital needs of the Company, and the acquisition of MedAppz which was announced earlier this month.

“We are extremely pleased to have the support of our investors who affirm our corporate vision, and the overwhelming interest in the offering is a testament to the MedLink team and the cutting edge technology we are providing to the healthcare market,” said Ray Vuono, CEO of MedLink International, Inc. “With this financing, the company is well positioned to deliver its suite of Electronic Health Record (EHR) and Healthcare Information Technology communication platforms, to meet the increasing demand of the industry as healthcare facilities of all sizes are adopting EHR technology to take advantage of the efficiencies and the incentives both on a State and Federal level.”

David Bocchi, Director of Investment Banking at Aegis Capital, said, “MedLink represents a rare and exciting opportunity in a competitive and consolidating space where it continues to demonstrate it has the tools and resources necessary to successfully become an industry leader.” He added, “The management team was instrumental in swiftly securing the capital in a placement with overwhelming investor demand, and we look forward to providing the company with the continued support necessary to assist in its growth.”

About MedLink

MedLink is a healthcare IT company providing the medical community with products and services for the creation, management, and sharing of medical information. The company’s flagship product, MedLink TotalOffice EHR 3.1, a CCHIT Certified® 08 Ambulatory EHR, provides physicians with full EHR and practice management functionality. For more information regarding MedLink’s products and services, please visit www.medlinkus.com.

About Aegis

Aegis Capital is a full-service boutique brokerage operation focused on middle-market corporate finance, research, and valuation services. Aegis actively manages over $2 billion of retail customer assets with over 200 registered representatives in 8 corporate locations. Aegis Capital Corporation was founded in 1984 by Robert Eide, the current CEO and Chairman. Its origins were based on servicing the specific needs of an extremely affluent customer base. For more information, please visit the Aegis website at www.aegiscapcorp.com.

Safe Harbor Statement

This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company’s future performance, as well as management’s expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, outlined in our 2009 Annual Report on Form 10-Kavailable through www.sec.gov. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:
Jameson Rose
(631) 342-8800
Email Contact

Filed Under: Medical And Healthcare

Fresh Start Private’s First Facility Operational With Potential Revenue of $120 Million in First Year

Posted on November 29, 2010 Written by Annalyn Frame

SOURCE: Fresh Start Private Management Inc.

Fully Certified Medical Center Located Strategically in Orange County, California

LOS ANGELES, CA–(Marketwire – November 29, 2010) – Fresh Start Private (OTCQX: CEYY) (PINKSHEETS: CEYY), a leader in the alcohol treatment and rehabilitation industry, today announced that its first facility is operational and able to treat up to 15 patients a day with a potential revenue of $120 Million per year per clinic.

According to the National Institute of Health there are an estimated 17.6 million alcoholics in the USA.

Fresh Start Private’s fully licensed and certified medical facility has three treatment rooms that are each able to process up to five patients per day. As part of the treatment, trained medical doctors insert Fresh Start Private’s exclusively licensed specially formulated biodegradable Naltrexone implant just beneath the skin below the patient’s lower abdominal area.

The FDA approved Naltrexone blocks the part of the brain that “feels” pleasure when patients use alcohol. When these areas of the brain are blocked, patients feel less need to drink alcohol, and they can stop drinking more easily. Once medical intervention has reduced the physical need for alcohol, the program goes on to address the patient’s physiological needs. The combination of these treatments results in sobriety in nearly 100% of all patients.

Fresh Start Private is the only alcohol treatment program to offer a single-administration, long-acting, Naltrexone implant procedure.

 “At Fresh Start Private we have created a comprehensive recovery program that includes state-of-the-art medical intervention, individually tailored Fresh Start Private Coaching Program sessions, rebuilding of family and friend connections and post-treatment continuing care,” stated Dr. Jorge Andrade, CEO of the Company. “Only through a comprehensive treatment solution can a patient have his/her best chance at recovery.”

There are many benefits to the Fresh Start Program compared to other traditional alcohol treatments. As the Fresh Start treatment is administered on an outpatient basis, there is no need for patients to leave their work and family for any extended period of time. In fact, many in treatment return to work the next day and not even co-workers or family members know they are being treated. The Fresh Start team has the experience to handle all alcohol addiction scenarios. The Fresh Start Private program can be less expensive than many traditional treatment centers.

About Fresh Start Private

Fresh Start Private is an alcohol addiction, alcohol withdrawal, alcohol abuse treatment and alcohol detox rehabilitation company on the leading edge of the alcohol addiction treatment. The Company has an exclusive license on a highly effective treatment (Naltrexone Implant) that delivers therapeutic levels of Naltrexone that significantly reduces patients’ cravings for alcohol.

Please visit http://www.freshstartprivate.com.

Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “potential,” “up to,” “estimate,” “over,” “intend,” “can be,” “nearly” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Fresh Start filings with the Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to the ability of Fresh Start to manage product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on Fresh Start’s website does not constitute a part of this release.

Contact
Tom Kennedy
Phone: 949.209.8964
Email Contact

Filed Under: Medical And Healthcare

St. Vincent Charity Medical Center Estimates $2.5 Million Savings With Medline Industries, Inc. Prime Vendor Supply Agreement

Posted on November 29, 2010 Written by Annalyn Frame

SOURCE: Medline Industries, Inc.

Medline Brand Products and Reduced Distribution Fees Drive Cost Savings

MUNDELEIN, IL–(Marketwire – November 29, 2010) – Medline Industries, Inc., the nation’s largest privately held manufacturer and distributor of healthcare supplies, announced today the signing of a cost-management prime vendor agreement with Cleveland, Ohio-based St. Vincent Charity Medical Center. The five year agreement is anticipated to save the hospital an estimated $2.5 million over the term of the contract.

St. Vincent’s patient-centered focus on quality has earned them the HealthGrades Distinguished Hospital Award for Clinical Excellence for five consecutive years (2006-2010). In keeping with their focus, the hospital plans to take advantage of the many clinical programs Medline offers including the Pressure Ulcer Prevention Program, the Perioperative Pressure Ulcer Prevention Program and the ERASE CAUTI (catheter-associated urinary tract infection) Program. Each of these evidenced-based programs was designed to help improve quality and safety outcomes, increase patient satisfaction and reduce errors for healthcare facilities.

Under the terms of the contract, Medline is expected to generate more than $10 million in annual medical and surgical product sales from the partnership over the term of the agreement. Under the agreement, Medline will provide its broad array of Medline brand medical and surgical products, including surgical procedure trays, patient care products, disposable protective gowns, exam gloves and bandages.

Cost savings and customer service were two key factors in making Medline St. Vincent Charity Medical Center’s prime vendor. Medline will drive cost savings to St. Vincent through delivering Medline manufactured products direct to the healthcare facility from Medline’s newly built 300,000 square foot, state-of-the-art distribution facility in Canton, OH. Medline will also deliver cost savings by reducing distribution fees on other national brand products and product standardization. In addition, Medline will provide enhanced reporting capabilities and offer comprehensive product utilization, education and practical solutions to help the facility control costs and improve patient care. 

About Saint Vincent Charity Hospital
St. Vincent Charity Medical Center is Cleveland’s faith-based, high-quality healthcare provider, with distinguished doctors and caregivers devoted to treating every patient with clinical excellence and compassionate care. St. Vincent Charity Medical Center is home to the renowned Spine and Orthopedic Institute and the Center for Bariatric Surgery. Owned by the Sisters of Charity Health System, St. Vincent Charity Medical Center delivers health for the heart of Cleveland. The Sisters of Charity Health System is a family of hospitals, grant-making foundations, elder care and outreach organizations devoted to healing individual, families and communities. For more information, visit www.stvincentcharity.com.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

Media Contact:
Jerreau Beaudoin
(847) 643-3011
John Marks
(847) 643-3309

Filed Under: Medical And Healthcare

International Alzheimer’s Researcher and Inventor to Speak at Quietmind Foundation

Posted on November 29, 2010 Written by Annalyn Frame

SOURCE: Quietmind Foundation

Quietmind Foundation: Promoting Research of Drug-Free, Noninvasive Treatments for Brain Disorders and Trauma

PLYMOUTH MEETING, PA–(Marketwire – November 29, 2010) – In advance of the first randomized, placebo-controlled clinical trial in the world of its type for Alzheimer’s disease and other dementias, Quietmind Foundation (QMF), Plymouth Meeting, Pa., is honored to host two presentations by Gordon Dougal, M.D., a National Health Service physician, inventor, and dementia researcher from Durham, U.K. Dr. Dougal will discuss the application of 1072nm infrared light therapy in the treatment of dementia. The presentations will include the pioneering research findings from studies conducted by Dr. Dougal’s colleagues at Durham University on the effects of this type of phototherapy on neuroprotection and beta amyloid plaque deposition and abeta42 oligomer levels.

Professional colleagues, caregivers, and family members of people struggling with neurodegenerative disorders are cordially invited. The free programs will take place on Sunday, December 12, from 4:00 p.m. to 5:30 p.m., and Monday, December 13, from 11:30 a.m. to 1:00 p.m., at the QMF offices, 521 Plymouth Rd., Suite 111, Plymouth Meeting, Pa., 19462. Light refreshments will be served.

Each program will begin with a brief scientific overview by Dr. Dougal directed toward professionals working in research and clinical care of people struggling with dementia. Marvin Berman, Ph.D., QMF’s president, will then discuss the foundation’s previous research in dementia and current clinical work. Following will be a demonstration of the 1072nm infrared light therapy and overview of parameters of the clinical trial to be conducted at the QMF offices.

For a fuller description of the upcoming clinical trial utilizing the 1072nm technology for the treatment of early stage dementia: http://clinicaltrials.gov/ct2/show/NCT01059877?term=1072&rank=3

About Quietmind Foundation

Quietmind Foundation, a 501(c)3 nonprofit founded in 2000, is an international center for cutting-edge research and consultation in the use of brainwave (EEG) biofeedback and related technologies. Its ongoing research agenda — and the nondrug, noninvasive treatments offered through its affiliate, Quietmind Associates — focuses on the spectrum of neurodegenerative disorders, including dementia, Parkinson’s, ALS, and MS as well as traumatic brain injury, PTSD, and learning disabilities. Its goal is to integrate innovative technologies and evidence-based behavioral interventions into governmental, public health, and educational service delivery systems.

QMF’s prior research on Alzheimer’s disease was accepted for presentation at the July 2009 International Conference on Alzheimer’s Disease (ICAD) in Vienna, Austria. This research demonstrated improvements in subjects’ memory, executive function, and psychiatric symptoms, and a reduction in medications.

For further information and reservations for either presentation: 610-940-0488 or [email protected]

Press Contact:

For more information, contact:
Marvin H. Berman, Ph.D., CBT, BCN
Principal, Quietmind Associates
President, Quietmind Foundation
Psychotherapy, Assessment, Neurofeedback, Consultation,
and Applied Clinical Research
521 Plymouth Road, Suite 111
Plymouth Meeting PA 19462
T: 610-940-0488
F: 215-359-0630
E: Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Sami Bittar, MD, Adds CoolSculpting by ZELTIQ(TM) to Patient Services

Posted on November 29, 2010 Written by Annalyn Frame

SOURCE: Dr. Sami Bittar

Trim Fat in Time for the Holidays With Revolutionary, Noninvasive Technique

CHICAGO, IL–(Marketwire – November 29, 2010) – Sami Bittar, M.D., has added a new, noninvasive fat-trimming procedure — known as CoolSculpting by ZELTIQ™ — to the aesthetic services he offers patients.

Recently seen on The Dr. Oz show, the CoolSculpting procedure is completely noninvasive, using no needles and no incisions, to selectively reduce fat bulges. The procedure uses a non-invasive applicator, applied to the skin surface, to deliver a controlled cooling to target areas. After exposure to the cooling, fat cells begin to be gradually eliminated, using the body’s normal metabolic processes. Most patients can read, listen to music or relax during the procedure and return to their normal activities on the same day as the procedure.

Benefits of the CoolSculpting by ZELTIQ™ include:

  • A reduction in fat bulges in about two to four months, with the most dramatic results occurring after two months.
  • A 20 percent reduction in the fat layer.

The CoolSculpting procedure is based on a science called Cryolipolysis™, a groundbreaking discovery by Drs. Dieter Manstein and R. Rox Anderson of Harvard Medical School and the Wellman Center for Photomedicine at Massachusetts General Hospital in Boston that subcutaneous fat cells are more vulnerable to the effects of cold than the surrounding tissue and that fall cells will be reduced after exposure to cold through a process called “induced apoptosis.”

Dr. Bittar works collaboratively with his patients to help create a more aesthetically pleasing physique. His practice currently offers liposuction, abdominoplasty, breast augmentation, reduction and reconstruction as well as face lifts and nose surgery.

More information about CoolSculpting™ by ZELTIQ™ is available at www.coolsculpting.com. Visit http://www.samibittarmd.com or call (708) 354-4667 for more information about Dr. Bittar and the services he provides.

Sami M. Bittar, MD, FACS is a board-certified Plastic and Reconstructive Surgeon with extensive experience in the field of aesthetic and reconstructive plastic surgery of the face, breast, and body. Visit http://www.samibittarmd.com or call (708) 354-4667 for more information.

Contact:
Tammy Petersen
Luxury Marketing Partners International
Phone: (312) 988-4811
E-Mail: Email Contact

Filed Under: Facilities And Providers

Indiana Hand to Shoulder Center Selects the SRS Unified Desktop(TM) for Its 35 Providers Across 6 Locations

Posted on November 29, 2010 Written by Annalyn Frame

SOURCE: SRSsoft

Adopts Integrated SRS Products — EMR, Practice Management, and PACS

MONTVALE, NJ–(Marketwire – November 29, 2010) – SRS, the leading provider of productivity-enhancing technology and services for high-performance specialty practices today announced that Indiana Hand to Shoulder Center has selected the SRS Unified Desktop™ for its 35 providers. Indiana Hand to Shoulder Center has 6 office locations providing specialized upper extremity treatment to the greater Indianapolis area.

“The value of an integrated package far exceeds the sum of the benefits of the individual parts,” says James J. Creighton, Jr., M.D., Indiana Hand to Shoulder Center. “Accessing PACS images directly from the patient’s chart in the EMR — without having to open another application and toggle back and forth — will be a huge time-saver for me.”

“The efficiency and ease of use produced by incorporating three vital core technologies into one product is invaluable,” says Audra Frezza, Chief Information Officer, Indiana Hand to Shoulder Center. “One of the reasons we chose SRS is its reputation for the highest levels of customer satisfaction, as well as its drive to stay at the cutting edge of technology. The success level achieved by SRS in the Orthopaedic arena is unparalleled.”

“The Unified Desktop is unique in the EMR industry,” according to Evan Steele, CEO of SRSsoft. “The open architecture upon which our EMR software is built allows us to deliver all clinical and business applications through one seamless user interface. The Unified Desktop is just one of the many ways that SRS boosts productivity for high-performance practices like Indiana Hand to Shoulder Center.”

About SRS
SRS is the leading provider of productivity-enhancing EMR technology and services for high-performance specialty practices — with a successful adoption rate unparalleled in the industry. Offered via the Unified Desktop™, the robust EMR, SRS CareTracker PM, and SRS PACS increase speed, free physicians’ time, boost revenue, and heighten patient care and satisfaction. For more information on SRS, visit www.srssoft.com, e-mail [email protected], fax 201.802.1301, or call 800.288.8369.

About Indiana Hand to Shoulder Center
Indiana Hand to Shoulder Center began in 1971 as a private hand surgery practice. Since then, it has grown to become a renowned center of excellence, recognized across the world for their specialization in problems and injuries of the hand, wrist, elbow and shoulder. Now located on the northwest side of Indianapolis, Indiana Hand to Shoulder Center is the largest free-standing facility of its kind in the world. For more information, visit www.indianahandtoshoulder.com.

Media Contacts
Jeremy Duca
SRSsoft
800.288.8369
Email Contact

Filed Under: Medical And Healthcare

RadTrac Creates Breakthrough Technology to Track Radiation Dosage, Protect Patients and Healthcare Facilities

Posted on November 29, 2010 Written by Annalyn Frame

SOURCE: RadTrac

OMAHA, NE–(Marketwire – November 29, 2010) – RadTrac, an informatics and biotech solutions firm, has created breakthrough radiation dosage tracking technology that will track and prevent unnecessary radiation exposure for patients and limit liability for hospitals. 

Overexposure to radiation can lead to serious health problems including cancer. There are currently standards set by the American Medical Association for radiation limits but no way exists to track how much cumulative radiation a patient receives. 

Patient radiation levels are tracked and monitored through RadTrac’s proprietary Radiation Dosage Tracking System (RDTS) software engine. Before a patient’s exposure level reaches an unsafe amount, health care providers are alerted and can review diagnostic options before exposing that patient to more radiation, making facilities aware of the potential for overexposure. RDTS allows the physician and medical team to concentrate on practicing medicine and make informed decisions about radiation exposure in real-time.

“The RDTS will not only prevent overexposure and track cumulative exposure, but can also be used as a research tool in the future,” said Gena Kriewald, Co-founder and Vice President of Clinical Development. “The educational benefits that come from creating a national database of radiation exposure on a variety of modalities are immeasurable. By sharing dosage level information across a network of hospitals throughout the nation, facilities can learn not only how to limit exposure but also what modalities are most effective while offering the least amount of radiation.”

“We are currently tracking several facilities with various modalities in regions throughout the United States,” said RadTrac Chief Executive Officer Jesse Fisher. “The RadTrac system takes a proactive approach to preventing radiation exposure by tracking the amount of radiation patients are exposed to — both at the procedure level and cumulatively — and alerting medical professionals before high levels of radiation exposure are reached.”

RadTrac implemented the initial phase of RDTS testing in March of 2010, and completed beta testing in June. The product is now available for release.

About RadTrac: RadTrac is a joint venture of Binovia, Inc., an informatics and biomedical services firm, and Study Overflow Solutions, Inc., (SOS), a teleradiology and practice management firm. RadTrac, a radiology software solutions firm, provides systems and implementation to medical facilities including hospitals, radiology departments and clinics to prevent radiation overexposure and promote x-ray and radiation safety. 

Contact:
Katie Adkisson
615-622-5542
[email protected]

Filed Under: Medical And Healthcare

Service Point Approved Vendor for Graphics and Signs for Healthcare GPO Yankee Alliance

Posted on November 29, 2010 Written by Annalyn Frame

SOURCE: Service Point USA

WOBURN, MA–(Marketwire – November 29, 2010) – Yankee Alliance (www.yankeealliance.com), a Group Purchasing Organization for Healthcare industry member organizations, has approved Service Point USA (www.servicepointusa.com) as a vendor for the provision of Large Format Graphics and Signage.

There are 69 YA member organizations which consist of Hospitals and Medical Centers. These are located primarily in the Northeast region of the U.S. where Service Point USA’s service center locations are concentrated.

In addition, YA has thousands of Affiliate Members throughout the U.S. that include Long Term Care Facilities, Clinics, Rehabilitation Facilities, and other Healthcare related businesses. These are potential users of Service Point’s products and services as well.

Member buyers include multiple professionals from each organization in departments of Marketing and Communications, Public Relations, Purchasing, Training and Education, and Facilities Management groups.

Service Point is unique among YA vendors with its specialization in Large Format Graphics, Signage, and Way Finding Systems. Example applications of these products and services for the Healthcare industry include:

  • Facility Way / Finding signage systems, interior and exterior
  • Educational / Public Relations Displays
  • Environmental Graphics / Murals / Posters
  • Eco-Friendly Display Graphics
  • Information Graphics / HIPAA Communication Posters
  • Clean Room / Laboratory moisture-resistant posters and safety signs
  • Floor Graphics and Way Finding visual aids
  • Event Banners and Flags
  • ADA Compliant Signage
  • Vehicle Graphics, Vinyl Lettering

YA buyers may send orders and graphic files for production electronically via their unique, online Digital Storefront site established by Service Point for the use of YA members only. Service Point’s Digital Storefront product provides authorized users a secure and efficient means to transmit and store files for future access within a custom branded environment.

The Yankee Alliance agreement augments Service Point USA’s continued pursuit of business within the Healthcare industry, one of its focus markets.

About Service Point
Service Point provides tools and services for greater efficiency in document, print, and information management via networked service centers, online, and through On-Site Services programs with client firms nationwide.

Service Point USA is a subsidiary of Service Point Solutions. It employs 2,400 people across 8 countries through a network of 127 service centers and 794 facilities management programs. SPS is headquartered in Spain and listed on the Madrid and Barcelona stock exchanges (ticker: SPS.MC).

Contact:
Christine Miller
Service Point USA
Email Contact

Filed Under: Medical And Healthcare

Healthcare Communications Go Mobile — A Varolii Webinar

Posted on November 29, 2010 Written by Annalyn Frame

SOURCE: Varolii

SEATTLE, WA–(Marketwire – November 29, 2010) – With changing consumer expectations and the increased use of mobile devices, healthcare organizations need to find ways to engage members and patients in new ways. But, if achieving behavioral change was as simple as sending a text message, everyone would be eating a healthy diet, exercising regularly and would never smoke.

In this complimentary Webinar, Dr. George Gellert, senior healthcare advisor for Varolii Corporation, and Elizabeth Boehm, principal analyst at Forrester Research, will share insights into how healthcare consumers’ expectations are changing and how healthcare organizations can use mobile devices to engage members and patients in an effective way.

WHEN: Thursday, December 2, 2:00 – 2:45 p.m. ET / 11:00 – 11:45 a.m. PT

WHAT: A complimentary Webinar discussing why patient communications are critical to changing patient behaviors. Attendees will learn:

  • How patient preferences impact the effectiveness of communications
  • How to improve program adherence with a cross-channel communication strategy
  • Why patient communications will be critical to achieving healthier outcomes

WHO: Dr. George Gellert, MD, senior healthcare advisor for Varolii, is a physician epidemiologist and executive with 20 years of experience in health information and communication. Dr. Gellert is the former Chief Medical Officer and EVP for HCORP Inc. and Senior VP of Strategic Alliances at WebMD. 

Elizabeth Boehm, principal analyst at Forrester Research, joined Forrester in 1997 and became co-founder of Forrester’s healthcare and life sciences practice in 1999. She continues to lead the healthcare and life sciences research community, and her own research focuses heavily on the topic areas relevant to healthcare customer experience.

REGISTER: https://www.varolii.com/en/go/2010/smshcwebinar

Media Contact:
Robin Rees
Varolii Corporation
206.902.3944
Email Contact

Jessica Kendall
Edelman PR for Varolii
206.268.2231
Email Contact

Filed Under: Medical And Healthcare

Imaging3 Set to Implement FDA Resubmission Strategy

Posted on November 29, 2010 Written by Annalyn Frame

SOURCE: Imaging3, Inc.

BURBANK, CA–(Marketwire – November 29, 2010) – Imaging3™, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, today provided insight into the Company’s strategy for resubmission to the FDA.

“After reviewing with our FDA counsel our prior application, files, images and recent FDA correspondence, Imaging3 plans to resubmit its application for clearance of the Dominion Vi Scanner under the FDA’s 510(k) process,” stated Dean Janes, Chairman and CEO of Imaging3, Inc. According to Mr. Janes, “The results of our review with counsel has determined that the 510(k) program remains the most appropriate and efficient route for FDA approval. It was determined that the ‘De Novo’ and ‘PMA’ processes were not necessary and with some minor adjustments to our existing package along with some additional information and potentially a pre-submission meeting with the FDA, the 510(k) submission should be successful. I am confident that with the assistance of our newly hired FDA consultants and our new strategy we will be able to provide the Agency with a package that meets their needs to expeditiously approve our device,” Mr. Janes added.

About Imaging3
Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company’s website at www.imaging3.com

Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.

Contact:
Imaging3, Inc.
Investor Relations
(800) 900-9729

Filed Under: Medical And Healthcare

Midlands Business Expansion Secures Position as Number One Cosmetic Surgery Provider

Posted on November 29, 2010 Written by Annalyn Frame

MANCHESTER, UNITED KINGDOM–(Marketwire – Nov. 29, 2010) – Bromsgrove based cosmetic surgery provider The Hospital Group, has announced the acquisition of Manchester based cosmetic surgery clinic, SurgiCare, after it bought the company out of administration.

The move secures The Hospital Group as the number one cosmetic surgery provider in Europe, with a network of 27 clinics situated across the UK and Ireland plus over 10 in Spain. The Group also expanded into the USA in 2009 with a base in Los Angeles.

Choosing to retain the SurgiCare brand independently, The Hospital Group and SurgiCare will tackle different areas of the market to gain a complimentary business strategy.

The deal has secured the jobs of 37 workers and follows the group’s recent acquisition of NU Age medical Spa in Newcastle Upon Tyne.

David Ross, Chief Executive at The Hospital Group, said: “This business deal shows the company’s commitment to consolidating and building our position in the UK and international market.

“Many people are struggling to find work in this tough economic climate but this partnership has helped to save jobs as well as open doors and create more opportunities.

“We are really excited about the potential that this opportunity has given us. There will doubtless be synergy and development on both sides.”

The Hospital Group are one of the UK’s leading providers of cosmetic surgery, providing cosmetic, dental and weight-loss solutions for thousands of patients every year. 

Since The Hospital Group was established in 1992, it has grown to become one of the world’s foremost cosmetic and weight loss surgery providers.

The flagship hospital, Dolan Park, is the largest specialist facility of its kind in the UK, dedicated to cosmetic and obesity surgery. All surgeons are GMC registered and cosmetic consultations are performed free of charge, with a lifetime free aftercare package included.

Filed Under: Medical And Healthcare

Fovia Showcases Perfect Scalability When Put to Test

Posted on November 28, 2010 Written by Annalyn Frame

SOURCE: Fovia

PALO ALTO, CA–(Marketwire – November 28, 2010) – Fovia, Inc., a leader in volume rendering technology, has demonstrated the scalability of its High Definition Volume Rendering® software on the newest generation of Apple® computers. Fovia’s HDVR® software performed 1.5x faster on a Mac Pro 12-core 2.93GHz than it did on a Mac Pro 8-core 2.93GHz (Apple’s previous generation), thereby showcasing perfect, core-for-core scalability. The benchmarking results can be found on Apple’s website at http://www.apple.com/macpro/performance.html.

Fovia’s HDVR algorithms and architecture take full advantage of the future directions in both imaging and computing (larger datasets, larger projection displays, multi-core processors, multi-threading, multi-CPU environments and server-side rendering for thin-clients) without sacrificing quality or performance. This scalability has been, and will continue to be, critical to ensuring the long-term superiority of Fovia’s solution. 

George Buyanovsky, Fovia’s President and C.T.O., remarked, “The highly-efficient multi-core scalability of HDVR has been a major focus of Fovia’s rendering technology. Our CPU-based Volume Ray Casting algorithms very effectively utilize available CPUs resources; therefore, the evolution of general purpose CPUs toward multi-cores and multi-threading are increasingly beneficial for our clients, and we are pleased that our benchmarking results have been published by such a well-respected third party.”

Fovia’s scalable, software-only solution has unparalleled interactive image quality, superior performance, and better memory utilization than other products currently available — including expensive, hardware-based approaches. In addition to its extraordinary scalability with respect to processor performance, Fovia’s HDVR® engine scales with both the exponentially increasing amount of data being generated by modern scanners, and with the continuing growth of larger and higher definition displays now being used for more accurate viewing.

About Fovia, Inc.

Fovia, Inc. was founded in 2003 to address the challenges of data explosion — the exponentially increasing amount of data being acquired by modern imaging modalities. The firm has developed a CPU-based, High Definition Volume Rendering® software solution that leverages and scales with multi-core, multi-processor and multi-threaded generational processor development. Fovia’s HDVR® solution is more scalable, cost effective, flexible, and easily deployable on an enterprise-wide basis than GPU or other hardware-based approaches and can be easily and natively integrated into various original equipment manufacturers’ offerings, therefore allowing OEMs to quickly and cost-effectively offer the world’s most advanced volume rendering to their customers.

For additional information, visit www.fovia.com.

Apple is a registered trademark of Apple Inc.

Fovia, High Definition Volume Rendering and HDVR are registered trademarks of Fovia Inc.

Contact Information:
Shay Kilby
Voice: 866.3D.FOVIA or 415.290.1717
Fax: 650.618.2797
Email Contact

Filed Under: Medical And Healthcare

TeraRecon Receives 2010 North American Growth Leadership of the Year Award From Frost & Sullivan

Posted on November 28, 2010 Written by Annalyn Frame

SOURCE: TeraRecon

FOSTER CITY, CA–(Marketwire – November 27, 2010) – TeraRecon, Inc. (www.terarecon.com), a global leader in advanced visualization and decision support solutions, has received the North American Growth Leadership of the Year Award in the category of Advanced Visualization and Clinical Applications by the respected independent research firm Frost and Sullivan. This award represents the sixth time in the past 10 years that TeraRecon, Inc. has been recognized with an award from Frost and Sullivan. It is the second time in 2010, following the European Company of the Year Award in the category of Medical Imaging, Advanced Visualization Applications. The full text of the new award can be reviewed on the company’s website at www.terarecon.com/fs2010-2.pdf

The Award is issued contemporaneously with the release of the new Frost and Sullivan market research report on the North American advanced visualization market, and is derived from independent and objective research performed by the Frost and Sullivan team, which was not commissioned or funded by TeraRecon. The research was based on two independent primary research efforts conducted during the last year by Frost & Sullivan researchers, each focused on decision makers for advanced visualization in the United States.

Quoting from the text of the Frost and Sullivan award, “In more than one aspect, TeraRecon has become the leading independent vendor in the North American advanced visualization industry today.” The award noted that TeraRecon is “…capturing a higher market share than all other vendors within its tier of competition” and also recognized the company’s focus on the role and potential of advanced visualization in the healthcare enterprise: “Indeed, TeraRecon’s solutions achieve the highest ratings with regard to their remote access and integration capabilities, making TeraRecon the market leader for delivering advanced visualization enterprise-wide.”

The research also revealed that TeraRecon is perceived as the vendor offering the most advanced technology and the highest performance, that TeraRecon obtained the highest ratings for customer satisfaction, and that the surveyed respondents rated TeraRecon’s solution with the highest ratings for ease of use.

Frost and Sullivan made particular note of iNtuition™ CLOUD, stating “The cloud-based solution launched recently by TeraRecon is yet another illustration of the company’s edge with technology and its ability to react swiftly to emerging industry trends and customer needs.”

Furthermore, the value of the company’s investment in research and development of clinical applications was acknowledged with the observation that “TeraRecon achieved the highest ratings among independent vendors not only from a technology standpoint, but also from a clinical standpoint.”

TeraRecon President & CEO Robert Taylor, Ph.D. commented on the award, “We are truly honored to have received a sixth Frost and Sullivan award — the second within a single year, now recognizing the company’s achievements in the North American market, following up on the recognition we received from Frost and Sullivan earlier in the year relating to our innovative business strategy in Europe. This independent research by Frost and Sullivan objectively proves what we have always strived for relating to our customers’ appreciation of our products’ performance, our customer service, our clinical excellence, and our commitment to enterprise workflow and integration with other informatics systems. The accompanying report also highlights that TeraRecon’s enjoys the highest attachment and integration rate to PACS systems deployed in the North American market, as further evidence of the company’s commitment to a radiologist-centric workflow.”

Dr Taylor continued, “TeraRecon is more committed than ever to innovation and technological and clinical excellence. We are defining new boundaries for advanced visualization every day, as our new iNtuition CLOUD offering gains more and more registered users and the clinical capabilities of iNtuition expands rapidly. We believe that the future of medical imaging will inevitably consist of a combination of on-site software, cloud-based hosting, and meaningful integration with other enterprise healthcare informatics systems, and we embrace this challenge with the greatest enthusiasm and commitment.”

Free evaluation accounts for iNtuition CLOUD can be obtained at terarecon.com/cloud.

About TeraRecon (www.terarecon.com)
TeraRecon is a global leader in advanced image processing, decision support and 3D visualization techniques. The company’s solutions provide advanced imaging support for medical and other visualization applications based on its unique and patented image processing technologies. A six-time winner of Frost and Sullivan awards, the company has developed a leading portfolio of products that advance the performance, quality, functionality, and integration of image processing and 3D visualization systems since its founding in 1997. TeraRecon is a privately held company with headquarters in Foster City, California, USA, European headquarters in Frankfurt, Germany, and branch offices in Concord, Massachusetts, USA and Tokyo, Japan.

About Frost & Sullivan:
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages almost 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com

iNtuition™ is a trademark of TeraRecon, Inc.

Filed Under: Medical And Healthcare

Type 1 Diabetes Mortality Rates Dropping

Posted on November 26, 2010 Written by Annalyn Frame

SOURCE: American Diabetes Association

Concerns Remain for Women, African Americans

ALEXANDRIA, VA–(Marketwire – November 26, 2010) – Mortality rates for people with type 1 diabetes are decreasing, but overall remain seven times higher than those of the general population — likely as a result of long-term complications, a study in the December issue of Diabetes Care reports.

And while there were no significant differences in mortality rates between genders, women with type 1 diabetes were 13 times more likely to die than women who did not have diabetes, reported researchers from the University of Pittsburgh. Also in this study, part of the Epidemiology Research International Study Group, a much higher proportion of African Americans (50.6 percent) died than Caucasians (24 percent).

“It’s unclear why, for both women and African Americans, type 1 diabetes has such a major effect compared to the general population,” said Dr. Trevor Orchard, senior author of the study. “This greater effect of diabetes for women is not seen as strongly in studies in other parts of the world. One thing that is clear is that we need to pay special attention to their care and treatment and continue to investigate why they might be disproportionately impacted by the long-term consequences of this disease.”

Overall, mortality rates for people with type 1 diabetes fell significantly in this community-based population from Allegheny County, PA, over the past several decades, the study found. For those diagnosed between 1965 and 1969, mortality rates were 9.3 times higher than the general population. However, for those most recently diagnosed (1975-1979), the rate was just 5.6 times higher, showing a clear decline.

“It looks like the main improvement in those most recently diagnosed is related to dramatically reducing mortality in the first five years after diagnosis,” said Dr. Aaron Secrest, lead author of the paper. “We think it’s probably a result of better management and awareness of diabetes control, leading to providers and patients doing a better job of monitoring for acute complications.”

Overall, reductions in mortality are most likely due to the tremendous improvements in treatment and care during the 1980s and 1990s, the researchers noted. In particular, blood glucose self-monitoring, A1C testing and use of new blood pressure medications such as angiotensin-converting enzyme inhibitors, which also help protect against diabetic kidney disease. These changes have greatly improved both blood sugar and blood pressure control, often the cause of life-threatening complications.

The study looked at people in Allegheny County the Pittsburgh area who had type 1 diabetes diagnosed as a child between 1965 and 1979 and at the time of analysis had a duration of diabetes between 28 and 43 years, and explored differences in mortality based on sex, race (Caucasian vs. African American) and year of diagnosis.

For more information, please contact Dr. Trevor J. Orchard, University of Pittsburgh, Department of Epidemiology, Graduate School of Public Health, at email: [email protected] or call 412-383-1032.
To contact Dr. Aaron Secrest call 940-597-1991.

Diabetes Care, published by the American Diabetes Association, is the leading peer-reviewed journal of clinical research into one of the nation’s leading causes of death by disease. Diabetes also is a leading cause of heart disease and stroke, as well as the leading cause of adult blindness, kidney failure, and non-traumatic amputations.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

Contact:
Dayle Kern
American Diabetes Association
(703) 549-1500 ext. 2290

id=”nav_links”>

Filed Under: Medical And Healthcare

The BC Medical Journal Now Interactive and Online

Posted on November 26, 2010 Written by Annalyn Frame

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Nov. 26, 2010) – The BC Medical Journal, BC doctors’ flagship medical journal, has completely revitalized its online presence. Beginning today, www.bcmj.org will not only continue with its tight focus on medical stories and advancements that occur in British Columbia, but will be adding the more dynamic qualities that the web is known for. 

BCMJ.org expanded upon its current website, which historically has simply provided the new monthly printed journal in an online method, by also including: 

  • Video content linked to clinical articles in the journal that will incorporate related surgical videos and author interviews
  • Health Notes for doctors and patients that will provide printable tips to improve your health on topics such as dealing with depression, reducing stress, and dementia, as well as reliable patient information related to clinical articles published in the BCMJ.
  • Interactive content such as a blog in which physicians can interact with each other and members of the public and the ability to comment directly on published articles.
  • A “people” section focusing on physician authors in the BCMJ, physicians who go above and beyond the call of duty, and stories about physicians’ own experiences in life.

“With the launch of our new website, the BCMJ takes giant leap forward in the brave new world of electronic communication. As the online home of BC physicians, we strive to keep doctors connected while providing them with fresh and relevant medical content,” says the BCMJ’s editor, Dr. David Richardson. 

The new interactive website is open to physicians in BC – and physicians around the globe – as well as all members of the public.

The British Columbia Medical Journal is a general medical journal featuring primarily scientific research, review articles, and updates on contemporary clinical practices written by British Columbian physicians or focused on topics likely to be of interest to them, such as columns from the BC Centre for Disease Control and ICBC. The print BCMJ is issued ten times each year, while bcmj.org will release stories throughout the month. The journal is peer reviewed and edited by an Editorial Board consisting of physicians from varying disciplines. Although it is published by the BC Medical Association (BCMA), it maintains distance from the BCMA in order to encourage open debate. It also hosts an online database for all BCMJ issues dating back to 2000.

Filed Under: Medical And Healthcare

Fresh Start Private Management, Inc. Appoints Recognized Community Leader Dr. Jorge Andres Jr. as CEO of the Company

Posted on November 26, 2010 Written by Annalyn Frame

SOURCE: Fresh Start Private Management Inc.

LAS VEGAS, NV–(Marketwire – November 26, 2010) – Fresh Start (OTCBB: CEYY) announces it appointed Dr. Jorge Andres as CEO and Director of the company.

Effective November 22, 2010, Michael Cetrone resigned as President and Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and as a member of the Board of Directors of Fresh Start Private Management, Inc. (the “Company”).

Concurrent with Mr. Cetrone’s resignation, Dr. Jorge Adrade, was appointed Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer. Dr. Andrade was already a member of the Board of Directors of the Company.

Dr. Jorge Andrade Jr. is founder, CEO and President of West Coast Consulting Inc. since 2004. Dr. Andrade is a licensed Doctor of Dental Surgery and National Dental Board Certified since 1998. One of Dr. Andrade’s current positions is Senior Program Co-coordinator for the Western Division of Colgate Palmolive “Bright Smiles Bright Futures Dental Program.” Dr. Andrade is a Licensed Medical Interpreter, a licensed Doctor of Dental Surgery since 1995, and co-founder of TM Cube Medical LLC. Dr. Andrade has exceptional knowledge of starting, building and managing small businesses.

Effective November 22, 2010 the Board of Directors appoints Neil Muller as President.

Neil Muller is one of the world’s leaders in alcohol treatment and recovery and the architect of the Fresh Start Private Program. Mr. Muller has treated over 5,000 patients worldwide and will now focus his efforts on directing the clinics in America to cure the 18 million alcoholics across the country.

About Fresh Start Private™

Fresh Start Private is a company on the leading edge for the treatment of alcohol addiction. The Company’s founder has treated over 5,000 patients. Fresh Start is the only alcohol treatment program in the world to offer a single-administration, long acting, Naltrexone implant™. The non-invasive Naltrexone implant is placed just under the skin in the patient’s abdominal area. The procedure takes about 20 minutes and in nearly every instance patients are released the same day.

For more information, visit www.freshstartprivate.com.

Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Fresh Start filings with the Securities and Exchange Commission. 

Jorge Andrade
CEO
1 714 541 6100

Filed Under: Medical And Healthcare

Media Advisory: Hospital Staff to Protest the Attack on Seniors’ Care

Posted on November 25, 2010 Written by Annalyn Frame

TORONTO, ONTARIO–(Marketwire – Nov. 25, 2010) – Across Ontario, care for seniors is being compromised by a spate of hospital bed and program cuts and the transfer of elderly ill patients to sub-standard, unregulated care in retirement homes or to languish alone in their homes.

In Windsor, a 93 year old woman, who has two months to live, has been told to move out of the hospital or pay $600 a day to remain. She is the human face of elderly patients who are demeaned as “bed blockers.”

In Scarborough, Providence Continuing Healthcare is cutting 120 beds a move that will adversely affect many programs including patient rehab, and palliative and chronic care.

In Sudbury, the Regional Hospital’s Memorial site is closing—128 beds will be lost and frail seniors are being moved.

This pattern of hospital service cuts is happening across Ontario and services for the frail and the elderly are the primary target.

Across Ontario, home care is in chaos, with a 57% annual turnover of caregivers and with hours of care more and more difficult to access.

“We believe that the elderly are being discriminated against in the provision of care. Hospital, long- term care and home care workers have had enough of the attack on services for seniors. Our protest today is the beginning of our push back. We are asking for dignity in care for the elderly. We are asking for their right to spend their last days in palliative care in hospital. We demand an end to the pushing of the frail and the ill into unregulated retirement homes or to home alone,” says Michael Hurley, the president of the Ontario Council of Hospital Unions. 

Rally information is as follows:

Rally speakers include:

Paul Moist, President, Canadian Union of Public Employees, Arlene Patterson, Chair of the Sarnia Lambton Health Coalition, and hospital, long-term care and home care workers.

Filed Under: Medical And Healthcare

Stem Cell Institute (Cellmedicine) Successfully Treats Spinal Cord Injury Patient With Adult Stem Cells

Posted on November 25, 2010 Written by Annalyn Frame

SOURCE: Stem Cell Institute

Peer-Reviewed Joint Publication Between Stem Cell Clinic and American Researchers

PANAMA CITY–(Marketwire – November 25, 2010) – The Stem Cell Institute (www.cellmedicine.com) reported today recovery of a spinal cord injury patient that was treated with a unique combination stem cell treatment. The patient suffered a crush fracture of the L1 vertebral body on May 13th, 2008 after a single propeller engine airplane crash. As a result of the spinal cord injury, the patient had severe neuropathic pain, loss of sexual and bladder function, as well as loss of movement and sensation in the legs. 

He was treated on Oct 31-Nov 20, 2008, Jan 21-30, 2009, and July 1-10, 2009 with an adult stem cell protocol. The patient underwent a progressive recovery of sensation, mobility, and sexual and bladder function subsequent to each cycle of stem cell administration. Currently the patient is capable of walking and neuropathic pain diminished substantially.

“The doctors at the Stem Cell Institute have changed my life. After the accident there was no hope. Now I have a new lease on life,” said Juan Carlos Murillo Rodriguez, the patient who was treated. “I have recently passed my physical and am flying again as a commercial pilot.”

Details of the scientific rationale for the treatment, as well as protocols and outcomes may be found in the peer-reviewed paper “Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report” which was published in the International Archives of Medicine and is available online at http://www.intarchmed.com/content/pdf/1755-7682-3-30.pdf.

“It is my honor that such a team of internationally recognized opinion leaders in the area of stem cells such as Doctors Amit Patel, Michael Murphy and Thomas Ichim have co-authored this publication,” said Dr. Jorge Paz Rodriguez, Medical Director of the Stem Cell Institute and co-author of the publication. “By combining our clinical experience with cutting-edge advances in molecular and cellular biology, we believe we have put forth a very innovative protocol that we anticipate will be attempted by other groups.”

About Stem Cell Institute

Stem Cell Institute is one of the leading adult stem cell research and treatment centers in the world. Using our pioneering treatment methods and utilizing partnerships with universities and physicians across the world, Stem Cell Institute has already treated over 800 patients with stem cell therapy and the company continues to expand. Stem Cell Institute is located in Panama City, Panama.

Contact Info

Dr. Jorge Paz Rodriguez
800 980 STEM (7836)
Email Contact
www.cellmedicine.com

id=”nav_links”>

Filed Under: Medical And Healthcare

W. Brett Wilson Investment in Anti-Aging, Cancer-Fighting Products a Natural Step

Posted on November 25, 2010 Written by Annalyn Frame

TORONTO, ONTARIO–(Marketwire – Nov. 25, 2010) – With aging baby boomers making up nearly a third of Canada’s population, the $1.2 billion natural health product industry has naturally caught the eye of well known entrepreneur and strategic investor W. Brett Wilson. Through his involvement with Dragons’ Den, Wilson has committed to a $250,000 investment in NuvoCare Health Science Inc., a company with a portfolio of health brands designed to sustain youth and longevity and prevent disease.

The company was founded by Ryan J. Foley, a food scientist and pharmacologist who has designed a clinically proven composition called AgeOFF® designed to stop the DNA damage that leads to cancer and is the primary culprit behind human aging.

Having battled an advanced state of prostate cancer at 43, Wilson has made personal health his number-one priority, a core philosophy that is shared by NuvoCare. An estimated 173,800 Canadians will be diagnosed with cancer this year with approximately 76,200 of those cases resulting in death.

“This is as much a personal investment as a financial one,” said Wilson, who is also a daily product user. “I know too many people who are fighting cancer, and too many who have fought it and lost. It’s gratifying to support a company focused on reversing this negative trend.”

NuvoCare is also in conversations with the federal government to explore how their products can help reduce the upward pressure on federal-provincial health care spending, expected to grow significantly as more baby-boomers become seniors. On average, seniors consume five times more health-care dollars than younger adults. NuvoCare products help seniors stay healthy, decreasing their consumption of health-care dollars. The first baby-boomers will turn 65 on January 1, 2011.

“Brett has a passion for our work and a brilliant marketing mind able to help us reach more people and keep them healthy,” said Foley who added that NuvoCare is in a strong position to tap into a large percentage of Canada’s natural health product industry over the next three years.

NuvoCare was in established in 2006 by Foley after 10 years of corporate research and development experience in the nutraceutical industry. “I wanted to align myself with my higher life purpose of health sustainability and I built NuvoCare to realize this potential,” says Foley. NuvoCare’s products help to decrease body weight safely, prevent loss of muscle and bone, decrease the appearance of wrinkles and fine lines, and improve sleep quality, to name just a few of their benefits. NuvoCare’s portfolio of health brands includes AgeOFF® (www.AgeOFF.com), SleepON® (www.SleepON.com), WeightOFF® (www.WeightOFF.ca), DNA-Essentials® (www.DNAessentials.ca), and Skin-Minus® (www.SkinMinus.com).

NuvoCare Health Science Inc. is a Canadian owned and operated company whose sole focus is to design and develop the worlds safest and most effective nutraceutical, nutricosmetic, and cosmeceutical brands clinically proven to address the major health concerns of today’s consumer using proven natural ingredients of the highest safety, efficacy and quality standards. www.NuvoCare.com.

W. Brett Wilson is Chairman of Canoe Financial, a privately owned investment management firm with over $1.5 billion in assets focused on providing investors with unique opportunities to profit from Canada’s increasing prominence on the global stage. He is also Chairman of Prairie Merchant Corporation; a private merchant bank focused on business opportunities in the energy, agriculture, real estate, sports, and entertainment industries. In 1993, he co-founded FirstEnergy Capital Corp., a Canadian brokerage firm that provides investment-banking services to Canada’s oil and natural gas sector. FirstEnergy is an industry leader, having participated in thousands of financing and M&A projects worth over $225 billion. After retiring from active duty in 2008, Brett remains an investor in the firm.

Filed Under: Medical And Healthcare

Allied Healthcare International Inc. to Host Fiscal 2010 Fourth Quarter and Year-End Conference Call and Webcast

Posted on November 24, 2010 Written by Annalyn Frame

SOURCE: Allied Healthcare International Inc.

NEW YORK, NY–(Marketwire – November 24, 2010) – Allied Healthcare International Inc. (NASDAQ: AHCI) will host a conference call and webcast to discuss the financial and operating performance for its fiscal 2010 fourth quarter and year ended September 30, 2010 on Tuesday, December 7, 2010, at 10:00 AM Eastern Time / 3:00 PM UK Time. The call will be hosted by Sandy Young, Chief Executive Officer, and Paul Weston, Chief Financial Officer. The Company will issue its earnings press release prior to the call.

Dial-In Information
Allied invites all those interested in listening to management’s discussion of the results to join the call by dialing (877) 407-8031 for domestic participants and (201) 689-8031 for international participants. Participants may also access a live webcast of the conference call through the “Investors” section of Allied Healthcare’s Website: www.alliedhealthcare.com. 

A telephone replay will be available for two weeks following the call by dialing (877) 660-6853 for domestic participants and (201) 612-7415 for international participants. When prompted, please enter account number 286 and conference ID number 360782. A webcast replay will also be available and archived on the Company’s website for ninety days.

ABOUT ALLIED HEALTHCARE INTERNATIONAL INC.
Allied Healthcare International Inc. is a leading provider of flexible healthcare staffing services in the United Kingdom. Allied operates a community-based network of approximately 115 branches with the capacity to provide carers (known as home health aides in the U.S.), nurses, and specialized medical personnel to locations covering approximately 90% of the U.K. population. Allied meets the needs of private patients, community care, nursing and care homes, and hospitals. For more news and information please visit: www.alliedhealthcare.com.

CONTACT
Allied Healthcare International Inc.
Sandy Young
Chief Executive Officer
Paul Weston
Chief Financial Officer
+44 (0) 17 8581 0600

Or

ICR, LLC
Sherry Bertner
Managing Director
+1 646 277 1200
[email protected]

Filed Under: Medical And Healthcare

Vet-Stem Provides Free Lifetime of Stem Cells for Canine War Hero

Posted on November 24, 2010 Written by Annalyn Frame

SOURCE: Vet-Stem

POWAY, CA–(Marketwire – November 24, 2010) – Lex Lee is a canine commemorative Purple Heart recipient who was a Marine Corps bomb-sniffing canine stationed in Fallujah. Lex survived a rocket-propelled grenade blast in March of 2007 that left him severely injured and took the life of his handler, Corporal Dustin J. Lee. 

Since that time, Lex has struggled with several problems related to his injuries including chronic arthritis. Dr. Lee Morgan of the Georgetown Veterinary Hospital teamed up with K9 Soldiers and Jerome and Rachel Lee in order to provide Lex with relief from the pain of his war injuries.

Dr. Morgan elected to use Vet-Stem Cell therapy to treat Lex’s arthritis and to hopefully regenerate damage from injuries sustained while serving in Fallujah. Dr. Morgan collected of a small amount of fat, sent it to Vet-Stem where the fat was processed, then Vet-Stem sent the isolated stem cells for injection two days later.

In honor of the contributions that Lex and the Lee family have made to the safety and freedom of people here and abroad, Vet-Stem will provide a free lifetime supply of Lex’s stem cells for as long as Lex might benefit from them. Approximately half the dogs treated with stem cell therapy will need to be re-treated within two years. Vet-Stem has over 18,000 doses of stem cells stored for thousands of animals and can create more by using stem cell culture technology. 

“We are pleased to be a part of this great effort and to do our small part in providing comfort to Lex and the Lee family and we appreciate Dr. Morgan’s contribution and discounted services,” says Vet-Stem Founder and CEO Robert Harman.

Dr. Morgan noted, “This is one of the most important patients that I have seen in 14 years of practice. I was surprised to see how quickly Lex was responding to the stem cell therapy. His owners and I are excited about the possibility of giving him an improved quality of life.”

About Vet-Stem, Inc.

Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. In January of 2004, Vet-Stem introduced the first veterinary stem cell service in the United States. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. Vet-Stem has exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells.

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

TomoTherapy to Participate in Two Upcoming Investment Conferences

Posted on November 24, 2010 Written by Annalyn Frame

SOURCE: TomoTherapy

Piper Jaffray Healthcare Conference on November 30 and Lazard Capital Markets Med Tech/Life Sciences Tools Day on December 2, 2010

MADISON, WI–(Marketwire – November 24, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that President and CEO Fred Robertson, M.D., will participate in two upcoming investment community conferences.

On Tuesday, November 30, 2010, Dr. Robertson will present at the Piper Jaffray Healthcare Conference at 3:00 p.m. EST. The conference will be held November 30 – December 1 at The New York Palace hotel in New York City, NY. A live Webcast of the presentation will be available on the Investor Relations page of TomoTherapy.com. For those who are unable to listen to the live presentation, an archive of the Webcast will be available on the company’s site for 30 days following the presentation.

On Thursday, December 2, 2010, Dr. Robertson will attend the Lazard Capital Markets Med Tech/Life Sciences Tools Day, where he will be available for interviews throughout the day. The conference is being held at JW Marriott Denver Cherry Creek in Denver, Colo.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

(C)2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

Investor Contact:
Thomas E. Powell
Chief Financial Officer
608.824.2800
Email Contact

Media Contacts:
Kevin O’Malley
Manager, Corporate Communications
608.824.3384
Email Contact

Filed Under: Medical And Healthcare

WEDI and ASC X12 Publish a Revised Companion Guide Template

Posted on November 24, 2010 Written by Annalyn Frame

SOURCE: ASC X12

The Companion Guide Template and Associated Principles Document Will Encourage Consistent Presentation and Content in Proprietary Companion Guides

FALLS CHURCH, VA–(Marketwire – November 24, 2010) – The Workgroup for Electronic Data Interchange (WEDI) and Accredited Standards Committee X12 (ASC X12), today released two documents, “Companion Guide Principles – Guidelines and Conventions for the Development of Proprietary Companion Guides to supplement published ASC X12 Implementation Guides” and the associated “Standard Companion Guide Transaction Information Template.”

The Principles Document clarifies the requirements for creating proprietary Companion Guides based on ASC X12’s published implementation guides. The Companion Guide Template is used to ensure a consistent look and feel with consistent content across the companion documents developed by various entities in the health care industry. 

A third document, the Communication/Connectivity Instructions template, is being finalized, and will be released soon.

Jim Schuping, Executive Vice President/CEO of WEDI, stated: “We are very pleased to have had the opportunity to collaborate with ASC X12 on the development and publication of these important documents. They will serve as a very useful tool and guideline to our respective memberships and the industry.”

“The Companion Guide Principles and Template documents will help several types of health care entities,” said Cathy Sheppard, Chair, ASC X12. “They will help those that create companion guides develop documents with all the needed information quickly and consistently and they will help those that use those companion guides by ensuring information from many sources has the same look and feel and the consistent content.”

You can download both of these free documents at http://store.x12.org/x12ip/cg.htm.

About WEDI
Workgroup for Electronic Data Interchange is a non-profit healthcare association dedicated to promoting the standardization of healthcare data and the implementation of administrative simplification in healthcare. WEDI’s membership includes providers, payers, integrated delivery networks, vendors, consumers, government organizations and standards groups. WEDI helped to secure the passage of the Health Insurance Portability and Accountability Act (HIPAA) in 1996, and was designated as an official Advisor to the Secretary in the legislation, acknowledging its influence and unique position in the healthcare industry. For additional information, visit www.wedi.org.

About ASC X12
ASC X12, chartered by the American National Standards Institute more than 30 years ago, develops and maintains EDI and CICA standards along with XML schemas which drive business processes globally. The diverse membership of ASC X12 includes technologists and business process experts, encompassing health care, insurance, transportation, finance, government, supply chain and other industries. For additional information, visit www.x12.org.

For additional information:
ASC X12
E-mail: Email Contact
phone: (703) 970-4480

Filed Under: Medical And Healthcare

ComplyTrack Poised to Become Key Solution for Risk and Compliance Management Teams in Hospitals Across Ontario as Excellent Care for All Act (ECFAA)…

Posted on November 24, 2010 Written by Annalyn Frame

TORONTO, ONTARIO–(Marketwire – Nov. 24, 2010) – The Excellent Care for All Act (ECFAA) is the Ontario government’s first step in putting patients first by improving the quality and accountability of the province’s health care system. Health care providers and executives will be held directly accountable for patient safety and will have added responsibilities to ensure that the patient is at the centre of the health care system. They will be required to develop quality improvement plans and report to their boards on the progress they are making. To help ensure that this new act is implemented effectively, executive compensation will be linked to performance improvements and satisfaction surveys will be utilized to monitor progress.

According to Toronto Grace Health Centre’s Shirley Atkinson, current Chair of the Canadian Healthcare Risk Management Network, “Compliance with the Excellent Care for All Act is top of mind for all hospital boards, healthcare executives and quality and risk management leaders in Ontario. Electronic tools like ComplyTrack can help hospitals manage quality improvement plans and other requirements stemming from the Act, to reduce errors and improve overall performance.”

ComplyTrack, published by CCH (www.cch.ca), a part of Wolters Kluwer Law & Business, supports a compliance and risk management team’s efforts to standardize and/or eliminate manual and redundant processes, and can help to quantitatively demonstrate a process’ effectiveness to a health care facility’s management and board. Tools like ComplyTrack will be essential to the successful implementation of the quality improvement plans mandated by the ECFAA. 

About ComplyTrack

ComplyTrack is the #1 healthcare compliance and risk management software solution in North America, used by more than 1,000 hospitals. ComplyTrack delivers a comprehensive enterprise risk management software solution for the healthcare industry. It addresses 3 key problems:

  • Which statutes, regulations, rules, best practices, standards and licensure requirements need to be complied with
  • How to assess and quantify compliance with legislation, rules and best practices
  • How to successfully manage and mitigate identified non-compliance and risk

For more information visit www.cch.ca/complytrack

About Wolters Kluwer Law & Business

Wolters Kluwer Law & Business is a leading provider of research products and software solutions in key specialty areas for legal and business professionals, as well as casebooks and study aids for law students. Its major product lines include MediRegs, Aspen Publishers, CCH, Kluwer Law International and Loislaw. Its markets include health care organizations, law firms, law schools, corporate counsel and professionals requiring legal and compliance information.

Wolters Kluwer is a leading global information services and publishing company providing products and services for professionals in the health, tax, accounting, corporate, financial services, legal, and regulatory sectors. Wolters Kluwer had 2008 annual revenues of €3.4 billion, employs approximately 20,000 people worldwide, and maintains operations in over 35 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Visit www.wolterskluwer.com for information about our market positions, customers, brands, and organization.

Filed Under: Medical And Healthcare

MoneyTV with Donald Baillargeon, 11/24

Posted on November 24, 2010 Written by Annalyn Frame

SOURCE: MoneyTV; Global Medical Equipment of America, Inc.; Park Place Energy Corporation; BioMedical Technology Solutions, Inc.

LOS ANGELES, CA–(Marketwire – November 24, 2010) – On Location in Phoenix, medical equipment sales, shale gas in Bulgaria, rendering biomedical waste harmless; this week on MoneyTV with Donald Baillargeon. MoneyTV is the internationally syndicated television program all about money and what makes it happen, (http://www.moneytv.net), featuring informative interviews with company CEOs, providing insights into their operations and outlooks for their futures.

Free information packages from the featured companies can be requested by sending an email to [email protected].

The television program can also be viewed online immediately at www.moneytv.net.

Featured companies on this week’s program include:

Global Medical Equipment of America, Inc. CEO Harold Halman detailed the company’s business model of providing durable medical equipment through retail and wholesale channels.

Park Place Energy Corporation (OTCBB: PKPL) CEO David Johnson and Co-Founder/Consultant George Tsafalas announced the company’s operations in Bulgaria, discussed the shale gas industry and the company outlook going forward.

BioMedical Technology Solutions, Inc. (OTCBB: BMTL) CEO Donald Cox, Jr. demonstrated the company’s technology, which converts hazardous biomedical waste to simple trash.

MoneyTV debuted in 1996 and is broadcast internationally in more than 170 million TV households in over 60 countries.

A complete menu of TV listings is available at the MoneyTV web site, http://www.moneytv.net.

MoneyTV Executive Producer and Anchor Don Baillargeon is also the host of MoneyRap Radio, http://www.moneyrap.com and the television program Health This Week, http://www.healththisweek.com.

MoneyTV television program, Copyright MMX, all rights reserved. MoneyTV does not provide an analysis of companies’ financial positions and is not soliciting to purchase or sell securities of the companies, nor are we offering a recommendation of featured companies or their stocks. Information discussed herein has been provided by the companies and should be verified independently with the companies and a securities analyst. MoneyTV provides companies a 3 to 4 month corporate profile with multiple appearances for a cash fee of $11,500.00 to $17,250.00, does not accept company stock as payment for services, does not hold any positions, options or warrants in featured companies. The information herein is not an endorsement by Donald Baillargeon, the producers, publisher or parent company of MoneyTV.

Contact:
Donald Baillargeon
Executive Producer
MoneyTV
949 388 5267
[email protected]

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

Zimek, Industry Leader in Automatic Infection Control Technology, Unveils Its New Corporate Video

Posted on November 23, 2010 Written by Annalyn Frame

SOURCE: zimek technologies

TAMPA, FL–(Marketwire – November 23, 2010) – Zimek Technologies, the industry leader in infection control and biohazard remediation, released its new corporate video which is available on the Zimek website (http://www.zimek.com/media.asp) or YouTube (http://www.youtube.com/watch?v=bGpOTrsTRQ8).

“Zimek’s new corporate video will allow visitors to gain a meaningful understanding of the ‘Perfect Storm’ of antibiotic-resistant microbes currently afflicting our society on a daily basis, and how Zimek’s technology is a vital part of the solution,” said Kurt Grosman, CEO of Zimek Technologies. “Zimek’s 21st Century infection control technology has the ability to access infectious pathogens wherever free air flows in an enclosed environment. This is achieved with micro-droplets of EPA-registered disinfectants in sizes equivalent to bacteria, viruses, and fungi, thereby effectively killing and reducing the spread of infectious microbes before they infect their victims.”

Zimek’s corporate video also provides expert testimony by Brad Spellberg, MD, the highly-regarded infectious disease specialist, scientist, and researcher at the David Geffen School of Medicine at UCLA and Harbor/UCLA Medical Center in Los Angeles, California and author of “Rising Plague.” Additional footage is included from Zimek Advisory Board Members Hon. Emil Jones, Jr. and James Lee Witt, Florida Governor-Elect Rick Scott, and Zimek customers.

Zimek Technologies, based in Tampa, Florida, has been developing and marketing its patented automatic Micro-Mist® decontamination technology for more than five years. Zimek’s industry-leading technology is used by the U.S. Department of Homeland Security, U.S. Department of Defense, U.S. Department of Veteran Affairs, fire and EMS departments, healthcare facilities, public health agencies, transit systems, correctional facilities, and local law enforcement agencies across America. For more information, please visit www.zimek.com.

Media Contact:
Bob Mazza
Email Contact
(310) 994-4847

Filed Under: Medical And Healthcare

Cain Brothers Advises Caritas Christi Health Care in Sale to Cerberus Capital Management’s Steward Health Care System

Posted on November 23, 2010 Written by Annalyn Frame

SOURCE: Cain Brothers

NEW YORK, NY–(Marketwire – November 23, 2010) –  Cain Brothers & Company served Boston-based Caritas Christi Health Care (CCHC) as financial adviser in the recently completed successful sale to Steward Health Care System LLC (Steward), a newly formed affiliate of private equity firm Cerberus Capital Management, L.P. (Cerberus). Caritas and Cerberus announced that the transaction was completed on November 8, 2010. The system will continue to operate under the Caritas Christi banner and be led by CEO Dr. Ralph de la Torre and the current senior leadership team of CCHC.

The transaction represents the largest conversion of a not-for-profit health system to taxable status in Massachusetts’ history and the largest in the U.S. in many years. The transaction brings to CCHC approximately $895 million of new capital to be utilized for the assumption of pension obligations, repayment of debt, funding for operations, and significant capital projects. The CCHC hospitals will undergo major infrastructure improvements and benefit from significant investments in clinical technology and health care information technology.

Robert J. Fraiman, CEO of Cain Brothers and the leader of Cain Brothers’ transaction team, said, “We were pleased to assist Caritas CEO Ralph de la Torre, the Board of CCHC and the senior management team to complete this exceptional transaction. It is forward-looking in scope, and it will be good for the system and the communities and patients it serves. We are confident that Steward will be at the forefront of the trend towards community-based accountable care organizations (ACOs), which is driven by the health care reform legislation enacted earlier this year combined with the need for more efficient delivery of care to patients.”

Carsten Beith, Managing Director of Cain Brothers and leader of the firm’s tax-exempt merger and acquisition advisory service, said, “Although the Caritas-Cerberus transaction is unusually large, consolidation activity among hospitals and hospital systems is accelerating nationally. We expect to see a dramatic increase in the number of hospital M&A transactions among both not-for-profit and for-profit health care providers. The most significant factors leading to this activity include: capital markets that continue to be challenging, especially for providers that have significant capital improvement needs, as well as health care reform, with its heavy information technology requirements and the need better manage the risks of utilization and outcomes, while providing increased transparency for both patients and regulators.”

Cain Brothers is a leading investment banking firm that focuses exclusively on the health care industry. The firm’s clients include investor-owned and tax-exempt providers, payors, health care information technology and medical technology companies, and financial sponsors. The firm has one of the largest teams of experienced bankers and capital markets professionals on Wall Street dedicated to the health care industry. Operating out of nine offices across the country, the firm creates custom-tailored, market-based capital raising, M&A, real estate, and strategic and financial advisory solutions for its clients. 

Contacts:

Robert J. Fraiman
212-981-6947
Email Contact

Carsten Beith
312-456-0500
Email Contact

Filed Under: Medical And Healthcare

CONMED Corporation to Present at the 22nd Annual Piper Jaffray Health Care Conference

Posted on November 23, 2010 Written by Annalyn Frame

SOURCE: CONMED Corporation

UTICA, NY–(Marketwire – November 23, 2010) – CONMED Corporation (NASDAQ: CNMD), a medical technology company specializing in medical devices for surgical and patient monitoring markets, announced today that the Company will participate in the 22nd Annual Piper Jaffray Health Care Conference, on Wednesday, December 1, 2010 at 11:00 AM Eastern time. The event will be held in New York at the New York Palace Hotel.

Mr. Joseph J. Corasanti, President and Chief Executive Officer of CONMED, will discuss the Company’s business. The live webcast of CONMED’s presentation will be available at www.conmed.com in the Investor Relations – Events Calendar section of the website and will be available for replay through December 10, 2010.

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company’s products serve the clinical areas of sports medicine-arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. Surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology use the Company’s medical devices. Headquartered in Utica, New York, the Company’s 3,300 employees distribute its products worldwide from several manufacturing locations.

Forward Looking Information

Certain statements made in the presentation may constitute forward-looking statements. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. They will be based upon management’s expectations and involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements therein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to: (i) the failure of any one or more of management’s assumptions to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and Quarterly Reports on Form 10-Q; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition (and its integration) or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw material, transportation, or litigation; and/or (viii) the Company’s ability to devise and execute strategies to respond to market conditions.

CONTACT:
CONMED Corporation
Robert Shallish
Chief Financial Officer
315-624-3206

FD
Investors:
Brian Ritchie
212-850-5600

Filed Under: Medical And Healthcare

TomoTherapy and NELCO Partner to Reduce Radiation Therapy Construction Costs

Posted on November 23, 2010 Written by Annalyn Frame

SOURCE: TomoTherapy

Total ShieldTM for TomoTherapy® Cuts Costs, Time Associated With Renovation of Treatment Vaults

MADISON, WI–(Marketwire – November 23, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced availability of a shielding solution that enables hospitals and cancer centers to quickly, easily and inexpensively build out treatment vaults that are properly shielded for use of the TomoTherapy® radiation therapy system. The Total Shield™ by NELCO, the worldwide leader in designing, manufacturing, and installing specialized products and services for the medical, industrial, and construction fields, is a customized shielding enclosure designed to fit around a TomoTherapy unit, making it possible for the radiation therapy system to be placed into existing under-shielded vaults or other treatment rooms where there may not be enough space to install necessary shielding using the existing infrastructure.

Total Shield provides hospitals and cancer centers with the flexibility to put the TomoTherapy system in an existing space, which may be too small or may not include enough shielding for modern intensity-modulated radiation therapy (IMRT) devices. Instead of adding shielding in the walls, the Total Shield enclosure is designed to wrap around the TomoTherapy system itself.

By taking this approach, TomoTherapy customers can potentially save hundreds of thousands of dollars in shielding costs and eliminate the months it takes to install conventional shielding solutions. Total Shield can be installed in just a matter of days. Additionally, because the Total Shield can be easily removed, it can be reused if the TomoTherapy system is eventually moved to a new location.

“Total Shield is the most recent example of how the TomoTherapy system’s unique design, and its small footprint, can allow hospitals and cancer centers to easily adopt cutting-edge cancer care technology in places where other solutions are not feasible,” said Harry Freeman, director of commercial operations at TomoTherapy. “Combined with the TomoTherapy system’s integrated beam stop technology, Total Shield can dramatically reduce the cost of building out a vault with extensive shielding, and enables facilities to get their TomoTherapy system up and running much quicker than other radiation treatment solutions.”

Total Shield was designed collaboratively by NELCO and will be on display in the TomoTherapy booth (#6406) at RSNA 2010, November 28 – December 3, at McCormick Place in Chicago, Illinois.

About NELCO 
NELCO, an ISO 9001:2008 certified company, is an industry leader in the design, manufacturing, and installation of specialized products and services, for the medical, industrial, and construction fields. Such products include shielding for medical radiation therapy, medical diagnostic imaging, anti-corrosive linings, and industrial radiation shielding. With offices around the US, United Arab Emirates, the United Kingdom and China, NELCO always has a facility nearby, cutting shipping costs, and helping excel in customer service. For more information, visit http://www.nelcoworldwide.com, or call 1-781-933-1940.

About TomoTherapy Incorporated 
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions includes its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoHD, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

Investor Contact:
Thomas E. Powell
Chief Financial Officer
608.824.2800
Email Contact

Media Contacts:
Kevin O’Malley
Manager, Corporate Communications
608.824.3384
Email Contact

Susan Lehman
Rockpoint Public Relations
510.832.6006
Email Contact

Filed Under: Medical And Healthcare

Fresh Start Private Management Inc. Enters Intellectual Property License and Asset Purchase Agreement

Posted on November 23, 2010 Written by Annalyn Frame

SOURCE: Fresh Start Private Management Inc.

LOS ANGELES, CA–(Marketwire – November 23, 2010) – Fresh Start Private Management Inc. (OTCBB: CEYY), a leader in the alcohol treatment and rehabilitation industry, today announced that it has entered into an agreement with Fresh Start Private Inc. that was subsequently filed as an 8K with the SEC.

Under the terms of the agreement, Fresh Start Private Management, Inc. (FSPM) has entered into an Intellectual Property License and Asset Purchase Agreement with Fresh Start Private Inc., a private Nevada Company in the alcohol treatment business.

Under the terms of the Agreement FSPM will own all assets and have exclusive rights in the United States of America for Fresh Start Private Inc.’s alcohol treatment program and methodology.

See the 8K filed with the SEC for more information.

About Fresh Start Private
Fresh Start Private is an alcohol addiction, alcohol withdrawal, alcohol abuse treatment and alcohol detox rehabilitation company on the leading edge of addiction treatment. The Company has developed a patented highly effective treatment delivers target therapeutic levels of Naltrexone that significantly reduce patients’ cravings for alcohol. To date, more than 5,000 patients have received the Fresh Start Private Naltrexone implant.

For more information visit www.freshstartprivate.com

The information in this release includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Although the company believes that its expectations are based on reasonable assumptions, actual results may differ materially. These forward-looking statements involve risks and uncertainties that include, among others, market demand for, and/or available supplies of products and services; unanticipated delays, risks related to competition, management of growth, new products, services and technologies, potential fluctuations in operating results, commercial agreements, acquisitions and strategic transactions, government regulation and taxation. More information about factors that potentially could affect the Company’s financial results is included in its filings with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact
Dr. Jorge Andrade
714-514 6100

Filed Under: Medical And Healthcare

Quantum Health Recognized as One of America’s Best Places to Work

Posted on November 23, 2010 Written by Annalyn Frame

SOURCE: Quantum Health, Inc.

COLUMBUS, OH–(Marketwire – November 23, 2010) – The adage “Choose a job you love and you will never have to work a day in your life” may well be true at Quantum Health. The company, after all, was recently recognized both locally and nationally as of one of America’s best places to work by two different publications.

In the 2010 Great Place to Work® Rankings of the Best Small & Medium Workplaces presented by Entrepreneur® magazine, Quantum Health ranked 23rd among the “50 Best” companies nationally. Columbus’s Business First also highlighted the company as a 2010 “Best Places To Work” in its small companies category. Quantum Health is a four-time recipient of this award and earned second place honors in this year’s competition — one spot higher than its third place finish in 2009.

“Quantum Health’s success in delivering value to its clients rests solely on recruiting, hiring and retaining the area’s best employees,” said Kara Trott, CEO. “We’re thrilled to be recognized as a great place to work by our employees and believe that it translates into great service to the people we serve every day.”

The Entrepreneur “50 Best” are selected and ranked by Great Place to Work® Institute, Inc., a workplace research and consulting firm. The determination of the best 50 companies is guided by a methodology that places the greatest weight on their responses to the survey, which accounts for two-thirds of the total score. The remaining one-third of the score comes from the Institute’s evaluation of each company’s culture. Companies are scored in five distinct areas: credibility, respect, fairness, pride and camaraderie.

Columbus Business First’s 2010 “Best Places To Work” honorees were chosen using an independent firm’s proprietary employee survey methodology and software to evaluate nominees. Companies were judged solely upon quantitative measurement of employee input.

ABOUT QUANTUM HEALTH
Quantum Health is an award-winning and fundamentally different healthcare company headquartered in Columbus, Ohio, serving employers nationally.

Quantum Health guarantees its clients a 5-8% reduction in total claims spend. By reorganizing benefits delivery and creating a “virtual medical home” for each member, Quantum Health maximizes each service opportunity to intercept patients when they have a problem to solve or questions about their benefits or healthcare. Real time, informed involvement allows our Care Coordinators to help patients, their families, and their physicians to work together to ensure proper care, eliminating redundant, delayed and questionable care — literally driving unnecessary medical events and cost out of the system. All with a 100% guarantee.

Filed Under: Facilities And Providers

Mi-Co Releases ICD9 Windows Phone 7 Reference Application for Physicians, Nurses and Other Healthcare Professionals

Posted on November 23, 2010 Written by Annalyn Frame

SOURCE: Mi-Co

DURHAM, NC–(Marketwire – November 23, 2010) – Mi-Co announced today the release of a new application for the Windows Phone 7 platform from Microsoft that will allow physicians, nurses and other healthcare professionals to lookup ICD9 codes for various disease conditions on the go. Documentation in healthcare frequently requires lookups of diagnosis codes for various disease states and the entry of those codes on forms for reimbursement, patient processing and more.

With Mi-Co’s ICD9 application, healthcare professionals using Windows Phone 7 devices can have access to the various codes literally anywhere, fitting their mobile workflow. As of this date, this is the only ICD9 reference application on the Windows Phone Marketplace. Chris DiPierro, Director of Software Development for Mi-Co, says “We see various app-based smartphone marketplaces as important in the future, for enterprises as well as consumers. This ICD9 application showcases the versatility of Mi-Co’s ability to design mobility-oriented healthcare software for a variety of different platforms and needs.“

To get Mi-Co’s ICD9 application, search for “ICD9” in the Windows Phone Marketplace.

Learn more about how applying electronic mobility to your data collection processes can streamline and positively impact workflows in your enterprise. Visit us at: www.mi-corporation.com or email us at [email protected].

About Mi-Co

Mi-Co, a leading provider of mobile data collection solutions, provides software to automate paper forms-based business processes. Mi-Co’s enterprise Mi-Forms Software System provides flexible electronic forms design for data capture using digital ink and has proven capabilities for the communication of forms-based data. Mi-Forms support Tablet PCs, Digital Pens, iPads, Pocket PCs, signature capture devices and industry standard software technologies. Mi-Co reaches historically paperwork intensive markets such as healthcare and government and supports an extensive network of channel partners. For more information on Mi-Co, visit www.mi-corporation.com

Media Contact:
Gautham Pandiyan
Email Contact
919-485-4819 x 1973

Click here to see all recent news from this company

Filed Under: Facilities And Providers

OtterBox Increases "Strength" of BlackBerry Torch 9800 Smartphone

Posted on November 23, 2010 Written by Annalyn Frame

SOURCE: OtterBox

FORT COLLINS, CO–(Marketwire – November 23, 2010) – Available for various BlackBerry® smartphones, the pink OtterBox® “Strength” line now offers protection for the BlackBerry® Torch™ 9800 smartphone. These innovative Commuter Series® cases are a stylish way to keep the BlackBerry Torch smartphone pristine while supporting a good cause. OtterBox donates 10 percent of the purchase price from each “Strength” case to the Avon Breast Cancer Crusade to support research to find a cure for breast cancer and programs that provide access to breast health care, regardless of a person’s ability to pay.

“Supporting the Avon Breast Cancer Crusade has been an amazing opportunity for OtterBox and our customers,” said OtterBox founder and CEO Curt Richardson. “We’ve enjoyed the reveal of each new ‘Strength’ case and to date have donated more than $80,000 to the cause.”

The OtterBox Commuter Series case for the BlackBerry Torch smartphone is unlike any other case on the market, providing customized layers for extra protection. First, a white silicone skin fits snuggly around the back with plugs that fit precisely into all ports to prevent damage from dirt and dust. Second, a pink polycarbonate shell snap onto the front and another piece to the back allowing full functionality of the phone’s sliding feature and touch screen. The case also includes a self-adhering screen protector to keep the display scratch free.*

See the complete pink line for all you BlackBerry smartphones, available at www.otterbox.com/strength. 

Additional information for OtterBox Commuter Series for the BlackBerry Torch 9800 smartphone:

Environmental Protection:

  • Added protection against bump and shock

Colors:

  • Silicone: white
  • Polycarbonate: pink

Dimensions (case only):

  • 4.56″ (115.71 mm) x 2.64″ (67.11 mm) x 0.72″ (8.28 mm)

Approximate Weight (case only):

  • 0.80 oz (22.68 g) 

About the Avon Breast Cancer Crusade:

The Avon Foundation for Women’s Avon Breast Cancer Crusade has supported programs in more than 50 countries since its creation in 1992 and to date has raised and awarded more than $640 million worldwide for advancing access to care and finding a cure for breast cancer, with a focus on the medically underserved. Funding supports five areas: awareness and education; screening and diagnosis; access to treatment; support services; and scientific research. For more information or free printable breast cancer information, visit www.avonfoundation.org. For information about participating in the Avon Walk for Breast Cancer events, visit www.avonwalk.org.

About OtterBox:

Built upon fundamentals of hard work, innovation and perseverance, OtterBox is a leader in the production of premier protective solutions for global handheld manufacturers, wireless carriers and distributors.

Incorporating creativity and cutting-edge design into every product, OtterBox creates sleek and durable cases that offer reliable device protection to complement any lifestyle.

OtterBox was founded in 1998 and is headquartered in Fort Collins, Colo.

For more information, visit www.otterbox.com or call 888-695-8820. We’ve Got Technology Covered.

Notes:

*Commuter Series cases NOT protected against water. Will provide some added protection against bump and shock.

The BlackBerry and RIM families of related marks, images and symbols are the exclusive properties and trademarks of Research In Motion Limited.

©2010 Otter Products, LLC. All rights reserved. OtterBox and all OtterBox logos, trademarks and symbols are the property of Otter Products, LLC.

Contact:
Kristin Golliher
(970) 372-6232
[email protected]

Click here to see all recent news from this company

Filed Under: Facilities And Providers

GoHealthInsurance.com Reminder for Flexible Spending Account Users

Posted on November 23, 2010 Written by Annalyn Frame

SOURCE: GoHealthInsurance

GoHealthInsurance.com Is Reminding Users of Flexible Spending Accounts (FSAs) to Use Their Account Funds on Medical Expenses Before They Expire at the End of the Year

CHICAGO, IL–(Marketwire – November 23, 2010) – GoHealthInsurance.com, the online marketplace for health insurance comparison shopping, is offering consumers a friendly reminder and help for how they can use their Flexible Spending Account (FSA) funds before they expire at the end of December.

“It’s getting towards the end of the year and any funds leftover in a Flexible Savings Account will be forfeited for 2011. Consumers should make sure they check their FSA balances and utilize any savings before it’s lost,” said Mark Colwell, Consumer Marketing Analyst at GoHealthInsurance.com.

Have a FSA but don’t know how to use the saved funds before they expire? Here are a few tips:

  • With the flu season right around the corner, one easy way to spend leftover money is to get flu shots and any vaccinations that are not up to date.

  • Schedule physicals, wellness and routine care visits with your family doctor to ensure that everyone in the family gets an annual check-up.

  • Purchase over-the-counter medication that you and your family typically use. Starting in 2011, FSA funds can longer be used on over-the-counter medications without a prescription. Medications that will require a prescription from a doctor include allergy and asthma, cold and flu, pain relief, anti-itch, antacids and acne medication.

  • Next year, consider the benefits of Health Savings Accounts (HSAs) with high-deductible health plans. The funds in HSAs roll over every year and earn interest.

Consumers can compare individual health insurance options, including plans compatible with Health Savings Accounts, at www.gohealthinsurance.com.

About GoHealthInsurance

GoHealthInsurance.com makes buying health insurance simple. GoHealthInsurance explains health coverage options in plain English, provides free health insurance quotes, connects shoppers with local agents, and helps consumers choose plans that meet their health and budget needs — making it the most robust health exchange.

Contact:
Michael Mahoney
GoHealthInsurance
888-250-3409
Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

For Millions With Untreated Hearing Loss, the Holiday Season Can Be Especially Difficult

Posted on November 23, 2010 Written by Annalyn Frame

SOURCE: HearUSA

HearUSA Audiologist Offers Strategies for Dealing With “Invisible Handicap”

WEST PALM BEACH, FL–(Marketwire – November 23, 2010) – For many of the millions of hearing impaired Americans, especially the 27 million living with untreated hearing loss, the holidays may not be all that happy, says audiologist Dr. Cindy Beyer.

Dr. Beyer, senior vice president of HearUSA, Inc. (NYSE Amex: EAR), one of America’s largest hearing care and hearing aids companies, said, “Studies have linked hearing loss to stress, frustration, and social isolation, which can easily be intensified at holiday gatherings with families and friends, when many of those with hearing impairment may find conversations both difficult and isolating.”

“Hearing loss is often labeled ‘the invisible handicap’ because there are no outward signs of a handicap or limitations,” said Dr. Beyer. “As a result, we are unlikely to be aware that accommodations may be necessary to avoid a breakdown in communication.”

Dr. Beyer offers suggestions for making holiday meals and celebrations more comfortable and enjoyable for those with hearing impairment, as well as for the people around them.

  • Speak clearly and distinctly, but not too fast — and never shout.
  • If you are asked to repeat something, do so without raising your voice and appearing annoyed.
  • If your comment or question is still not being understood after repetition, reword it. Some words are easier to understand than others.
  • In a group situation, be sure the hearing-impaired person is included in the conversation. If not, bring them back in.
  • When speaking, look directly at the person and try not to be more than five feet away. 
  • Your facial expressions, gestures and overall body language are important aids in communicating, so try to be sure you have the listener’s attention and that the room is well lit.
  • Conversation is greatly enhanced when there is no distracting background noise from a radio or television.
  • Dining out? Choose a quiet restaurant. Noisy conversations and the clatter of dishes and tableware in a crowded dining area are barriers to effective communication.
  • Ask if there is anything you can do to make communication easier. For example, conversation will be much easier to understand in a room with carpeting and well-upholstered furniture than in a room with tiled floors, high ceilings or wooden furniture.

While almost all hearing loss can be successfully treated with hearing aids, only 25% of the 36 million Americans with hearing loss have hearing aids, according to the Better Hearing Institute. They note that most hearing aids users report significant improvement in their interpersonal relationships and social lives.

“Today’s digital hearing aids are smaller, smarter and more comfortable than ever before,” added Dr. Beyer. “During this holiday season, I can think of no kinder act than encouraging a loved one or a friend with untreated hearing loss to consider the positive impact hearing aids could have on their lives, and help them arrange for an evaluation by a licensed hearing care practitioner.”

About HearUSA
HearUSA, Inc. (NYSE Amex: EAR) is the recognized leader in hearing care for the nation’s top managed care organizations through its network of more than 2,000 hearing care providers and 176 company-owned centers. HearUSA is the nation’s only hearing care network accredited by URAC, an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation. HearUSA is also the administrator of the AARP Hearing Care program, designed to help millions of Americans aged 50+ who have untreated hearing loss. For more information about HearUSA visit www.hearusa.com.

Filed Under: Facilities And Providers

Toronto’s Newest Family Day Out Offers Something for Everyone

Posted on November 23, 2010 Written by Annalyn Frame

TORONTO, ONTARIO–(Marketwire – Nov. 23, 2010) – The ultimate family funfest Funday Sunday arrives on November 28, 2010 to entertain Torontonians of all ages in support of Sunnybrook’s Women & Babies Program and the Canadian Hadassah-WIZO Toronto (CHW), which is dedicated to the health care of women and children in Israel. The event will run from 9 a.m. to 5 p.m. at the Metro Convention Centre, and with family passes priced at only $39, this is one event that Toronto families will not want to miss!

Presented by Dancap Productions, Funday Sunday offers something for everyone:

  • a marketplace with designer goods and deep discounts
  • a Children’s Village with bouncy castles, face painting, games and talented performers 
  • a fun zone with an arcade and a skateboard park for teens
  • an “ask an health expert” booth hosted by Sunnybrook staff

“We are honoured to have the support of this joint partnership between Sunnybrook and the CHW,” says Dr. Andrew Shennan, chief of the Women & Babies Program. “A part of the proceeds from Funday Sunday will help our world-class staff continue to deliver the highest level of care in what is now one of the most advanced maternity wards in North America.”

The new Women & Babies facility at Sunnybrook officially opened its doors to the public in September 2010. This 120, 000 square foot facility, which has received international acclaim for its leading-edge design, will now be able to accommodate up to 4,250 births each year – 500 more births than the previous facility.

“CHW Toronto’s partnership with Sunnybrook allows us to continue the important work of supporting our most vulnerable women and children,” says Sarah Granatowicz, president of the Canadian Hadassah-WIZO Toronto. “CHW has a long and rich history of supporting children, healthcare, and women both here in Toronto and in Israel.” 

For more information about Funday Sunday or to register online, visit fundaysunday.ca or email [email protected].

About CHW

Founded in 1917, Canadian Hadassah-WIZO (CHW) Organization of Canada is a non-political women’s volunteer organization dedicated to the support of education, career training, healthcare, women and youth services in Israel and Canada.

About Sunnybrook Health Sciences Centre’s Women & Babies Program

At Sunnybrook, women and babies get the very best care available, delivered in a family-centred environment. With a focus on high-risk pregnancy and critically premature babies, Sunnybrook accepts more emergency maternal transfers than any other hospital in Ontario.

Filed Under: Facilities And Providers

ECG Management Consultants, Inc. Releases Findings From Its Eleventh Annual Northwest Provider Compensation, Production, and Benefits Surveys

Posted on November 23, 2010 Written by Annalyn Frame

SOURCE: ECG Management Consultants, Inc.

SEATTLE, WA–(Marketwire – November 23, 2010) – ECG Management Consultants, Inc., one of the nation’s premier healthcare management consulting firms, today announced the release of its eleventh annual Northwest Provider Compensation, Production, and Benefits Surveys.

ECG’s Northwest surveys analyze and report information from over 4,200 healthcare providers representing 56 physician specialties and 8 midlevel provider specialties in the states of Washington and Oregon. The surveys contain critical data such as compensation-to-production ratios, including work and total relative value units (RVUs), procedure code distributions, trends in provider recruiting and retention, and specialty-specific benefit and malpractice comparisons. This information, coupled with ECG’s interpretation of market trends, enables survey participants to assess their performance relative to the competitive local market.

General findings in the 2010 surveys based on 2009 data are as follows:

  • Compensation relative to work RVU production increased for Northwest physicians by 6.1 percent as a result of compensation gains of 5.2 percent on declining work RVU production of 1.1 percent.

  • Retirement contributions remained flat at $13,351 per physician, while benefit costs overall fell to 17.9 percent of compensation as a result of increased compensation levels, even though actual costs continue to rise.

  • The top three recruited specialties in the Northwest for the fourth year in a row include family practice without OB, internal medicine, and internal medicine – hospitalists.

  • Health system-employed groups continue to experience significant losses (approximately 23 percent of collections), while independent groups are borrowing funds or accessing reserves equal to 1 percent of collections to cover expenses in excess of revenue.

  • Provider organizations are targeting 191 percent of Medicare reimbursement for their commercial contracts for professional services, up from 178 percent in 2009. In reality, organizations are earning 187 percent for these same contracts.

“ECG’s Northwest surveys, now in their eleventh year, have become the most reliable source for physician performance benchmarks and trends in the Northwest,” said Ms. Maria C. Hayduk, Senior Manager at ECG and head of its Custom Survey and Proprietary Research practice. “Our members value receiving the most up-to-date information regarding regional and national trends in physician performance and compensation methodologies. This information is made even more critical as these areas are impacted by healthcare reform.”

“Continuing economic pressures and healthcare reform have been the story of 2010 for physician organizations in the Northwest,” stated Mr. Kevin M. Kennedy, Principal and leader of ECG’s Healthcare – Northwest practice. “The changing strategic landscape means it is more important than ever for both independent and hospital-affiliated practices to build groups of motivated, aligned physicians. Our surveys are the premier source of information organizations need for recruiting and retaining their key providers to accomplish this objective.”

ECG Survey Methodology
The Provider Compensation, Production, and Benefits Surveys are developed in partnership with local healthcare leaders and ECG’s physician compensation and production experts. These experts go to extraordinary lengths to ensure data quality and validity. Raw survey data is reviewed by ECG’s survey analysts, who identify outliers for verification by the surveys’ participants; if data cannot be validated, it is removed. At the conclusion of this process, ECG converts the raw data into succinct, proprietary information.

About ECG Management Consultants, Inc.
ECG offers a broad range of strategic, financial, operational, and technology-related consulting services to healthcare providers. ECG provides specialized expertise in developing and implementing innovative and customized solutions that effectively address hospital/physician relationships, strategic and business planning, specialty program development, information technology, and the complexities of the academic healthcare enterprise. ECG has offices in Boston, San Diego, Seattle, St. Louis, and Washington, D.C. For more information, visit www.ecgmc.com. 

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Keeping Our Youth and Our Future Healthy: Building Resilience to Substance Abuse and Mental Health Issues

Posted on November 23, 2010 Written by Annalyn Frame

WATERLOO, ONTARIO–(Marketwire – Nov. 23, 2010) – The Waterloo Wellington community is working diligently to ensure that young people who are struggling with addiction and mental health issues are getting the help they need. But treatment is only one part of the equation. When it comes to addiction and mental health issues and youth, an ounce of prevention really is worth a pound of cure.

The Education and Training Working Group of the Waterloo Wellington Addiction and Mental Health Network is turning the focus to prevention by bringing Dr. David Wolfe, a psychologist and author specializing in issues affecting children and youth at the Centre for Addiction and Mental Health (CAMH) Centre for Prevention Science, to Waterloo on November 26th to speak about youth risk and resiliency.

The event being held at Luther Village is at capacity, with over 170 community members registering to attend including City of Waterloo Mayor Brenda Halloran and Kitchener – Waterloo MPP Elizabeth Witmer.

Approximately 26% of Ontario students in grades 7 through 12 used cannabis in the past year, peaking at 46% in grade 12. A quarter of grade 12 students report being drunk or high at school within the past year. These statistics from the Ontario Student Drug Use and Health Survey (2009, CAMH) are just the tip of the iceberg.

Our young people are also experiencing emotional and mental health issues at disturbing rates. More than 30% of students in grades 7 to 12 reported elevated psychological distress. About 10% of students reported they had seriously considered suicide in the past year.

Being resilient is no guarantee that a person will not experience challenges. Resilience means having the ability to face difficulties and move forward from them. Resilient youth tend to be empathetic and adaptable with good communication and problem solving skills. They tend to have future goals and be hopeful about what they can achieve. Young people’s resilience is determined by a number of things including individual characteristics, the characteristics of their families, and the physical and social environments where they live.

Building resilience in our young people is not easy but we can teach them skills that will help them cope with problems they may encounter. By developing these skills and creating supportive relationships, young people are more likely to be protected from life’s challenges, including substance use and mental health problems.

Dr. Wolfe’s presentation will address coping and resilience, review best practices for development of effective substance use and mental health prevention programs, and provide examples of community and school based initiatives that help youth build healthy relationships.

The Education and Training Working Group intends for this event to be a starting point to increase collaboration, coordination, and impact of youth substance use and mental health prevention in Waterloo Wellington.

To register, please contact Paul Radkowski, [email protected].

The Addiction and Mental Health Network is made up of many people with lived experience, families, agencies and committees within Waterloo Wellington who are committed to working together to develop a seamless and integrated system of mental health and addiction services. The Network works in partnership with the Waterloo Wellington Local Health Integration Network to ensure that the Mental Health and Addiction priorities identified in the Integrated Health Services Plan are achieved. For more details about the vision and objectives of the Network, please visit www.wwamh.ca.

Filed Under: Facilities And Providers

Transax International Reports Third Quarter Results

Posted on November 23, 2010 Written by Annalyn Frame

SOURCE: Transax International

PLANTATION, FL–(Marketwire – November 23, 2010) – Transax International Limited (Transax) (PINKSHEETS: TNSX), a network solutions company for healthcare providers and health insurance companies, today reported financial results for the first nine months of 2010 and third quarter ended September 30, 2010.

For the quarter ended September 30, 2010, Transax generated net revenues of $1,211,511 compared to $1,155,060 in net revenues during third quarter of 2009, a 4.9% increase. The increase in revenues is principally due to the continued roll out of new contracts signed during the previous year and organic growth from existing clients. Transaction volume increased to 2.61 million for the third quarter of 2010 with some 66% of transactions being performed by the company’s proprietary Web based solution compared with 50% during the same period in 2009.

Loss from operations in the third quarter of 2010 was $332,240 compared with a $448,694 loss during the same period in 2009 a decrease of 26%. The Company recorded a loss prior to income taxes, for the third quarter of 2010 of $460,823 compared with Income prior to income taxes of $1,781,821 in the third quarter of 2009. The increase in loss was principally due to a reversal from the gain in the fair value of the recording of derivative liabilities.

For the nine months ended September 30, 2010 revenues increased by 2.5% to $3,280,772 from $3,201,083 during the same period in 2009. The increase in revenue is predominantly due to increase in roll out of the additional solutions. The Company recorded a loss from operations of $1,271,420 for the nine months ending September 30, 2010 compared to a $1,009,865 loss from operations during the same period in 2009. The increase in loss is primarily attributed to increases in general and administrative costs and compensation expenses. Net Loss for the first nine months of 2010 was $1,828,306 compared to Net Loss of $1,939,994 during the same period in 2009.

At the end of the third quarter 2010 the Company had 24,833 solutions operational in Brazil including over 3,100 Point of Sales (POS) Solutions. During the nine months ended September 30, 2010 the company installed approximately 7800 Web solutions and disconnected over 100 Interactive Voice Response (IVR) Solutions allowing for greater operational flexibility and increased functionality for the client. The Company undertook 7.1 million real-time transactions during the nine months ending September 30, 2010 compared to 6.3 million transactions during the same period in 2009. The Company has twelve contracts in place in Brazil eleven of which were generating revenues and one under a pilot test environment. At the end of the third quarter 2010 approximately 68% of the Company’s transactions were being undertaken by the Company’s Web solution compared to 52% at the start of 2010.

In announcing the results Stephen Walters, President & CEO, stated, “Since January 2010 revenues have increased approximately 19% in line with the transaction volume which has increased from 2.2 million in the first quarter of 2010 up to 2.6 million transactions for the third quarter 2010. The company continues to seek operating efficiencies to reduce costs and operational losses while undertaking continued development of its product in the Brazil market place.” 

About Transax International Limited

Transax International is an emerging network solutions provider for the healthcare sector. Utilizing its proprietary MedLink™ technology, Transax provides a service similar to credit card processing for the health insurance and providers industries. A transaction consists of: approving eligibility, authorization, auto-adjudication of the health claim and generating the claim payable files — provided instantaneously in “real time” — regardless of method of claim generation.

Transax’s solutions have been proven to significantly decrease health insurance claim expenditures and healthcare provider costs. Based in Plantation, Fl, Transax maintains a major operations office in Rio de Janeiro, Brazil with approximately 40 staff and a Sales Office in Sao Paulo, Brazil. The Company has contracts in place with major health insurers in Brazil and currently undertakes approximately 850,000 transactions per month.

SAFE HARBOR STATEMENT: “THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, THE COMPANY’S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE ‘SAFE HARBOR’ PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.”

Contacts:
Stephen Walters
President & CEO
Tel: 888.317.6984
http://www.transax.com

Filed Under: Facilities And Providers

First Annual Grayson’s Gift Foundation Event Raises Over $150,000 for Pediatric Brain Cancer Research

Posted on November 23, 2010 Written by Annalyn Frame

SOURCE: Grayson’s Gift Foundation

SANTA MONICA, CA–(Marketwire – November 22, 2010) – The first annual Grayson’s Gift Foundation Event, hosted on November 11, 2010, was a huge success, raising more than $150,000. The charity event took place in the ballroom at Hotel Casa del Mar in Santa Monica.

Grayson’s Gift Foundation is a non-profit committed to raising money for the brain cancer research department at the Children’s Hospital of Los Angeles. Money was raised through ticket sales, an extravagant silent auction, and generous donations made by attendees.

The Grayson’s Gift Foundation was founded in 2010 by Leslie and Cliff Katab, whose son Grayson died from a brain tumor just over two years ago. Cliff Ketab said, “We went through many surgeries and chemo and countless days in hospitals, as well as traveling to Europe for experimental treatments. Although we did everything humanly possible, we lost our beloved baby boy two years ago.

“Pediatric brain cancer is the second leading cause of children’s death only behind social causes (car accidents, etc). Being immersed in this world taught us many life lessons. One thing we know is that we must help find a cure for these children. We created Grayson’s Gift Foundation just for this reason. Our charity donates its contributions directly to support research and training for pediatric brain cancer.”

A festive evening, it was a fusion of determined oncologists, compassionate celebrities, friends and family. Thrown into the mix were individual demonstrations of state-of-the-art brain-computer controlled games using NeuroSky technology. The day before the event, NeuroSky donated several games to the pediatric cancer ward at Children’s Hospital Los Angeles. At the event, David Westendorf, Vice President of NeuroSky, talked about how Children’s Hospital LA saved his niece’s life, and then he gave away NeuroSky-powered Mindflex games from Mattel as table prizes.

Celebrity guests included: actor Jonathon Goldsmith, recognized as “The Most Interesting Man in the World” in recent Dos Equis commercials; Corey Feldmen of “The Goonies”; Taylor Armstrong of Bravo’s “Real Housewives of Beverly Hills”; Vienna Girardi who starred in ABC’s “The Bachelor”;” Jennifer Elise Cox, known for her appearance in The Brady Bunch Movie; actress Delphine Chaneac; and actor James Preston of “The Gates.”

Photos: http://www.ballantinesbiz.com/Green_Oct_2010/CHLA/CHLA_GraysonsGift_112210.html

Contact:
Kelley Coughlan
Email Contact
Ballantines PR
LA Office:
Tel: 310 454 3080
Cell: 310 570 9970

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Assisted Living Concepts, Inc. Responds to New Jersey Actions

Posted on November 22, 2010 Written by Annalyn Frame

SOURCE: Assisted Living Concepts, Inc.

MENOMONEE FALLS, WI–(Marketwire – November 22, 2010) – Assisted Living Concepts, Inc. (NYSE: ALC) stated today that it is disappointed with recent actions taken by the New Jersey Department of Health and Human Services and disputes allegations in an order issued by the Department on Friday, November 19, 2010. ALC will pursue appropriate legal remedies for dismissal of the order and related penalties.

“While at certain of our New Jersey buildings we have removed the assisted living licenses and changed our operations over to independent living communities, we are still in the process of registering those buildings with the New Jersey Department of Community Affairs as either multiple dwellings or boarding homes,” stated Laurie Bebo, President and Chief Executive Officer. “This registration process can be lengthy. In the interim, we have demonstrated that seniors living in these retirement communities either receive no health care services or receive services from a variety of home health or personal companion service companies just like many senior living communities in New Jersey. We are not marketing these buildings as assisted living facilities and the staff employed by these communities provides no health care services. We believe the communities will become registered as multiple dwellings or boarding homes under New Jersey’s Department of Community Affairs.

“We are disappointed with the recent actions by the Department of Health and Human Services as they are fully aware of our ongoing participation in the administrative registration process with the Department of Community Affairs. We hope the bureaucratic process will move along more quickly and look forward to an open dialogue with the Department of Community Affairs to accomplish the registrations. We continue to meet the expectations of the tenants who reside with us and believe last Friday’s action by the Department of Health unnecessarily creates disruption for the peace of mind and well being of our tenants and their families.” 

About Us

Assisted Living Concepts, Inc. and its subsidiaries operate 211 senior living residences comprising 9,305 residents in 20 states. ALC’s senior living residences typically consist of 40 to 60 units and offer residents a supportive, home-like setting and assistance with the activities of daily living. ALC employs approximately 4,100 people.

Forward-looking Statements

Statements contained in this release other than statements of historical fact, including statements regarding anticipated financial performance, business strategy and management’s plans and objectives for future operations, including management’s expectations about improving occupancy and private pay mix, are forward-looking statements. Forward-looking statements generally include words such as “expect,” “project,” “point toward,” “intend,” “will,” “indicate,” “anticipate,” “believe,” “estimate,” “plan,” “strategy” or “objective.” Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. In addition to the risks and uncertainties referred to in the release, other risks and uncertainties are contained in ALC’s filings with United States Securities and Exchange Commission and include, but are not limited to, the following: changes in the health care industry in general and the senior housing industry in particular because of governmental and economic influences; changes in general economic conditions, including changes in housing markets, unemployment rates and the availability of credit at reasonable rates; changes in regulations governing the industry and ALC’s compliance with such regulations; changes in government funding levels for health care services; resident care litigation, including exposure for punitive damage claims and increased insurance costs, and other claims asserted against ALC; ALC’s ability to maintain and increase census levels; ALC’s ability to attract and retain qualified personnel; the availability and terms of capital to fund acquisitions and ALC’s capital expenditures; changes in competition; and demographic changes. Given these risks and uncertainties, readers are cautioned not to place undue reliance on ALC’s forward-looking statements. All forward-looking statements contained in this report are necessarily estimates reflecting the best judgment of the party making such statements based upon current information. ALC assumes no obligation to update any forward-looking statement.

Contact:
Assisted Living Concepts, Inc.
262-257-8800

Filed Under: Facilities And Providers

Educational Packaging for Wound and Skin Dressing Improves Nurses’ Accuracy and Confidence: New Study in Journal of Wound Ostomy and Continence…

Posted on November 22, 2010 Written by Annalyn Frame

SOURCE: Medline Industries, Inc.

71% of Nurses Would Change Practice Based on New Packaging With Education

MUNDELEIN, IL–(Marketwire – November 22, 2010) – Educational guides on wound dressing packages can lead to increased patient safety and greater accuracy when applying the product, according to a just-released study in the Journal of Wound Ostomy and Continence Nursing (Journal of WOCN).  Published in the November/December issue of the peer-reviewed Journal of WOCN, the study included 173 clinicians and found that the nurses who used wound care dressings that had educational instructions attached to the outer package were 88 percent more likely to apply the products correctly than nurses who used the dressings in a traditional package.

“The results clearly show that just-in-time education in the form of educational instructions on a dressing package improves nurses’ confidence and accuracy when applying the dressing,” said Dea Kent, MSN, RN, NP-C, CWOCN, the author of the study and the manager of the Wound Ostomy Clinic at Riverview Hospital in Noblesville, Indiana. “The implication for manufacturers of wound dressings is that they should make it hard for the nurse to do the wrong thing by providing clear, easy-to-understand instructions that are accessible on the outside of the package so the nurse can review the process before treating the patient.”

The study used a wound dressing packaging system from Medline Industries, Inc. based on a concept of “just-in-time” education. Instructions for appropriate dressing use are attached to each package. The study was undertaken to assess the effects of this educational resource. The wound dressing used in the study was not familiar to the participants in order to more accurately assess the effect of the educational packaging and self-reported confidence with application.

The participants were randomly divided into two groups: a control group receiving the traditional wound education and an “intervention” group using Medline’s just-in-time educational packaging. None of the 62 nurses in the control group (using the traditional packaging) were able to apply the dressing correctly as compared to 68 of the 77 (88%) in the intervention group.

Similarly, 88% of the nurses in the intervention group reported that the educational packaging gave them confidence that they can correctly apply the dressing. Moreover, 71% in this group said they would change their nursing practice in relation to application of wound dressings based on the education on the package.

“The study findings provide evidence that manufacturers of wound dressings should apply just-in-time education techniques by placing an educational guide on all wound dressing packages in order to enhance the accuracy and safety of application and, ultimately, its efficacy in wound healing,” said Kent in the study’s conclusion.

Kent attributed the application failures by the nurses in the control group to a lack of knowledge about dressing application, since no information was available on the dressing package itself.

The study included nurses from a variety of backgrounds possessing all levels of education ranging from licensed practical nurse to Master of Science in nursing. Both novice and seasoned nurses were included. The study was conducted at eight facilities in central Indiana, including community hospitals, critical access hospitals, long-term care acute units, long-term care facilities and home health agencies.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

Media Contacts:
Jerreau Beaudoin
(847) 643-3011

John Marks
(847) 643-3309

Filed Under: Facilities And Providers

Healthmed Services, Ltd. Enters Into Software Development Contract With Veritas Software Systems

Posted on November 22, 2010 Written by Annalyn Frame

SOURCE: Healthmed Services, Ltd.

SUNNYVALE, CA–(Marketwire – November 22, 2010) – Healthmed Services, Ltd. (PINKSHEETS: HEME) announced that it has entered into a software development agreement with Veritas Software Systems. Veritas will produce for Healthmed 10 exclusive healthcare software suite systems by December 2011. “Healthmed is committed to bridging the information technology gap that plagues doctor, patient, and practice related issues that keep professionals and patients from experiencing the highest level of care and efficiency,” stated CFO Dale Paisley. Healthmed will continue to be committed to expanding its inventory of products to meet every aspect of efficiency and care, in additional to maximizing internal corporate growth and profitability.

Please read more about the Company and its product developments on its website: www.healthmedltd.com.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed with the Securities and Exchange Commission.

Contact:
Financial Highlights
888-572-7934

Filed Under: Facilities And Providers

Midwest Center for Emerging Infectious Diseases Combats Epidemic Outbreaks

Posted on November 22, 2010 Written by Annalyn Frame

SOURCE: University of Cincinnati Foundation

The University of Cincinnati’s Collaborative Research Center Identifies Effective Treatments for Epidemic and Bio-Terrorism Attacks

CINCINNATI, OH–(Marketwire – November 22, 2010) – In the midst of flu season, millions of Americans are rushing to get vaccinated before becoming one of the approximately 200,000 flu victims the Centers for Disease Control (CDC) estimates are hospitalized every year. They aren’t the only ones suffering: according to study findings presented in a 2006 CNN story, the flu and other infectious disease outbreaks cost the nation’s employers about $10 billion a year.

That’s why the University of Cincinnati’s Midwest Center for Emerging Infectious Diseases (MI-CEID) exists. The center serves as a touchstone for advanced medical breakthroughs to provide protection and preparedness for biological events throughout the country — including bioterrorism, biological threats, pandemic outbreaks and even seasonal flu viruses.

“The best way to head off potential public health disasters is to have a targeted means to prevent, quickly diagnose, contain and treat infections. This can only be possible through diligent and comprehensive interdisciplinary research,” said Malak Kotb, Ph.D., chair of the department of molecular genetics, biochemistry and microbiology at the University of Cincinnati College of Medicine, and senior career research scientist at the VA Medical Center.

The MI-CEID is a unique model for collaboration across diversified medical disciplines, including:

  • UC Academic Health Center;
  • Local hospitals including the Cincinnati Children’s Hospital Medical Center;
  • Environmental Protection Agency (EPA);
  • VA Medical Center;
  • Regional health department;
  • Public safety agencies;
  • Community leaders;
  • Professional associations.

“Solutions to disease treatment and prevention require innovation — and you can’t be innovative and be in silos. We achieve the best outcomes by utilizing teams of people who are skilled in their areas of knowledge,” said Kotb. “By doing this, we create something novel and effective. We need to be ahead of the curve, and at UC we have the capabilities and technology to be able to make these strides in healthcare.”

Kotb credits the cross-disciplinary nature of UC’s research facility as key to the center’s early and continued successes. Whereas similar research centers rely on collaborators that may be spread across the country, the MI-CEID brings researchers from each of the organizations above, plus the university’s College of Medicine, under one roof for optimal communication and exchange of ideas and expertise.

To combat potential health threats, the collaborative team uses a state-of-the-art approach to identify and study different types of infectious bacteria, viruses and toxins to improve their detection. The team is also conducting research to identify genetic markers that may predict disease severity in individual patients and inform the most beneficial treatment for each based on genotypes of their DNA. 

“Once we find which genes are engaged in the disease process, we can determine how they are connected through the biological networks that influence disease,” said Kotb. “This allows us to create a roadmap that can predict responses, increase protection, reduce the severity or prevent the illness or disease altogether. This helps save time, money and lives when outbreaks occur.”

Organizations have been quick to realize the potential of the MI-CEID: the National Institutes of Health (NIH), the Department of Defense and Homeland Security, the Defense Threat Reduction Agency (DTRA) and other government agencies have tapped the center for research projects with national implications. In addition, Kotb cites the importance of private support via UC’s billion-dollar Proudly Cincinnati fundraising campaign. The center also relies on corporations that contribute to the research center’s ability to remain operational year-round and expand on its research capabilities.

But while this support can fund specific research initiatives, Kotb says that funding for truly cutting-edge research can sometimes be scarce. Financial support and partnerships are always being sought to further support research and discovery, build a stronger infrastructure, and attract high caliber scientists to effectively fight existing and emerging pathogens. These activities create jobs and boost the economy.

“Private industry is an essential ingredient to successful disease-mitigation and prevention strategies. Without private support to spur on ground-breaking research, essential studies –including those that can predict infection severity in different patients and/or can help suggest the best treatment strategies, and/or predict adverse reactions to certain drugs or vaccines can certainly save lives and reduce medical costs,” Kotb said.

There will always be another pandemic disease or public health scare, but with the UC’s MI-CEID program unique vision and collaborative model the treatments will be more timely and effective. For more information on this innovative program, visit www.uc.edu.

About the University of Cincinnati
 
Ranked by the National Science Foundation among the top 20 public, urban research universities in the United States, the University of Cincinnati is the region’s largest employer, with a diverse student population of more than 39,000. UC’s faculty has distinguished themselves worldwide for their creative teaching and research, including members of the National Academy of Science, Institute of Medicine and winners of Tony, Grammy and Pulitzer Prizes. The University’s 15 Colleges set the foundation for a university dedicated to undergraduate, graduate, and professional education, experience-based learning, and research. U.S. News has described UC as one of 15 “up and coming” universities and Forbes Magazine named UC one of the world’s most beautiful campuses.

About the University of Cincinnati Foundation
The University of Cincinnati Foundation is leading Proudly Cincinnati: Tower of Strength, Rock of Truth, the University’s most ambitious campaign in history, supporting the vision for UC to become the finest urban research university in the United States. Proudly Cincinnati’s goal is to raise $1 billion by 2013. To date, approximately $696 million has been raised for scholarships, innovative teaching and groundbreaking research. For more information about the Proudly Cincinnati campaign, visit www.uc.edu/foundation.

The University of Cincinnati Foundation
University Hall, Suite 100
51 Goodman Drive
Cincinnati, OH 45219
www.ProudlyCincinnati.org
www.Twitter.com/ProudlyCincy
www.Facebook.com/ProudlyCincinnati

Media Contact:
Lauren Boettcher
UC Foundation
(513) 556-7703 desk
(513) 460-5648 cell
Email Contact

id=”nav_links”>

Filed Under: Facilities And Providers

Technology Medical Partners Awarded Qualifying Therapeutic Discovery Grant From Federal Government

Posted on November 22, 2010 Written by Annalyn Frame

SOURCE: Technology Medical Partners

CINCINNATI, OH–(Marketwire – November 22, 2010) – Healthcare information technology solutions and services provider Technology Medical Partners (TMP), today announced that it has been awarded a Qualifying Therapeutic Discovery grant from the Federal government. The $113,000 grant was awarded as part of the Patient Protection and Affordable Care Act of 2010, which was passed by Congress to provide an immediate $1 billion boost to U.S. biomedical research and the small businesses conducting the research. Only companies with less than 250 employees were eligible for the tax credits or grants. TMP’s Clinical Quality Manager (CQM) provides real-time quality of care information allowing real-time actions and improvements to patient outcomes for caregivers.

According to the National Institute of Health’s web site, the Qualifying Therapeutic Discovery tax credit or grants are tax benefits targeted to therapeutic discovery projects that show a reasonable potential to:

  • Result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions
  • Reduce the long-term growth of health care costs in the United States
  • Significantly advance the goal of curing cancer within 30 years

“Our CQM solution was created to help improve quality of care, reduce costs of care and improve income for health care providers, including increasing pay-for-performance, value based purchasing and meaningful use incentives,” stated Dr. Sunil Rao, managing partner at TMP. “This federal grant will help enhance our product development efforts so that we can continue to grow the number of patient-centered medical homes, clinics, hospitals, physicians and nurses that can benefit by having access to our system, delivering the right data at the right time. With better, timelier data, healthcare providers can provide more accurate evidence-based medicine and CMS reporting, which will help improve quality measures, patient outcomes and enhance their eligibility for government funds through pay for performance. As we like to say, quality data improves outcomes.”

TMP’s CQM solution allows healthcare providers to abstract quality of care data from any system; provide real time reports and dashboards to anyone; and support quality analytics and process improvement anywhere; functions that are not adequately provided by most electronic health records (EHR) systems to this level of detail. TMP’s CQM solution is built on the Microsoft SharePoint portal platform and abstracts patient information from disparate departments and systems, including EHR systems. Data is automatically abstracted, captured, populated and formatted into the report forms required by the Centers for Medicaid and Medicare Services. A quality database is maintained to drive all system reports, dashboards, analytics and process alerts.

About Technology Medical Partners
TMP delivers value-added information technology solutions and services to the Healthcare Industry. We focus on the business performance and quality improvement of healthcare providers (Hospitals, Clinics and Physician Practices). We bring a comprehensive array of software solutions, platform products and implementation services together with experience and leadership in Healthcare Solutions delivery. Founded in 2004, Technology Medical Partners is an Independent Software Vendor (ISV) focused on Healthcare Quality Improvement. We build Composite Software Solutions based on several technologies such as SharePoint and other Microsoft products as a Microsoft Certified ISV. We are also a partner with InterSystems and can provide our solutions built on the Cache` or Ensemble platforms. For more information, please visit www.t-m-partners.net. 

Media Contact:
Kevin Wilson
Email Contact
513-898-1008

Click here to see all recent news from this company

Filed Under: Facilities And Providers

BroadcastMed Wins Gold eHealthcare Leadership(R) Award

Posted on November 22, 2010 Written by Annalyn Frame

SOURCE: BroadcastMed, Inc.

ORLive.com Broadcasting Portal Named Best Overall Internet Site

WEST HARTFORD, CT–(Marketwire – November 22, 2010) – BroadcastMed, Inc., an interactive broadcasting company, has been recognized by the 2010 eHealthcare Leadership® Awards for its ORLive.com broadcasting portal, as a top overall internet site. The ORLive.com site was acknowledged along with The Cleveland Clinic and Mt. Sinai Medical Center. “We are extremely grateful and appreciative to be named a leading internet site by our peers in the health community,” said Ross Joel, CEO and Co-founder. Winners were recognized during a special presentation at the Fourteenth Annual Healthcare Internet Conference held November 15-17, 2010 in Las Vegas. 

Nearly 1,300 entries were received from a wide range of healthcare organizations. Factors considered in selecting the best overall internet site included delivery of strong health content, interactivity, medical care support, as well as strength of Web design and ease of navigation. Another Gold Award was bestowed on the Virtual Brain Tumor Board (MethodistHealth.or-live.com/vbtb) which BroadcastMed has developed for the Methodist University Hospital Neuroscience Institute. The Award was presented in the category of Best Health/Healthcare Content. Additionally, BroadcastMed’s work for CMEducation Resources was also cited with 12 additional awards. “Our commitment to provide comprehensive online solutions to a global audience makes this honor a huge motivator in continuing to educate our audiences with relevant content,” added Peter Gailey, President and Co-founder.

The eHealthcare Leadership Awards program exclusively recognizes the very best Web sites of healthcare organizations, online health companies, pharmaceutical/medical equipment firms, suppliers, and business improvement initiatives. The awards highlight the Internet’s role in achieving an organization’s business objectives and recognize the hard work that has gone into creating outstanding health Web sites. A total of 123 individuals familiar with healthcare and the Internet evaluated entries. Web sites were rated based on a standard of Internet excellence and how they compare with others in their group classification. For a list of winners, see: www.strategichealthcare.com/awards/winners.php. 

About BroadcastMed, Inc.

Since 1994, BroadcastMed has been providing online video solutions to hospitals, device manufacturers, and other health-related organizations. Our audience has access to thousands of hours of surgical broadcasts through our ORLive.com portal along with medical programs in other clinical disciplines, many of which include continuing medical education (CME) credit. 

Contact:

Todd Leddy
Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Advancing Diabetes Therapies, Integrium Clinical Research Finds the Sweet Spot

Posted on November 22, 2010 Written by Annalyn Frame

SOURCE: Integrium

TUSTIN, CA–(Marketwire – November 22, 2010) – November is American Diabetes Month and Integrium LLC, a Contract Research Organization (CRO) with a therapeutic focus on cardiovascular and metabolic diseases, is at the forefront of clinical research to improve diabetes treatment. Eileen McAuley, Chief Operating Officer of Integrium, explains that the company has conducted 18 clinical trials of interventions for diabetes at 557 study sites. In addition to trials targeting diabetes, Integrium has conducted more than 100 cardiovascular and renal disease trials, which have an impact on diabetes care since diabetes is a leading cause of kidney failure and more than two-thirds of people with diabetes die of heart disease or stroke.

Integrium’s dedicated team of clinical researchers specializing in diabetes has pioneered therapies to improve the quality of life for people living with diabetes. Integrium’s Director of Project Management and Field Operations, Liza Moore, heads up a team with special expertise in wound healing. She explains that diabetic foot ulcers are among the most serious complications of the disease and untreated, often result in infection and amputation. “Our experience encompasses not only drugs to help manage blood glucose, but also medical devices such as bioengineered tissue products to speed wound healing. We are interested in preventing complications and effective treatment for those that can not be prevented.”

Integrium founder Dr. David H. G. Smith observes that the diabetes epidemic is not limited to the U.S. “One of our recent diabetes trials followed subjects in India, which has the largest diabetes population in the world, as well as subjects in the United States.” With its global reach, Integrium has completed trials in North America, Central and South America, the European Union and Asia for 12 of the top 20 biopharmaceutical companies.

About Diabetes
The United States is in the throes of a diabetes epidemic. An estimated 24 million children and adults have diabetes. Another 57 million others have pre-diabetes, elevated blood glucose levels that increase their risk of developing diabetes, heart disease and stroke.

One in ten American adults has diabetes and the Centers for Disease Control and Prevention (CDC) say that number could triple in the coming decades. The disease is the seventh leading cause of death in the U.S. and it is likely to be underreported as a cause of death.

Diabetes is a leading cause of kidney failure, blindness, amputations and pregnancy complications. Tighter blood glucose control reduces the symptoms and life-threatening complications of diabetes.

About Integrium, LLC
Integrium is a full-service clinical research organization (CRO) designing, conducting, and analyzing clinical trials for pharmaceutical research in dermatology, cardiovascular and metabolic disorders. It is committed to focused, specialized and long-term personalized service to its partners. It has a strong reputation for delivering high-quality management of clinical development programs. Combining the Integrium Clinical Excellence (ICE) study start-up and management methodology and therapeutic expertise leads sponsors to more confident, better-informed drug and device development decisions. For more information please visit www.integrium.com.

For More Information, Contact:
Juli Greenwood
CHEN PR, Inc.
781-672-3137
Email Contact

Filed Under: Facilities And Providers

The Residence on Greenbelt Hosts Open House and Holiday Shoppe Wednesday, December 15, 2010 From 11:00 am – 7:00 pm

Posted on November 22, 2010 Written by Annalyn Frame

SOURCE: The Residence on Greenbelt

LANHAM, MD–(Marketwire – November 22, 2010) – The Residence on Greenbelt (www.theresidenceongreenbelt.com) will be filled with the holiday spirit when it opens its doors for the 1st Annual Open House and Holiday Shoppe scheduled for Wednesday, December 15, 2010 from 11:00 am – 7:00 pm. The event will feature a variety of quality vendors including handcrafted items, jewelry, food products and more. A bake sale with delicious treats made by the residents will add to the festivities and enjoyment of the event. Hot apple cider, coffee and cookies for all who attend.

Event:
Open House and Holiday Shoppe

Date:
Wednesday, December 15, 2010

Location:
The Residence on Greenbelt
9885 Greenbelt Road, Lanham, MD 20706

Time:
11:00 am – 7:00 pm

Cost:
Free and open to the public

Activities:
More than a dozen vendor booths, bake sale, free treats and property tours

More Info:
Visit www.theresidenceongreenbelt.com or call (301) 486-1590

In conjunction with the Holiday Shoppe, The Residence on Greenbelt is hosting an Open House with guided tours of the property to learn more about living in a modern assisted living community. See first-hand how the community offers charm, extensive care and superior care, while allowing residents to experience its modern set of amenities including a Skype lounge and stately movie theatre equipped for the hearing impaired. Conveniently located on Greenbelt Road, The Residence on Greenbelt has recently undergone a complete renovation that has created a vibrant and interesting senior living residence, where residents can experience unrivaled service in modern and fun surroundings.

Four different service programs exist at The Residence on Greenbelt, providing the right match for the needs of seniors. In addition to Independent and Assisted Living, the community offers a Special Needs living area that provides for residents with higher acuity and mobility needs in an environment with features focused on maximizing independence while offering comfort and service. The Residence on Greenbelt also provides a unique memory care program through the Pathways Memory Care Program, an exceptional option for seniors with memory impairments as it offers a stimulating and engaging environment for residents created by each resident’s individual life story and peace of mind for their families and friends.

For more information about the Open House and Holiday Shoppe please visit www.theresidenceongreenbelt.com or call (301) 486-1590 or follow us on Facebook. For information about move-in opportunities or to set-up a private tour, please contact Patty Bay, Director of Sales and Marketing, at (866) 712-1172. The Residence on Greenbelt is located at 9885 Greenbelt Road, Lanham, MD 20706.

About IntegraCare:

IntegraCare’s mission is to “improve the quality of life for its employees, residents, and their families.” The company’s goal is to create an environment where its primary customer, the employee, experiences respect, dignity, and personal development. By providing this environment for its employees, the second half of our mission, “improve the quality life for our residents and their families,” will be achieved.

Media Contact:
Stephanie Orton Lynch
Delucchi+
Phone: 202.248.5855
E-mail: [email protected]

Click here to see all recent news from this company

Filed Under: Facilities And Providers

DiaMedica Accelerates Warrant Expiry Date

Posted on November 22, 2010 Written by Annalyn Frame

WINNIPEG, MANITOBA–(Marketwire – Nov. 22, 2010) – DiaMedica (TSX VENTURE:DMA) today announces that in accordance with the terms of the warrant indenture for those warrants issued on June 30, 2010 the Company has provided the required written notice to holders of such warrants that the expiry date has been accelerated to the close of business December 22, 2010.

Under the terms of the indenture and the broker warrant certificates, if the 10-day volume weighted average trading price of the common shares of DiaMedica on the TSX Venture Exchange exceeds $0.75, then at any date subsequent to this date, the expiry date of the warrant shall be the day that is 30 days following the later of (i) the date that written notice of the accelerated expiry is sent to warrantholders; and (ii) the date on which the announcement of the warrant expiry acceleration is made by news release. As of the close of business on November 19, 2010, the 10-day volume-weighted average trading price of the common shares exceeded $0.75. Warrants may be exercised through payment of the exercise amount of $0.50 per full warrant up to the close of business on December 22, 2010. If all of the 6,215,000 outstanding warrants subject to this acceleration are exercised, DiaMedica will receive additional proceeds of $2.8 million. Any warrants not exercised prior to the accelerated expiry date and time will expire without any further action being taken.

About DiaMedica

DiaMedica is a biopharmaceutical company focused on developing novel treatments for type I diabetes, type 2 diabetes and other disorders. DiaMedica has completed two successful proof-of-concept II studies with DM-71 and DM-99, which demonstrate human efficacy in lowering blood glucose levels in patients with type 2 diabetes.

DiaMedica’s lead product DM-199 is a novel next generation recombinant form of DM-99, which has shown the potential to increase insulin sensitivity, reduce the autoimmune attack and trigger proliferation of pancreatic beta cells, neural stem cells and bone marrow cells. DiaMedica is listed on the TSX Venture Exchange under the trading symbol “DMA”. For further information please visit www.diamedica.com.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the “forward-looking statements“). These forward-looking statements relate to, among other things, DiaMedica’s objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Specifically, this press release contains forward-looking statements regarding matters such as, but not limited to, the anticipated use of proceeds from the Offering, management’s assessment of DiaMedica’s future plans, information with respect to the advancement of DiaMedica’s research and development programs, and DiaMedica’s other estimates and expectations. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to our research and development programs, the availability of additional financing, risks and uncertainties relating to the anticipated use of proceeds, changes in debt and equity markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, the cost and supply of raw materials, management of growth, effects of insurers’ willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters.
Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading “Risk Factors” contained in DiaMedica’s 2009 annual information form. DiaMedica cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on DiaMedica’s forward-looking statements to make decisions with respect to DiaMedica, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions, which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of additional financing for research and development companies, and general business and economic conditions. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, DiaMedica cannot provide assurance that actual results will be consistent with these forward-looking statements. DiaMedica undertakes no obligation to update or revise any forward-looking statement. Additional risk factors, factors which could cause actual results to differ materially from expectations, and assumptions relating specifically to our acquisition of Sanomune may be found in our press releases dated February 18, 2010 and April 20, 2010.

Filed Under: Facilities And Providers

BRIC Countries Present Patient Recruitment and Retention Advantages for Clinical Trials

Posted on November 22, 2010 Written by Annalyn Frame

SOURCE: Cutting Edge Information

Patient Availability Is a Key Driving Force for Companies Conducting Clinical Studies in Emerging Markets, Finds Cutting Edge Information

RESEARCH TRIANGLE PARK, NC–(Marketwire – November 22, 2010) – The population of Brazil, Russia, India and China, roughly three billion people, coupled with these countries’ growing emphasis on strong physician-patient relationships, makes Emerging Markets a hotbed of clinical research activity, according to a new study. 

Emerging Markets Clinical Development Series: Brazil, Russia, India and China (BRIC) provides in-depth analysis on each of these countries’ benefits, advantages and challenges. The study is the latest in a series of studies from Cutting Edge Information about managing clinical trials in Emerging Markets. According to the research, patient availability is one of the top reasons driving drug companies to look to Emerging Markets for clinical trial management.

“Overall, the benefits outweigh the challenges of entering these markets,” said Jason Richardson, president of Cutting Edge Information. “Patients’ respect for their physicians’ recommendations in these markets provides clinical teams with a better chance to finish clinical testing with complete data and on time.”

A scientific advantage of the new clinical model is that much of the patient population is treatment naive, meaning that they have not already used other treatments that could change clinical results. These treatment-naive patients provide clearer effectiveness results when testing new medications. 

Emerging Markets Clinical Development Series: BRIC (http://www.cuttingedgeinfo.com/bric-clinical-trials/) provides quantitative analysis of patient availability and retention within the BRIC countries.

“For example, clinical development executives ranked India as the emerging market with the greatest patient availability, followed closely by China,” said Shaylyn Pike, senior research analyst at Cutting Edge Information. “With regard to patient retention, China, with the largest population of any country, took the top spot, followed by India.”

The new research study analyzes the potential of the BRIC markets to fulfill clinical protocols and ultimately realize significant cost and time savings. It is designed to provide clinical development teams with best practices, strategies and metrics to develop the strongest possible Emerging Markets strategies:

  • Eliminate stakeholder confusion about BRIC strategy
  • Master trial management in Emerging Markets
  • Clarify advantages and disadvantages to boost success rates

For more information, contact
Eric Bolesh
+1 919-403-6583

For media inquiries, please contact
Stephanie Swanson
+1 919-403-6583
Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

American College of Radiology Chooses Prometric to Launch Computerized Diagnostic Radiology In-Training Exam

Posted on November 22, 2010 Written by Annalyn Frame

SOURCE: Prometric

BALTIMORE, MD–(Marketwire – November 22, 2010) – Prometric, the leading provider of testing and assessment services, today announced that it has signed an exclusive long term contract with the American College of Radiology to convert its paper and pencil Diagnostic Radiology In-Training exam (DXIT™) to computer based format for the first time in the exam’s history. Prometric will also manage the final paper based administration for the College, which will occur in February 2011.

Beginning in 2012, physicians in residency training programs served by the American College of Radiology will be able to take the Diagnostic Radiology In-Training exam on a computer at any of Prometric’s hundreds of secure test centers across North America. The computerized test will also be available at select non-U.S. locations. In addition to the increased exam accessibility, computerized delivery will enable candidates to use convenient online registration and their residency programs will receive their scores much more quickly than with the paper based version.

“As a leading test services provider our goal is to work with each client to design a test program that matches their unique needs and requirements,” said Bill Murtagh, senior vice president, sales and client services at Prometric. “The logistical details surrounding paper based exams, such as exam publishing, printing, shipping, scanning, scoring or security, are more manually laborious, and can add time to the overall test process. It also requires a longer turnaround to produce scores, which the residency programs are obviously anxious to get. Offering the test in a modern computerized format will create efficiencies throughout the entire test lifecycle, speeding up the entire process and making it more manageable for the College.”

“Historically, the paper and pencil version of the Diagnostic Radiology In-Training Exam has been offered to candidates once per year,” said Ronald Freedman, assistant executive director, education, marketing, and business development at the American College of Radiology. “Computerizing the test allows us to better leverage technology to enhance security, widen the window of time during which it is available, facilitate easy access for our residents and get the residency programs their scores more quickly.”

About Prometric

Prometric, a wholly-owned subsidiary of ETS, is the recognized global leader in technology-enabled testing and assessment services. Its comprehensive suite of services, including test development, test delivery and data management capabilities, allows clients to develop and launch global testing programs as well as accurately measure program results and data. Prometric reliably delivers and administers more than nine million tests a year on behalf of approximately 400 clients in the academic, professional, healthcare, government, corporate and information technology markets. It delivers tests flexibly via the Web or by utilizing a robust network of more than 10,000 test centers in 163 countries. For more information, please visit www.prometric.com.

About the American College of Radiology

The 34,000 members of the American College of Radiology include radiologists, radiation oncologists, medical physicists, interventional radiologists and nuclear medicine physicians. For over three quarters of a century, the ACR has devoted its resources to making imaging safe, effective and accessible to those who need it.

The mission of the ACR is to serve patients and society by maximizing the value of radiology, radiation oncology, interventional radiology, nuclear medicine and medical physics by advancing the science of radiology, improving the quality of patient care, positively influencing the socio-economics of the practice of radiology, providing continuing education for radiology and allied health professions and conducting research for the future of radiology.

Media Contact:
Jodi Katz
Public Relations Manager
Prometric
+ 1 443.455.6811
Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Healthmed Services, Ltd. Announces the Launch of HealthTrac

Posted on November 22, 2010 Written by Annalyn Frame

SOURCE: Healthmed Services, Ltd.

SUNNYVALE, CA–(Marketwire – November 22, 2010) – Healthmed Services, Ltd. (PINKSHEETS: HEME) is pleased to announce the launch of “HealthTrac” software. HealthTrac is a Web-based open-source practice management solution for hospitals and physicians focusing on creating practice management as well as sales and marketing. Healthmed is committed to the continued expansion of its state of the art products that meet the demands of the healthcare industry.

According to Compass Intelligence, the U.S. market for health information technology will expand to $85 billion in 2014 from an estimated $73.1 billion in 2010, representing a 4.5 percent compound annual growth rate. Analysts have reported that nearly $2.5 trillion in healthcare was spent in 2009, which was $134 billion more than the previous year, when healthcare consumed 16.2 percent of the gross domestic product.

Please read more about the Company and its product developments on its website: www.healthmedltd.com.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed with the Securities and Exchange Commission.

Contact:
Dale Paisley
Email Contact

Filed Under: Facilities And Providers

UPDATE: Phase 2b Study Demonstrates GlobeImmune’s GI-5005 HCV Therapeutic Vaccine Increases Sustained Virologic Response by 12 Percent in Patients Who…

Posted on October 30, 2010 Written by Annalyn Frame

SOURCE: GlobeImmune Inc.

Additional Data Suggest That Cellular Immunity May Be a Fundamental Deficit in Hardest-to-Treat IL28B T/T Genotype Patients and Is Corrected by GI-5005

Data to Be Presented at Annual Meeting of the American Association for the Study of the Liver Diseases

LOUISVILLE, CO–(Marketwire – October 30, 2010) –  GlobeImmune Inc. today announced additional data from the GI-5005-02 Phase 2b study demonstrating that GI-5005, the Company’s investigational Tarmogen® product, improved sustained virologic response (SVR) by 12% in patients with genotype 1 chronic hepatitis C virus (HCV) infection who had failed prior treatment with standard of care (SOC, pegylated-interferon alpha 2a plus ribavirin). This study suggests that GI-5005 may have the potential to be the first successful therapeutic vaccine for patients chronically infected with HCV. 

Paul J. Pockros, M.D., of Scripps Clinic will deliver the oral presentation of the results in a late-breaker session at 6 p.m. EDT Monday November 1, 2010 at the 61st Annual Meeting of the American Association for the Study of the Liver Diseases (AASLD) in Boston.

On an intent-to-treat basis (subjects who received at least one dose of combination therapy), prior non-responders receiving GI-5005 plus SOC as a triple therapy had an SVR rate of 17%, compared to an SVR rate of only 5% in patients receiving SOC alone. Prior non-responders in this study were defined as patients who did not clear virus after a minimum of 12 weeks of SOC, including null responders, poor responders, and partial responders. Relapsers and on-treatment breakthroughs were not enrolled in the study. The most common adverse events associated with GI-5005 were injection site reactions that were generally mild and transient in nature. Discontinuation rates due to adverse events in the GI-5005 triple therapy arm were comparable to the discontinuation rates in the SOC alone arm.

“Only 4-7% of patients with genotype 1 HCV who were null, poor or partial responders to their first course of pegylated interferon-based therapy would be expected to achieve a sustained virologic response with a second course of treatment,” said Dr. Pockros. “In this study, GI-5005 conferred a three-fold improvement in SVR, an important treatment effect in this challenging patient population.” 

Additional immunology data from the study will be presented in a poster on Tuesday, November 2, 2010 by John M. Vierling, M.D., of Baylor College of Medicine. These data show that GI-5005 improved HCV-specific T cell responses 10-fold over SOC alone in patients with the IL28B T/T genotype (~20% of chronically infected patients), the subgroup most likely to fail treatment with SOC alone. Patients with the IL28B T/T genotype receiving SOC alone had an HCV-specific cellular immune response that was 17-fold lower than patients in the IL28B C/C or C/T subgroups. The improved HCV-specific T cell immunity in IL28B T/T patients receiving GI-5005 plus SOC correlates with previously reported data that demonstrated GI-5005 increased SVR rates by 60% in interferon-naïve T/T patients compared to T/T patients receiving SOC alone.

“These data suggest that the fundamental deficit in patients carrying the T allele of the IL28B gene is a deficit in adaptive cellular immunity, the mechanism that GI-5005 was designed to address,” said David Apelian, M.D., Ph.D., Chief Medical Officer at GlobeImmune. “We are confident that GI-5005 will become a cornerstone of HCV therapy, particularly for difficult to treat populations, such as IL28B T/T patients.”

A 40 patient expansion of this study in patients having the IL28B T/T genotype was initiated last week to further explore the potential treatment effect of GI-5005 in this patient population.

GI-5005 is a therapeutic vaccine candidate designed to generate HCV-specific T-cell responses and improve virologic responses in patients with chronic hepatitis C virus infection. 

About GlobeImmune

GlobeImmune Inc. is a private company developing therapeutic vaccines called Tarmogens for the treatment of cancer and infectious diseases. Tarmogens generate activated killer T cells that are designed to locate and eliminate virally-infected cells and/or cancer cells. The Company’s lead product candidate, GI-5005, is a Tarmogen being developed for the treatment of chronic hepatitis C virus (HCV) infection. GI-5005 is designed to complement both the current standard of care and emerging novel therapies for HCV. The Company’s lead oncology program, GI-4000, targets cancers caused by mutated versions of the Ras oncoprotein. GI-4000 is being investigated in clinical trials for the treatment of pancreas cancer as well as other cancers that contain mutated Ras, including non-small cell lung cancer and colorectal cancer. In May 2009, the Company announced a global partnership with Celgene focused on the discovery, development and commercialization of multiple product candidates for the treatment of cancer.

For additional information, please visit the company’s website at www.globeimmune.com.

This news release and the anticipated presentation contain forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of the Company’s clinical trial programs and the results from the clinical trials. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in the release and anticipated presentation.

Filed Under: Facilities And Providers

Phase 2b Study Demonstrates GlobeImmune’s GI-5005 HCV Therapeutic Vaccine Increases Sustained Virologic Response by 12 Percent in Patients Who…

Posted on October 30, 2010 Written by Annalyn Frame

SOURCE: GlobeImmune Inc.

Additional Data Suggest That Cellular Immunity May Be a Fundamental Deficit in Hardest-to-Treat IL28B T/T Genotype Patients and Is Corrected by GI-5005

Data to Be Presented at Annual Meeting of the American Association for the Study of the Liver Disease

LOUISVILLE, CO–(Marketwire – October 30, 2010) –  GlobeImmune Inc. today announced additional data from the GI-5005-02 Phase 2b study demonstrating that GI-5005, the Company’s investigational Tarmogen® product, improved sustained virologic response (SVR) by 12% in patients with genotype 1 chronic hepatitis C virus (HCV) infection who had failed prior treatment with standard of care (SOC, pegylated-interferon alpha 2a plus ribavirin). This study suggests that GI-5005 may have the potential to be the first successful therapeutic vaccine for patients chronically infected with HCV. 

Paul J. Pockros, M.D., of Scripps Clinic will deliver the oral presentation of the results in a late-breaker session at 6 p.m. EDT today at the 61st Annual Meeting of the American Association for the Study of the Liver (AASLD) in Boston.

On an intent-to-treat basis (subjects who received at least one dose of combination therapy), prior non-responders receiving GI-5005 plus SOC as a triple therapy had an SVR rate of 17%, compared to an SVR rate of only 5% in patients receiving SOC alone. Prior non-responders in this study were defined as patients who did not clear virus after a minimum of 12 weeks of SOC, including null responders, poor responders, and partial responders. Relapsers and on-treatment breakthroughs were not enrolled in the study. The most common adverse events associated with GI-5005 were injection site reactions that were generally mild and transient in nature. Discontinuation rates due to adverse events in the GI-5005 triple therapy arm were comparable to the discontinuation rates in the SOC alone arm.

“Only 4-7% of patients with genotype 1 HCV who were null, poor or partial responders to their first course of pegylated interferon-based therapy would be expected to achieve a sustained virologic response with a second course of treatment,” said Dr. Pockros. “In this study, GI-5005 conferred a three-fold improvement in SVR, an important treatment effect in this challenging patient population.” 

Additional immunology data from the study will be presented in a poster on Tuesday, November 2, 2010 by John M. Vierling, M.D., of Baylor College of Medicine. These data show that GI-5005 improved HCV-specific T cell responses 10-fold over SOC alone in patients with the IL28B T/T genotype (~20% of chronically infected patients), the subgroup most likely to fail treatment with SOC alone. Patients with the IL28B T/T genotype receiving SOC alone had an HCV-specific cellular immune response that was 17-fold lower than patients in the IL28B C/C or C/T subgroups. The improved HCV-specific T cell immunity in IL28B T/T patients receiving GI-5005 plus SOC correlates with previously reported data that demonstrated GI-5005 increased SVR rates by 60% in interferon-naïve T/T patients compared to T/T patients receiving SOC alone.

“These data suggest that the fundamental deficit in patients carrying the T allele of the IL28B gene is a deficit in adaptive cellular immunity, the mechanism that GI-5005 was designed to address,” said David Apelian, M.D., Ph.D., Chief Medical Officer at GlobeImmune. “We are confident that GI-5005 will become a cornerstone of HCV therapy, particularly for difficult to treat populations, such as IL28B T/T patients.”

A 40 patient expansion of this study in patients having the IL28B T/T genotype was initiated last week to further explore the potential treatment effect of GI-5005 in this patient population.

GI-5005 is a therapeutic vaccine candidate designed to generate HCV-specific T-cell responses and improve virologic responses in patients with chronic hepatitis C virus infection. 

About GlobeImmune

GlobeImmune Inc. is a private company developing therapeutic vaccines called Tarmogens for the treatment of cancer and infectious diseases. Tarmogens generate activated killer T cells that are designed to locate and eliminate virally-infected cells and/or cancer cells. The Company’s lead product candidate, GI-5005, is a Tarmogen being developed for the treatment of chronic hepatitis C virus (HCV) infection. GI-5005 is designed to complement both the current standard of care and emerging novel therapies for HCV. The Company’s lead oncology program, GI-4000, targets cancers caused by mutated versions of the Ras oncoprotein. GI-4000 is being investigated in clinical trials for the treatment of pancreas cancer as well as other cancers that contain mutated Ras, including non-small cell lung cancer and colorectal cancer. In May 2009, the Company announced a global partnership with Celgene focused on the discovery, development and commercialization of multiple product candidates for the treatment of cancer.

For additional information, please visit the company’s website at www.globeimmune.com.

This news release and the anticipated presentation contain forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of the Company’s clinical trial programs and the results from the clinical trials. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in the release and anticipated presentation.

Filed Under: Facilities And Providers

MYA Introduce Advanced Laser Lipolysis, One of the Latest Technologies in Laser Lipo!

Posted on October 29, 2010 Written by Annalyn Frame

LEEDS, UNITED KINGDOM–(Marketwire – Oct. 29, 2010) – MYA Cosmetic Surgery is now offering Advanced Laser Lipolysis as a less invasive way to shape your body compared to conventional liposuction. Advanced Laser Lipo is ideal to remove unwanted deposits of fat that won’t respond to diet and exercise, perfect for those of us looking for quicker recovery times and a less invasive method of fat removal.

MYA is always looking to push forward with new techniques and methods developing in cosmetic surgery and we are proud to announce that we now offer Advanced Laser Lipolysis (A.L.L.) alongside our other popular services. While there are various forms of Liposculpture, A.L.L. is the one chosen by MYA since it actually removes fat from the body giving you the body shape and contour you desire.

John Ryan, MYA Chairman says, “I think it’s amazing. I’ve seen the operation being done myself and I’ve seen the great results that can be achieved. The beauty of this procedure is that it uses local anaesthetic and the procedure is much less disruptive to the patient’s life.” He continues “Liposuction is the number one procedure in the United States and Laser Liposuction is going to be really big in the future”. With over 1.6 million liposuction procedures performed worldwide in 2009*, A.L.L. is destined to be the next big thing for the cosmetic surgery industry.

The Laser Lipo treatment involves making tiny incisions and using the laser technology to ‘melt’ the fat away. After the unwanted fat is removed, the laser is used to encourage contraction to ensure an even, natural looking result is achieved. This is another great advantage of the procedure. Results can usually be seen from day one and the most popular areas for treatment include the abdomen, flanks (love handles), thighs, bra area and arms.

Advanced Laser Lipolysis is proving popular with both men and women as the benefits are comparable to traditional liposuction with a lot less downtime for the patient. The A.L.L. process provides a smooth, uniform result thanks to the accuracy of the Laser Lipolysis machine and our highly skilled surgeons.

One of our recent patients Charlotte comments, “I am a personal trainer and work out five times a week but despite the amount of exercise I do I just couldn’t get rid of the fat around my thighs and hips. I had the procedure over two weeks ago and I can already see a huge difference in my shape. I just wish I had it done sooner!”

Liposuction was the most popular cosmetic surgery procedure in the UK during 2009* with Breast Enlargement following closely behind and with no signs of slowing, Laser Liposuction shows great promise to capture the market and help people shift those stubborn areas of fat in a less invasive way.

For information please call 08000 27 97 76 or visit us at www.mya.co.uk/cosmetic-surgery/laser-liposuction.php

*From The International Society of Aesthetic Plastic Surgery’s “Raw Data – Total Procedures for Top 25 Countries”

Notes to editors:

MYA Profile

MYA (Make Yourself Amazing) Cosmetic Surgery Ltd is a pioneering cosmetic surgery provider brought to you by John Ryan, the former owner of Transform Medical Group and current chairman of Doncaster Rovers. John has over 25 years experience and has returned to cosmetic surgery enlisting the experience of the very best cosmetic surgeons and medical professionals in the industry. MYA pride themselves on their commitment to high quality service and medical supplies and have a comprehensive after-care policy. MYA’s world class expertise, competitive finance and state of the art national consultation centres are designed to ensure that Making Yourself Amazing is a reassuringly unique experience.

Filed Under: Facilities And Providers

Sun Healthcare Group, Inc. to Present at the Credit Suisse 2010 Healthcare Conference

Posted on October 29, 2010 Written by Annalyn Frame

SOURCE: Sun Healthcare Group, Inc.

IRVINE, CA–(Marketwire – October 29, 2010) –  Sun Healthcare Group, Inc. (NASDAQ: SUNH) today announced that L. Bryan Shaul, chief financial officer, and Brandi Riddle, treasurer, will be presenting at the Credit Suisse 2010 Healthcare Conference on Thursday, Nov. 11, at 1 p.m. Mountain. 

The conference is being held at the Arizona Biltmore Resort and Spa in Phoenix, Ariz., Nov. 10-12. 

A copy of the presentation material will be available on the company’s web site at www.sunh.com immediately prior to Sun’s scheduled presentation.

About Sun Healthcare Group, Inc.  

Sun Healthcare Group, Inc.’s (NASDAQ: SUNH) subsidiaries provide nursing, rehabilitative and related specialty healthcare services principally to the senior population in the United States. Sun’s core business is providing, through its subsidiaries, inpatient services, primarily through 166 skilled nursing centers, 16 combined skilled nursing, assisted and independent living centers, 10 assisted living centers, two independent living centers and eight mental health centers. On a consolidated basis, Sun has annual revenues of $1.9 billion and approximately 30,000 employees in 46 states. At Oct. 1, 2010, SunBridge centers had 23,189 licensed beds located in 25 states, of which 22,407 were available for occupancy. Sun also provides rehabilitation therapy services to affiliated and non-affiliated centers through its SunDance subsidiary, medical staffing services through its CareerStaff Unlimited subsidiary and hospice services through its SolAmor subsidiary.

Contact:
Investor Inquiries
(505) 468-2341

Media Inquiries
(505) 468-4582

Filed Under: Facilities And Providers

Cosmetic Surgery Magazine: Reconstructive Surgeons Essential for Breast Cancer Patients

Posted on October 29, 2010 Written by Annalyn Frame

SOURCE: New You Publishing

MIAMI BEACH, FL–(Marketwire – October 29, 2010) –  When it comes to breast cancer, removal of the cancerous tissue is only part of the healing process. Reconstructing the breast at the same time can be critical for the wellbeing — and even survival — of the patient.

In support of Breast Cancer Awareness Month, New You magazine’s current issue addresses the issue of breast reconstruction at the time of initial surgery. In fact, say experts interviewed by New You, having a cosmetic or plastic surgeon involved right from the start means a more successful outcome for recreating a normal appearance and returning a woman’s sense of self and self-confidence.

“The cosmetic surgeon should be consulted right away, prior to any other surgery, and it should be a joint effort between the plastic or cosmetic surgeon and the breast surgeon,” says Dr. Michael S. Kluska, a board-certified plastic and cosmetic surgeon who practices near Pittsburgh, PA.

According to New You, the national consumer magazine for cosmetic surgery, the reasons for this include making sure the procedure performed by the breast surgeon removing the cancer is done so that optimal reconstruction is possible. The results can make a huge difference for the patient.

“Patients who undergo a mastectomy with simultaneous reconstruction tend to have better results long term than those who have the mastectomy [and] wait a few years,” Dr. Kluska told the magazine.

Kluska’s comments are supported by new research released last week in Toronto at the joint annual scientific meetings of the American Society of Plastic Surgery and the Canadian Society of Aesthetic Plastic Surgery, which showed that reconstruction of the breast immediately after mastectomy is associated with significantly improved breast-cancer-specific survival. Analysis of figures from the U.S. National Cancer Institute showed a 26% reduction in breast-cancer specific mortality for patients with immediate reconstruction; reasons included reduced depression and an improved sense of wellbeing.

About New You Magazine

New You is the official magazine of the American Academy of Cosmetic Surgery (AACS), published by Miami Beach-based New You Publishing, LLC. The mission of New You is to inform readers about the latest cosmetic procedures, to educate them about safety, cost and personal experience, and to locate the best possible cosmetic surgeon. For more information visit: http://newyoumag.com.

About The American Academy of Cosmetic Surgery

The American Academy of Cosmetic Surgery is a professional medical society dedicated to patient safety and physician education in cosmetic surgery. The AACS represents cosmetic surgeons in the American Medical Association through its seat in the AMA House of Delegates. Members of AACS are dermatological, facial plastic, head and neck, oral and maxillofacial, general, plastic, gynecological or ocular plastic surgeons specializing in cosmetic surgery. Founded in 1985, the AACS has over 2,500 members.

For further information please contact:
J.P. Faber
New You editor-in-chief
Email Contact
305-590-8549

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Critical Healthcare Management Reporting Made Possible by Redwood Software’s Report2Web

Posted on October 29, 2010 Written by Annalyn Frame

SOURCE: Redwood Software

Banner Health Delivers Critical Patient Load, Staffing and Billing Reports

MORRISVILLE, NC–(Marketwire – October 29, 2010) –  Banner Health, one of the largest nonprofit healthcare systems in the United States, with more than 23 hospitals in seven states, uses Redwood Software‘s Report2Web to achieve secure, fast, and efficient delivery and management of clinical, financial, and IT reports throughout the organization. Report2Web gives executives, along with clinical, staffing, and billing managers the specific information they need to keep the hospital system working at optimum levels at all times.

Every day, healthcare organizations rely on up-to-date staffing, patient load, and payment reports to manage the dynamic balance necessary to maintain quality of care. For Banner, these reports were often extremely large and complex. Typically, the final reports were emailed around the organization in their entirety and stored multiple times on multiple networks, creating a bandwidth and storage nightmare. In addition, the reports could not be split apart, which made simply finding key information an inexact, labor-intensive manual process, delaying critical decision making. “Since we have implemented Report2Web, essential reporting processes that once took many people and days to complete, now take one person a few minutes to accomplish,” says Bill Beaver, IT Director, Enterprise Integration Services for Banner Health. “We save time and money every day because of Report2Web.”

Through strict security and control, Report2Web gives managers only the information required for their specific role or task. “Banner has more than 6,000 unique reports, and we store this information indefinitely,” says Beaver. “We currently have more than seven million reports in our system. That’s equivalent to 24,000 four-drawer filing cabinets. These filing cabinets would completely fill 1.3 football fields. We needed a powerful solution to make this information more readily available and useful to us. With Report2Web we have it.”

Report2Web’s flexibility and ease of customizing reports resulted in even greater time savings. Now Banner can automatically create custom report packages and apply business rules to extract totals from specific reports. This allows managers to focus on analyzing key figures rather than just finding them. “This saves us immeasurable time. If the totals are correct, managers often don’t need to see the detail,” says Beaver. “If the totals are incorrect, the manager can quickly get that detail and investigate.”

For Banner, Report2Web was not just an improvement, it is a core solution. It provides the organization with the system they needed to enforce security and make critical, time-sensitive business decisions that directly impact the hospital’s critical care and financial health — every single day. Report2Web offers the flexibility and power to handle high volumes of sensitive information quickly and efficiently. As Banner Health continues to grow, they can focus on providing world-class healthcare while their report management system grows right along with them.

About Redwood
Redwood Software is a global company providing enterprise report management, workload automation, job scheduling, and financial process automation solutions that enable organizations to maximize the value of their information management and technology investments. Serving thousands of customer installations worldwide, Redwood helps companies meet the challenges of today’s competitive environment by delivering solutions that make business operations faster, more effective, and more efficient. Redwood serves businesses worldwide through locations in Europe, North America, and Australia, and through its alliances, including its strategic partnership with SAP AG.

About Banner Health
Headquartered in Phoenix, Banner Health is one of the largest, nonprofit health care systems in the country. The system owns or manages 23 acute-care hospitals, long-term care centers, outpatient surgery centers and an array of other services including family clinics, home care and hospice services, and a nursing registry. Banner Health is in seven states: Alaska, Arizona, California, Colorado, Nebraska, Nevada and Wyoming. In 2010, Thomson Reuters named Banner Health one of the Top 10 Hospital Systems in the U.S.

The original press release can be viewed at: www.redwood.com/banner-health

Redwood, Cronacle and Cronacle Mobile are trademarks or registered trademarks of Redwood Software. All other products or company names mentioned are used for identification purposes only and may be trademarks of their respective owners.

Contact Redwood Software:

Patricia Kelly
Director of Analyst and Public Relations
+1 248.628.3563
[email protected]

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Ansell Protects Program Launched to Help Prevent Allergic Contact Dermatitis

Posted on October 29, 2010 Written by Annalyn Frame

RED BANK, NEW JERSEY–(Marketwire – Oct. 29, 2010) – Ansell Healthcare announces the launch of the Ansell Protects Program, a major new initiative aimed at helping healthcare facilities understand the risks associated with chemical allergies and providing solutions for them.

It is estimated that hand dermatitis affects up to 33% of all nurses, costing the U.S. an estimated $1 billion per year. The Ansell Protects Program was developed to improve the health of employees and also significantly reduce long-term costs for healthcare facilities.

Chemical allergies – otherwise known as Type IV allergies or allergic contact dermatitis – can cause physical, emotional and occupational issues for those affected. The only treatment is allergen avoidance. The Ansell Protects Program provides the tools to help healthcare facilities understand the impact of chemical allergies, assess their risk level, estimate their potential savings and find the right medical gloves to ensure they promote a healthy workplace.

“The effects of chemical allergies are wide-ranging, and the costs are high,” explained Patty Taylor, RN, BA, Vice President of Marketing – Medical Division, of Ansell Healthcare. “The Ansell Protects Program will help facilities understand the threat of chemical allergies – and will identify solutions that will foster better health and significant long-term savings.”

Costs associated with chemical allergies include diagnosis, workers’ compensation, disability, increased sick leave, decreased job productivity, and medical care costs.

Supporting its Ansell Protects Program are products that help reduce risk for facilities. Ansell is the first manufacturer to offer both a surgical and exam glove that help protect against Type I and Type IV allergies, including Derma Prene® Ultra neoprene surgical gloves; Derma Prene® Ultra HydraSoft® hand friendly neoprene surgical gloves; and Micro-Touch® NitraFree™ nitrile examination gloves.

For more information on the physiology and effects of allergic contact dermatitis – including a breakdown of costs – visit www.AnsellProtects.com

About Ansell

Ansell Limited (“Ansell”) is a global leader in protection solutions. With operations in the Americas, Europe and Asia, Ansell employs over 10,000 people in 33 countries. Ansell designs, develops, manufactures and markets a wide range of surgical, examination, industrial and household gloves, protective clothing and condoms. People in over 100 countries around the world put their trust in Ansell’s innovative, high-quality solutions that offer superior protection, combined with high levels of comfort and performance. Operational headquarters are located in Red Bank, NJ.

Filed Under: Facilities And Providers

Spine Centers of America Opening Advanced Spine Surgery Center for Minimally Invasive Spine Surgery in NJ

Posted on October 29, 2010 Written by Annalyn Frame

SOURCE: Spine Centers of America

Center Offers Innovative Endoscopic Spine Surgery for Faster Recovery, Improved Success Rates

UNION, NJ–(Marketwire – October 29, 2010) –  Considering that more than 80 percent of Americans will suffer from back pain at some point in their life, it isn’t surprising that Spine Centers of America is opening its second endoscopic spine surgery center in the New Jersey area in early November.

Advanced Spine Surgery Center, at 855 Lehigh Ave, Union, NJ, is a state-of-the-art facility that has been developed under the leadership of Bryan J. Massoud, M.D., a board certified, Fellowship-trained orthopedic spine surgeon. Dr. Massoud founded the New Jersey Back Institute and Spine Centers of America, which currently operates one other spine surgery center in New Jersey. Specializing in minimally invasive endoscopic laser spine surgery, diagnostic, and pain management procedures, Advanced Spine Surgery Center is an ambulatory surgery center that relieves patient neck and back pain when other treatments have failed. 

Key advantages of new endoscopic laser spine surgery over traditional open spine surgery include:

  • Less trauma to body
  • Reduced post-operative pain
  • Less scarring and smaller scars
  • Shorter recovery time
  • Improved post-surgical function and mobility
  • Reduced blood loss
  • Reduction/elimination of time under general anesthesia

Advanced Spine Surgery Center has three Class C operating suites featuring the latest equipment and endoscopic spine surgery technologies. The operating suites, pre-op and post-op areas, occupying 10,000 sq. ft., will be staffed with board certified orthopedic spine surgeons, anesthesiologists, pain management physicians and nursing staff to provide outpatient care. The facility includes numerous medical offices for affiliated medical professionals.

The Grand Opening event for healthcare professionals will take place on November 16 with private previews available in advance by appointment. Healthcare professionals interested in attending should call 1.877.722.6008.

Spine Centers of America offers the advantage of numerous advanced endoscopic spine surgery techniques developed by Dr. Massoud and his associates that will be performed at the Advanced Spine Surgery Center. These procedures include:

  • Anterior cervical endoscopic foraminotomy for treating bone spurs and foraminal stenosis
  • Epiduragram-guided endoscopic discectomy to further enhance safety of discectomy procedures;
  • The “between” technique in transforaminal endoscopic lumbar procedures for disc herniations.

Endoscopic laser spine surgery techniques that are employed by Advanced Spine Surgery Center use “twilight” or local anesthesia, which allows patients to remain alert during surgery and usually walk out of surgery under their own power. Dr. Massoud has personally performed more than 1000 endoscopic spine surgeries with a high success rate, enabling patients with debilitating spinal pain to get “back to life” free of pain. 

Spine Centers of America surgeons at Advanced Spine Surgery Center will treat spine conditions including: bone spurs; bulging disc, disc degeneration; disc tear; facet joint disease; failed back and neck surgery; foraminal stenosis; herniated disc; pinched nerve; radiculitis; radiculopathy; sciatica; spinal stenosis and spondylolisthesis. SCA’s surgeons have extensive experience performing the endoscopic spine procedures to diagnose or treat these conditions.

Because Spine Centers of America offers highly successful endoscopic techniques not yet available elsewhere, the new center, located minutes from Newark Airport, is expected to draw patients from across the country. Spine Centers of America hosts monthly seminars to educate the public about spinal conditions and advanced options for spinal pain relief via minimally invasive spine surgery techniques. For more information call 201.870.3030 or visit www.SpineCentersOfAmerica.com.

About Spine Centers of America:

Spine Centers of America offers the newest techniques in endoscopic spine surgery always performed by board certified spine surgeons. Considered a pioneer in minimally invasive spine surgery, SCA’s founder Dr. Bryan J. Massoud is among the most experienced Board certified orthopedic spine surgeons performing endoscopic laser spine procedures in the country. Recognized as an expert by his peers, Dr. Massoud instructs orthopedic residents and colleagues in new procedures such as kyphoplasty and endoscopic techniques. 

CONTACT:
Business Development:
Fernando Vega
201.870.3030

Media:
Julie Shepherd
+1-815-479-1833
Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Vangent Wins $3.7 Million Contract From Military Health System to Manage Patient Movement Item Tracking System

Posted on October 28, 2010 Written by Annalyn Frame

SOURCE: Vangent

Vangent to Manage Award-Winning MHS System That Ensures Medical Equipment Is Accessible and Available for Wounded Warriors

ARLINGTON, VA–(Marketwire – October 28, 2010) –  Vangent, Inc., a leading global provider of information management and strategic business process solutions, today announced it was awarded the Patient Movement Item Tracking System (PMITS) Sustainment contract from the Military Health System in support of the Defense Health Services Systems Program Office.

PMITS is an award-winning MHS system, receiving the Agency Information Technology Award from Government Computer News in 2009. PMITS automatically tracks the storage of patient movement items during peacetime and its movement during contingency and wartime operations. PMITS ensures critical patient-movement equipment is available throughout patient evacuation to save critically injured warfighters’ lives.

Military commanders use PMITS to manage and redistribute patient movement assets to avoid shortages during patient evacuations. PMITS prevents the loss, shortages, and overages of aeromedical equipment by managing the equipment inventory, tracking its movement, and providing valuable information to personnel supporting aeromedical equipment, such as item identification, item location, and status. 

“Vangent is proud to support the Military Health System with a mission-critical system that provides essential equipment for our military’s wounded warriors,” said Kerry Weems, Senior Vice President and General Manager of Vangent’s Health Solutions business. 

Vangent’s subcontractor partner on this contract is Akimeka, LLC.

About Vangent, Inc. 
Vangent, Inc. is a global provider of consulting, systems integration, human capital management, and business process services to the U.S. federal and international governments, higher education institutions, and corporations. Vangent’s 8,500 employees support clients including the Centers for Medicare & Medicaid Services, the U.S. Departments of Defense, Education, Health and Human Services, Labor and Veterans Affairs; and the U.S. Office of Personnel Management, the U.S. Census Bureau, as well as Fortune 500 companies. Headquartered in Arlington, Virginia, the company has offices throughout the U.S. and in the U.K and Canada. For more information, visit www.vangent.com.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are those that do not relate solely to historical fact. They include, but are not limited to, any statement that may predict, forecast, indicate or imply future results, performance, achievements or events. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “projects,” “likely,” “will,” “would,” “could” and similar expressions or phrases identify forward-looking statements. All forward-looking statements involve risks and uncertainties. The occurrence of the events described, and the achievement of the expected results, depend on many events, some or all of which are not predictable or within our control. In light of these risks and uncertainties, expected results or other anticipated events or circumstances discussed in this press release might not occur. We undertake no obligation, and specifically decline any obligation, to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Eileen Cassidy Rivera
(703) 284-5674
Email Contact

Filed Under: Facilities And Providers

Beach Business Bank Reports Strong Quarter and Record 12 Month Trailing Earnings

Posted on October 28, 2010 Written by Annalyn Frame

SOURCE: Beach Business Bank

MANHATTAN BEACH, CA–(Marketwire – October 28, 2010) – Beach Business Bank (OTCBB: BBBC) (the
“Bank”) is pleased to report its results of operations for the third
quarter of 2010, the year to date 2010, and the trailing 12 months which
includes the fourth quarter of 2009.

Third Quarter Highlights

-- Improving After-Tax Earnings.  For the trailing 12 months, the Bank
   earned $1,201,000, a historical earnings record for the Bank.
   All three of the Bank's offices: Orange County, Long Beach and
   Manhattan Beach, performed well in the quarter.


                                        Third
(U.S.         Third       Second       Quarter      First 9      First 9
 Dollars)  Quarter 2010 Quarter 2010     2009     Months 2010  Months 2009
           ------------ ------------ -----------  ------------ -----------
Net Income      450,000      256,000  (5,895,000)    1,058,000  (5,693,000)
           ------------ ------------ -----------  ------------ -----------

-- Loan Growth and Improving Funding Quality.  The Bank's niche lending
   businesses to physicians and dental professionals and the Bank's SBA
   lending practice showed strength, resulting in further loan
   originations. Development of non-interest-bearing deposits was strong
   during the quarter. The Bank's non-CD based deposits were 89% of total
   deposits at the end of the third quarter.


                                        9/30/2010   9/30/2010   9/30/2010
                                            vs.         vs.         vs.
% growth                                6/30/2010   12/31/2009  9/30/2009
                                        ---------   ----------  ----------
Net Loans                                    (.04)%      13.51%      30.22%
                                        ---------   ----------  ----------
Total Assets                                 18.7%        18.5%       18.7%
                                        ---------   ----------  ----------
Demand deposits (non-interest-bearing)       11.9%        52.0%       56.5%
                                        ---------   ----------  ----------
Total Deposits                               10.8%       22.71%       23.1%
                                        ---------   ----------  ----------

-- Total new loan commitments in the quarter amounted to more than
   $20 million. Non-interest bearing demand deposits totaled $49.1 million
   at quarter end. Overall deposits totaled $260.3 million at quarter end.
   Total assets increased by $47.6 million, to $302.5 million at
   quarter-end, as compared to $254.9 million for the same quarter end
   last year.

Stronger Operating Performance


                                                                    YTD
                          3Q 2010   2Q 2010   3Q 2009   YTD 2010    2009
                          --------  --------  -------   --------  -------

Return on Average Assets      0.60%     0.38%   (9.08)%     1.52%   (2.30)%
                          --------  --------  -------   --------  -------
Return on Average Common
 Equity                       6.09%     3.50%  (68.21)%    14.41%  (65.81)%
                          --------  --------  -------   --------  -------
Net Interest Margin           3.85%     3.98%    3.33%      3.92%    3.56 %
                          --------  --------  -------   --------  -------
Efficiency Ratio             65.79%    68.52%  144.56%     72.85%  110.35 %
                          --------  --------  -------   --------  -------
Tangible Book Value per
 Common Share             $   7.30  $   7.21  $  7.10   $   7.30  $  7.10
                          --------  --------  -------   --------  -------

“We are pleased to be able to report these strong results,” commented Jim
Gray, the co-chairman of the Bank’s board of directors. He continued, “We
are committed to helping the small businesses in our market area to get
back to hiring new employees and increasing their business again. The
recently passed Small Business Bill that the President signed into law on
September 27 will be a huge benefit for business banks like ours, and for
our small business customers.”

Robert Franko, president and chief executive officer of the Bank,
commented, “Our team of skilled bankers has worked tirelessly to achieve
these results, by continuing to build our franchises among small businesses
in our local market areas and among medical professionals nationwide. To
support further growth we continue to make additional provisions from our
core earnings to give us the necessary balance sheet strength. Our local
community has continued to provide us with strong core deposit
relationships, even as our funding costs have continued to decline. We are
fortunate to be located in the finest market areas in the world, and to
have the support of so many excellent and enduring business relationships.”

Loan Portfolio and Credit Quality

-- The Bank's Allowance for Loan & Lease Losses (ALLL) stood at
   $6.2 million or 2.5% of loans outstanding at the quarter end.
-- As of the quarter end, non-accrual loans stood at $5.0 million, with
   no other loans more than 30 days past due.
-- The Bank had net charge-offs of $361,000 in the quarter. The Bank
   provided $520,000 to the ALLL in the quarter.
-- As of the quarter end, the aggregate of non-accrual loans and OREO
   measured as a percentage of Capital and Reserves (sometimes referred to
   as the Texas Ratio) stood at 12.03%.
-- At the quarter end, the Bank's Total Risk-based Capital Ratio was
   14.89%, compared to the regulatory minimum of 10.0% to be
   "Well Capitalized."
-- The Bank's other regulatory Capital measurements also continued to be
   significantly above the regulatory minimums for Well Capitalized.
   For example, the Bank's Tier 1 Risk-Based Capital was 13.62%, compared
   to the regulatory minimum of 6.0%, and the Bank's Tier 1 Leverage Ratio
   was 11.88%, compared to the regulatory minimum of 5.0%.

Financial statements in the form of the Bank’s Call Report, as filed with
the FDIC, will be available on the Bank’s web site at
www.beachbusinessbank.com, and should be available for review or
downloading from the FDIC web site at www.fdic.gov shortly after the end of
this month.

Beach Business Bank is headquartered at 1230 Rosecrans Avenue, Lobby Level,
in Manhattan Beach, and has two other full-service offices at 180 E. Ocean
Blvd. in Long Beach, CA and at 650 Town Center Drive in Costa Mesa, CA. The
Bank is first and foremost a community business bank serving Los Angeles,
Long Beach, the South Bay and Orange County residents and businesses. The
Bank also has a division named The Doctors Bank®, which serves physicians
and dentists nationwide. In addition, Beach Business Bank provides loans to
small businesses, focused around the SBA 7(a) and Express lending programs.
For more information on the Bank, please visit www.beachbusinessbank.com or
call toll-free to (866) 862-3878.

“Safe Harbor” statement under the Private Securities Litigation Reform Act
of 1995:

The financial information in this press release is based on our unaudited
financial results. Certain statements in this press release, including
statements regarding the anticipated development and expansion of the
Bank’s business, and the intent, belief, and current expectations of the
Bank, its directors, or its officers, are “forward-looking” statements (as
such term is defined in the Private Securities Litigation Reform Act of
1995). Such forward-looking statements are subject to risks and
uncertainties and therefore the Bank’s actual results may differ materially
from those expressed or implied by such forward-looking statements. The
risks and uncertainties that the Bank is subject to include, but are not
limited to, risks related to the local and national economy, including
fluctuations in interest rates and costs and changes in economic policy;
the ability of the Bank to perform in accordance with its plans;
competition; regulatory matters; and other risks detailed in its filings
with the State of California Department of Financial Institutions and the
Federal Deposit Insurance Corporation. The Bank cautions readers not to
place undue reliance on any forward-looking statements. The Bank does not
undertake, and specifically disclaims any obligation, to revise any
forward-looking statements to reflect the occurrence of anticipated or
unanticipated events or circumstances after the date of such statements.

Summary Financial Information

The following tables present relevant financial data from
Beach Business Bank's recent performance.

                                           September  December   September
                                           30, 2010   31, 2009   30, 2009
                                           ---------  ---------  ---------
Balance Sheet Results (In thousands),
 except per share data:
       Total Assets                        $ 302,465  $ 255,321  $ 254,883
       Gross Loans                         $ 245,496  $ 217,361  $ 193,687
       Loans Held for Sale                 $   1,542  $   1,026  $   4,285
       Allowance for Loan Losses           $   6,188  $   6,870  $   6,819
       Total Net Loans                     $ 237,765  $ 209,465  $ 182,582
       Total Deposits                      $ 260,293  $ 212,083  $ 211,465
       Other Real Estate Owned             $       -  $   2,100  $   2,399
       Preferred Stock                     $   6,078  $   6,033  $   6,018
       Common Stock                        $  29,618  $  28,899  $  28,680
       Total Shareholders' Equity          $  35,696  $  34,932  $  34,698
       Net Loans to Deposits                   91.35%     98.77%     86.34%
       ALLL to Loans HTM                        2.54%      3.18%      3.60%
       Equity to Assets                        11.80%     13.68%     13.61%
       Ending Shares outstanding           4,055,972  4,036,984  4,036,984
       Ending Book Value per Common Share  $    7.30  $    7.16  $    7.10

                                                  Three Months Ended
                                           September  December   September
                                           30, 2010   31, 2009   30, 2009
                                           ---------  ---------  ---------
Quarterly Operating Results (In
 thousands):
       Net Interest Income                 $   2,780  $   2,230  $   2,041
       Non-interest Income                 $      57  $     583  $     302
       Non-interest Expense**              $   1,866  $   1,770  $   3,387
       Income Before Provision & Taxes     $     970  $   1,043  $  (1,045)
       Provision for Loan Losses           $     520  $     900  $   4,850
       Income Tax Expense                  $       -  $       -  $       -
       Net Income                          $     450  $     143  $  (5,895)
       Quarterly Return on Average Assets*      0.60%      0.22%     -9.08%
       Quarterly Return on Average Equity*      5.05%      1.63%    -58.11%
       Quarterly Net Interest Margin*           3.85%      3.46%      3.33%
       Quarterly Efficiency Ratio*             65.79%     62.93%    144.56%

                                            Nine Months Ended
                                           September  September
                                            30, 2010   30, 2009
                                           ---------  ---------
YTD Operating Results (In thousands):
       Net Interest Income                 $   7,909  $   6,410
       Non-interest Income                 $   1,072  $   1,060
       Non-interest Expense                $   6,542  $   8,243
       Income Before Provision & Taxes     $   2,438  $    (773)
       Provision for Loan Losses           $   1,380  $   4,920
       Income Tax Expense                  $       -  $       -
       Net Income                          $   1,058  $  (5,693)
       YTD Return on Average Assets*            0.38%     -2.30%
       YTD Return on Average Equity*            2.99%    -14.24%
       YTD Net Interest Margin*                 3.92%      3.56%
       YTD Efficiency Ratio*                   72.85%    110.35%


       *Percentages are reported on an annualized basis.
       Source: FDIC quarterly Call Reports for Beach Business Bank for the
       periods indicated.

Filed Under: Facilities And Providers

Hunt Regional Medical Center Becomes the First Hospital in Texas to Implement ClearCount to Prevent Retained Surgical Sponges

Posted on October 28, 2010 Written by Annalyn Frame

SOURCE: Medline Industries, Inc.

SmartSponge System, Distributed by Medline, Provides Counting and Detection

MUNDELEIN, IL–(Marketwire – October 28, 2010) –  ClearCount Medical Solutions and Medline Industries, Inc. today announced that Hunt Regional Medical Center has become the first Texas hospital to deploy the most comprehensive technology for the prevention retained surgical sponge incidents. Hunt Regional Medical Center (HRMC) has implemented the SmartWand-DTX, part of ClearCount’s radio-frequency identification (RFID)-based platform that uniquely identifies each sponge so that they can be easily counted and detected. Medline is the exclusive distributor for the SmartWand-DTX and the SmartSponge System, the first FDA-cleared systems using RFID.

“The deployment of the latest safety technology in our OR is consistent with our commitment to both our community and our employees,” said Richard Carter, chief executive officer at HRMC. “We are pleased to be on the cutting edge of technology in this area, and our deployment reinforces our commitment to bringing the best care to the community we serve.”

“The SmartWand-DTX provides a safety net for human error. Anything that we can do to improve patient safety is extremely crucial. This technology not only allows our staff to operate at an exceptional level of patient safety, but also provides staff with a safer and more efficient method for reconciling our surgical counts,” said Katherine Magee, RN, OR director at Hunt Regional Medical Center.

HRMC has implemented the SmartWand-DTX into its full suite of operating rooms. The hospital is part of Hunt Regional Healthcare which is affiliated with Baylor Health Care System.

“We’re pleased to add Hunt Regional Medical Center to our rapidly expanding customer base,” said David Palmer, chief executive officer of ClearCount. “Their selection of our safety technology demonstrates the trend that many hospitals are now taking action to make retained sponge incidents a true ‘Never Event’ through the use of RFID technology.”

Despite designation as a “never event,” retained items are estimated to occur in one of every 1,000 to 1,500 abdominal surgical procedures, which can lead to hospital inefficiencies, unnecessary costs, serious infections and even death. Hospital infections add an estimated $30.5 billion to the nation’s hospital costs each year. In one study using a retrospective review of medical malpractice claims data from a statewide insurer in Massachusetts, sponge counts had been falsely thought to be correct in 76 percent of non-vaginal surgical cases involving retained sponges. “Falsely correct” sponge counts were attributed to team fatigue, difficult or long operations, sponges “sticking together,” shift changes or procedures with a large number of sponges. In July 2010, new Association of periOperative Registered Nurses (AORN) Recommended Practices for the Prevention of Retained Surgical Items highlighted that membership may consider use of adjunct technologies to enhance surgical count procedures in order to avoid retained incidents.

About ClearCount Medical Solutions
ClearCount Medical Solutions is a medical device company focused on patient safety solutions. ClearCount has assembled an extendable RFID-based platform that provides a comprehensive solution to improve efficiency while preventing medical errors, distributed exclusively by Medline. ClearCount Medical Solutions has been recognized with a Popular Science 2009 Best of What’s New Award, and has received additional recognition from TIME and WIRED magazines, the 2009 Wall Street Journal Technology Innovation Award, the International Design Excellence Award (IDEA) and more. ClearCount’s SmartSponge and SmartWand-DTX systems are the first RFID enabled systems for counting and detecting surgical sponges, thereby improving patient and OR safety, enhancing productivity, and reducing cost. To learn more, visit www.clearcount.com.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

Medline Media Contacts:
Jerreau Beaudoin
(847) 643-3011
John Marks
(847) 643-3309

ClearCount Medical Solutions:
Jennifer Bannan
(412) 580-3675

Filed Under: Facilities And Providers

Joint Commission Center for Transforming Healthcare Establishes Leadership Advisory Council

Posted on October 28, 2010 Written by Annalyn Frame

SOURCE: The Joint Commission

Supporters, Hospital Leaders to Help Guide Progress

OAKBROOK TERRACE, IL–(Marketwire – October 28, 2010) –  The Joint Commission Center for Transforming Healthcare today announced the establishment of a Leadership Advisory Council to guide the progress of the Center as it addresses and develops solutions to improve health care quality and patient safety. The first meeting of the Center’s Leadership Advisory Council will be held October 29.

Meeting three times a year, members of the Leadership Advisory Council include executives from among the Center’s major sponsors and CEOs representing the participating hospitals. The CEOs will serve on a rotating basis to allow new membership each year. The Council will be chaired by Mark Chassin, M.D., M.P.P., M.P.H., president, The Joint Commission. Council members are:

  • Jack E. Bailey, GlaxoSmithKline
  • Paul Chaffin, Ecolab
  • George Halvorson, Kaiser Permanente
  • Donny C. Lambeth, Wake Forest University Baptist Medical Center
  • Alberto Mas, BD
  • Rich Miller, Virtua
  • Andy Mills, Medline Industries
  • Ronald R. Peterson, The Johns Hopkins Hospital and Health System
  • Thomas M. Priselac, Cedars-Sinai Health System
  • Gary Pruden, Johnson & Johnson Company
  • Michael J. Swinford, GE Healthcare
  • Richard Umbdenstock, American Hospital Association
  • Dan Wolterman, Memorial Hermann Healthcare System

“The response from accredited health care organizations to the Center has been extremely positive, a fact due in large part to the ongoing commitment of participating hospitals and health systems and sponsors to address the toughest and most persistent problems facing health care across the country,” says Dr. Chassin. “The perspectives of the Leadership Advisory Council members will help us to bring everyone interested in safe, reliable health care together to create lasting solutions.”

Established in 2009, the Joint Commission Center for Transforming Healthcare aims to solve health care’s most critical safety and quality problems. The Center’s participants — which include some of the nation’s leading hospitals and health systems — use a systematic approach to analyze specific breakdowns in care and discover their underlying causes to develop targeted solutions that solve these complex problems. Center projects include hand hygiene, wrong-site surgery, hand-off communications and the reduction of surgical site infections (SSI) following colorectal surgery. Future projects are expected to focus on preventable hospitalizations, medication errors, and other aspects of infection control.

All Joint Commission-accredited health care organizations can access the solutions on their secure Joint Commission Connect extranet through the Targeted Solutions Tool™ (TST). The TST provides a step-by-step process to measure performance, identify barriers to excellent performance, and implement the Center’s proven solutions that are customized to address an organization’s specific barriers.

The first set of targeted solutions, created by eight hospitals and health care systems working in collaboration with the Center, focuses on improving hand hygiene. The second set of solutions, announced last week, focuses on improving hand-off communications. The targeted solutions for hand-off communications will be pilot tested to prove their effectiveness in demographically diverse hospitals and will be added to the TST in the second half of 2011.

For more information about the Joint Commission Center for Transforming Healthcare, visit www.centerfortransforminghealthcare.org.

Established in 2009, the Joint Commission Center for Transforming Healthcare aims to transform American health care into a high-reliability industry that ensures patients receive the safest, highest quality care they expect and deserve. The Center’s participants — the nation’s leading hospitals and health systems — use a proven, systematic approach to analyze specific breakdowns in care and discover their underlying causes to develop targeted solutions for health care’s most critical safety and quality problems. The Center is a not-for-profit affiliate of The Joint Commission, which shares the Center’s proven effective solutions with its more than 18,000 accredited health care organizations. Learn more about the Center at www.centerfortransforminghealthcare.org.

To view this release in a media-rich format, go to: http://www.pwrnewmedia.com/2010/jointcommission_01028_leadership_council/index.html

Media Contact:
Elizabeth Eaken Zhani
Media Relations Manager
630.792.5914
Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Chubb Establishes a Healthcare Information Technology Program

Posted on October 28, 2010 Written by Annalyn Frame

SOURCE: Chubb Group of Insurance Companies

WARREN, NJ–(Marketwire – October 28, 2010) –  Health care reform has spawned a host of privacy, information security and other liability exposures for the emerging healthcare information technology industry. In response, the Chubb Group of Insurance Companies has established a program to address the industry’s specialized risk needs.

“Chubb has brought together its information and network technology and life sciences expertise to tailor insurance and loss control solutions to this rapidly growing market sector,” said Stephen Harris, a Chubb vice president and co-program manager.

More than 1,000 companies supply information technology products and services to the healthcare and medical research industries in the United States and Canada. The sector is poised for additional growth after the allocation of nearly $20 billion in federal stimulus funds to incentives to create electronic health records and to other investments in the sector.

“Chubb’s Healthcare Information Technology program will provide insurance products and services, on a global basis, that can help this emerging industry face privacy and information security requirements, as well as a host of new professional liability exposures,” said Richard Reed, a Chubb vice president and co-program manager.

An integrated liability solution from Chubb can help protect healthcare information technology companies from:

  • general and products liability when software or hardware that is defective or contains inaccurate or incomplete information causes or contributes to patient injuries;
  • errors and omission liability when a product defect or service deficiency results in economic injury to a customer;
  • third-party liability to patients, healthcare providers and others associated with database security breaches; and
  • costs incurred to comply with state, federal and foreign laws requiring companies to notify consumers of a privacy data breach.

In addition, Chubb can provide these firms with insurance addressing property, business interruption, workers compensation and auto exposures.

The member insurers of the Chubb Group of Insurance Companies form a multi-billion dollar organization providing property and casualty insurance for personal and commercial customers worldwide through 8,500 independent agents and brokers. Chubb’s global network includes branches throughout North America, Europe, Latin America, Asia and Australia.

Chubb Group of Insurance Companies
15 Mountain View Road
P.O. Box 1615
Warren, New Jersey 07059

Contact:
Jodi Dorman
(908) 903-2608
Email: [email protected]

Filed Under: Facilities And Providers

HealthEd Expands Executive Team, Focusing on Future Growth

Posted on October 28, 2010 Written by Annalyn Frame

SOURCE: HealthEd

CLARK, NJ–(Marketwire – October 28, 2010) –  HealthEd, a specialized agency focused on turning health education into positive outcomes, today announced several key senior-level appointments — Mike Brzozowski as chief strategy officer, Sonja “Sunny” Foster-Storch as executive vice president, managing director for HealthEd, and Paul Steiner as executive vice president, managing director for Encore, a HealthEd company. With these additions to the executive leadership team, HealthEd Group signals its focus on expanding its strategic and consultative services to meet changing client needs.

“We are very excited to have Mike, Sunny, and Paul on board,” said Roy Broadfoot, CEO and president of HealthEd. “The business needs and requirements of our clients are becoming increasingly complex. We have heard them and have responded by recruiting top executives who can strategically lead our cross-functional teams to deliver innovative and engaging solutions.”

Mr. Brzozowski comes to HealthEd with more than 20 years of experience in relationship marketing, strategic planning, and business analysis. He is responsible for leading and expanding strategic marketing and health education consulting services. With Mr. Brzozowski at the helm, the health educators and marketers combine to provide a unique insight into patient motivations and behaviors. Most recently, Mr. Brzozowski worked at Draftfcb as executive vice president of customer relationship marketing and before that was at Ogilvyone Worldwide as senior partner, executive director of relationship marketing strategy.

Ms. Foster-Storch will lead HealthEd’s client services group, while Mr. Steiner will lead Encore’s. The two help form a structured leadership team for both organizations by integrating resources and focusing on client development. Both report directly to Larry Moran, chief operating officer.

Ms. Foster-Storch comes to HealthEd from The CementBloc, where she led the market development and marketing strategy team. Before that, she cofounded Clinical CONNEXION, a medical education company. 

Mr. Steiner joins Encore from Draftfcb, where he was senior vice president, director of customer relationship marketing. Previously, he served as senior vice president, group account director, at Omnicom’s Unit 7 relationship marketing agency. 

“Sunny and Paul both bring over 20 years of strategic planning and healthcare marketing experience to our company,” said Anita St. Clair, HealthEd’s chief client development officer. “And Mike’s success in creating integrated marketing solutions is just what the doctor ordered. His belief that effective relationship marketing helps deliver engaging, individualized, dialog-driven customer experiences aligns perfectly with our clients’ needs and our company mission.”

About HealthEd
HealthEd is a specialized agency that uses education to help people develop the knowledge, skills, motivation, and confidence to manage important health decisions and activities and ultimately achieve better health outcomes. For more information about HealthEd and the services we offer, please visit http://www.HealthEd.com or contact Anita St. Clair, chief client development officer, at 908-389-2133.

CONTACT INFORMATION:
Kindra Harting-Smith
Marketing Communications
HealthEd
Tel: 908-389-2118
Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Visionary HealthWare’s Alteer Office Solution Receives 2011 CCHIT(R) Certification

Posted on October 28, 2010 Written by Annalyn Frame

SOURCE: Visionary HealthWare

Topic: CCHIT Certification Alteer Office Solution Issuing Entity: CompuGroup Medical US, Visionary HealthWare

TAMPA, FL–(Marketwire – October 28, 2010) –  The Certification Commission for Health Information Technology (CCHIT®) today announced that Visionary HealthWare’s Alteer Office 8.0 is a pre-market CCHIT Certified®  2011 Ambulatory EHR. Ambulatory EHRs are designed for physician offices and clinics where most Americans get their healthcare. Alteer Office is part of Visionary HealthWare’s offerings of practice management and electronic healthcare record solutions. Visionary HealthWare is a subsidiary of CompuGroup Medical U.S.

As a CCHIT Certified 2011 product, Visionary HealthWare’s Alteer Office demonstrated compliance with the advanced ePrescribing module requirements and has passed all required criteria in the CCHIT 2011 Ambulatory and Security test scripts for:

  • Functionality (ability to create and manage electronic records for all patients, as well as automating workflow in a physician’s office),
  • Interoperability (ability to receive and send electronic data to other entities such as laboratories), and
  • Security (ability to keep patients’ information safe).

The CCHIT Certified program is an independently developed certification that includes a rigorous inspection of an EHR’s integrated functionality, interoperability, and security using criteria developed by CCHIT’s broadly representative, expert work groups. By looking to products with the CCHIT Certified seal, physicians and other providers can be assured they are making a reliable investment and insurers and other payers know the products meet expected industry standards. This program is intended to serve health care providers looking for greater assurance that a product will meet their complex needs.

“We believe that achieving CCHIT Certification confirms the quality and comprehensiveness of Visionary HealthWare’s Alteer Office as well as validates VHW’s commitment to providing our customers with the most up-to-date advancements in healthcare IT,” said Chris Grady, CIO of Visionary HealthWare. “Alteer Office provides the features, functionality, and ease of use necessary for physicians to adopt the EHR quickly while minimizing disruption to their current workflow.”

“Visionary HealthWare’s solution improves clinical outcomes by providing more comprehensive and timely information for clinical decision-making, and decreases time spent on administrative activities that can better be spent on direct patient care,” adds Jason Patchen, CEO of Visionary HealthWare. “All of these improvements contribute to a safer care environment for patients.”

About Visionary HealthWare
Visionary HealthWare (VHW) is a provider-based healthcare information technology company with operations in Florida, California and Maryland. VHW delivers innovative, effective, easy-to-use, services and software solutions designed to manage patient, clinical and financial information at all levels while helping practices prove “meaningful use”. Solutions include fully integrated Electronic Health Records, Practice Management, Laboratory Information Systems, Revenue Cycle Management, Document Management, e-Prescribing, and services for any size practice. VHW reaches over 60,000 providers nationwide and was ranked by Healthcare Informatics Magazine in the top 100 Healthcare Information Technology companies in America. VHW brands include Visionary Medical Systems, Antek HealthWare, Soft-Aid, USMD, and Alteer Corporation. Visionary HealthWare (www.visionaryhealthware.com). Visionary HealthWare is a subsidiary of CompuGroup Medical U.S.

About CompuGroup Medical

CompuGroup Medical is one of the leading e-health companies worldwide. Its software products, designed to support all medical and organizational activities in doctors’ offices and hospitals, its information services for all parties involved in the healthcare system and its web-based personal health records, contribute towards safer and more efficient healthcare.

The services of CompuGroup Medical are based on its unique customer base of around 370,000 doctors, dentists, hospitals and networks as well as other service providers. CompuGroup Medical is the e-Health company with one of the biggest coverage among e-health service providers worldwide. The company operates in 14 European countries as well as in Malaysia, Saudi Arabia, South Africa and in the USA and currently employs around 3,000 people.

ABOUT CCHIT
The Certification Commission for Health Information Technology (CCHIT®) is an independent, 501(c)3 nonprofit organization with the public mission of accelerating the adoption of robust, interoperable health information technology. The Commission has been certifying electronic health record technology since 2006 and is recognized by the Office of the National Coordinator for Health Information Technology (ONC), U.S. Department of Health and Human Services (HHS) as an Authorized Testing and Certification Body (ONC-ATCB). More information on CCHIT, CCHIT Certified® products and HHS certified electronic health record technology is available at http://cchit.org and http://ehrdecisions.com. 

“CCHIT®” and “CCHIT Certified®” are registered trademarks of the Certification Commission for Health Information Technology.

Filed Under: Facilities And Providers

Bay Area Foot & Laser Podiatry Group Receives FDA Approval for Laser Procedure

Posted on October 28, 2010 Written by Annalyn Frame

SOURCE: Bay Area Foot and Laser Podiatry Group

WALNUT CREEK, CA–(Marketwire – October 28, 2010) –  Dr. Mark Wolpa, founder of the Bay Area Foot & Laser Podiatry Group, is proud to announce that the PinPointe laser has received official FDA clearance for the treatment of toenail fungus. PinPointe™ is the first and only laser to receive this coveted FDA clearance specifically for treating toenail fungus, an embarrassing infection that causes a thickening and yellowing of the toenails. It is estimated that about 10 percent — or nearly 35 million adults in the United States alone have this embarrassing condition.

The PinPointe™ FootLaser™ is the only laser that has been clinically proven and has passed the rigorous testing by the FDA to receive clearance. Dr. Wolpa has successfully treated over 1600 patients and has seen dramatic results. “After many years of not having a successful way to treat my patients suffering with toenail fungus, I am thrilled to see such positive results using this leading edge laser technology,” says Dr. Wolpa.

About Bay Area Foot & Laser Podiatry Group

The Bay Area Foot & Laser Podiatry Group’s Dr. Mark Wolpa is Board Certified by the American Board of Podiatric Surgery and has been in practice in the Bay Area for over 30 years. He was the Chief of Podiatry at Alta Bates-Summit Hospital in Berkeley for the past 10 years and has authored articles, books, and appeared on radio and television programs discussing foot problems.

He has offices in Berkeley, Walnut Creek, Santa Rosa, and Marin. For more information about Dr. Wolpa and The PinPointe FootLaser visit www.BayAreaFootandLaser.com

Contact:
Lisa Patino
For the Bay Area Foot & Laser Podiatry Group
510-849-3800
[email protected]

Click here to see all recent news from this company

Filed Under: Facilities And Providers

XTend Medical Corporation (XMDC) Set to Launch New Website

Posted on October 28, 2010 Written by Annalyn Frame

SOURCE: XTend Medical Corporation

SUN VALLEY, CA–(Marketwire – October 28, 2010) –  XTend Medical, (PINKSHEETS: XMDC), a company that specializes in delivering life changing medical technology to healthcare organizations globally, announced today that the company will soon be launching a new website within the next few weeks. The company issued the following statement:

“XTend has contracted with GoDaddy’s website design professionals to build a new website for the company. After the issues they ran into last year using an independent web developer, the need for professionally trained web engineers and graphics persons was instrumental in their decision to have the GoDaddy Team of experts build out the site. The information has been sent to the website team and we’re awaiting the Beta version so we can make any last minute changes before launching the new site. We expect to have the site live within the next week or so and feel this new site will properly represent the company in cyberspace.”

In other news, the company is working to position itself so the auditing process for becoming a fully reporting company is met and the company is strategically positioned to attract the proper investment structure to commercialize the BioHarp. Any changes made to the company will be done in accordance with corporate counsel’s advice and with the future of the company and its shareholders securely in the minds of management. 

About XTend Medical
XTend Medical is a company that specializes in the sales, manufacturing and distribution of the latest in medical devices and telemedicine solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their recent acquisition of the BioHarp medical device will assist the company in becoming known as a leader in the healthcare sector globally. For further information, please contact them at [email protected] or visit their website at www.bioharpunius.com

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.

CONTACT
XTend Medical
[email protected]

Filed Under: Facilities And Providers

MWI Veterinary Supply, Inc. Announces Its Fiscal Year 2010 Earnings Release Date and Conference Call Information

Posted on October 28, 2010 Written by Annalyn Frame

SOURCE: MWI Veterinary Supply

MERIDIAN, ID–(Marketwire – October 28, 2010) –  MWI Veterinary Supply, Inc. (NASDAQ: MWIV) announced today that the Company will release financial results for its fourth quarter and fiscal year ended September 30, 2010 and provide its business outlook for its fiscal year ending September 30, 2011 on Thursday, November 4, 2010. MWI will host a conference call the same day at 11 am eastern time to discuss these results and its business outlook.

For calls within the United States you can access the conference call by dialing (877) 638-4561 and international callers can access the conference by dialing (720) 545-0002. Participants will be required to register their name and company affiliation for the conference call. The conference call will also be carried live on the Company’s web site at www.mwivet.com. Audio replay will be made available through November 18, 2010 by calling (800) 642-1687 for calls within the United States or (706) 645-9291 for international calls using the passcode 19698332 or by accessing the Company’s web site.

About MWI Veterinary Supply, Inc.
MWI Veterinary Supply, Inc. is a leading distributor of animal health products to veterinarians across the United States and United Kingdom. The products MWI sells include pharmaceuticals, vaccines, parasiticides, diagnostics, capital equipment, supplies, veterinary pet food and nutritional products. We market these products to veterinarians in both the companion animal and production animal markets.

Contact:
Mary Pat Thompson
Senior Vice President of Finance and Administration, and Chief Financial Officer
(208) 955-8930
Email Contact

Filed Under: Facilities And Providers

GetWellNetwork Chief Outcomes Officer Speaks on "Pay for Performance" at South Florida Healthcare Trade Faire & Regional Conference

Posted on October 28, 2010 Written by Annalyn Frame

SOURCE: GetWellNetwork

MIAMI, FL–(Marketwire – October 28, 2010) –  GetWellNetwork, Inc. today announced that David Wright, the Company’s chief outcomes officer, will address the South Florida Healthcare Trade Faire & Regional Conference, sponsored by HIMSS South Florida Chapter on how hospitals can strengthen their position in the “Pay for Performance” provisions of the new health care reform law (1). The fall regional health information symposium is being held today at the Signature Grand hotel.

Mr. Wright is an expert on patient-centered care models and uniquely qualified to help hospitals prepare for “Pay for Performance” provisions by targeting performance areas such as clinical care processes; health outcomes; patient safety; patient experience and satisfaction; and IT investment and use.

Mr. Wright will also explain how leading hospitals and health systems are using interactive patient care technology to achieve evidence-based outcomes and to improve hospital performance in the areas that directly impact “Pay for Performance” provisions.

“Forums such as the regional HIMSS conference provide an opportunity for clinicians and hospitals to engage in important discussions about policy changes that directly impact the patient care factors of the Pay for Performance provision,” said David Wright, chief outcomes officer, GetWellNetwork, Inc. “To ensure continuation of current reimbursement rates from the Federal government, all hospitals should be developing strategic plans that not only elevate patient safety and care but deliver operational efficiencies through the use of technology solutions.”

About GetWellNetwork
GetWellNetwork, Inc. uses the bedside TV to entertain, educate and empower hospital patients and caregivers to be more actively engaged in their care. This patient-centered approach improves both satisfaction and outcomes for patients and hospitals. GetWellNetwork is the leader in interactive patient care solutions and exclusively endorsed by the American Hospital Association. More information about GetWellNetwork can be found at www.GetWellNetwork.com.

(1) More information about CMS’ Value-Based Purchasing Program is available at http://www.cms.gov/AcuteInpatientPPS/downloads/HospitalVBPPlanRTCFINALSUBMITTED2007.pdf and http://www.cms.gov/QualityInitiativesGenInfo/downloads/VBPRoadmap_OEA_1-16_508.pdf

Media Contact:
Jenny Song
(703) 338-8434
Email Contact

Filed Under: Facilities And Providers

Radient Pharmaceuticals Launches New Investor Relations Video Channel

Posted on October 28, 2010 Written by Annalyn Frame

SOURCE: Radient Pharmaceuticals Corporation

TUSTIN, CA–(Marketwire – October 28, 2010) –  Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today the launch of the RPC Investor Channel — a new and innovative video website developed to enhance communications and corporate access for key audiences interested in RPC.

Through this dynamic mode of communication everyone from existing and prospective shareholders, the broad investment community at large, healthcare professionals and their patients can learn about Radient Pharmaceuticals and its portfolio of in vitro diagnostic (IVD) cancer tests and products. In addition, financial Advisors have the ability to distribute RPC Investor Channel content to clients and securely track consumption when campaigning to clients about RPC, enhancing Radient’s ability to scale consideration into new investor communities.

The site also features videos communicating RPC’s business model, target markets and international distribution, sales and growth strategy; RPC as an investment opportunity; updates and progress on RPC’s portfolio of cancer diagnostic products, including its FDA-approved Onko-Sure® IVD cancer test kit; and educational information specifically targeted towards patients, physicians and the healthcare community in general.

According to Mr. Douglas Maclellan, Executive Chairman and CEO of RPC, “As a publicly-traded Company, superior investor communications is of utmost importance to our executive management team. With the launch of RPC’s new Investor Relations Video Channel, we are expanding our traditional lines of communication to now include a multi-media platform that offers added flexibility, reach and the ability to disseminate relevant Company information in a ‘high-touch’. We are very excited to offer this service to our valued stakeholders.”

Videos are accessible and viewable through personal computers and handsets with a 3G connection by visiting http://investorchannel.radient-pharma.com. For additional information on Radient Pharmaceuticals and its portfolio of IVD cancer products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its Onko-Sure® In Vitro Diagnostic cancer test. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve patient outcomes. Radient Pharmaceutical’s current Onko-Sure® cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.Radient-Pharma.com.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Radient Pharma Contact:
Kristine Szarkowitz
Director-Investor Relations
Email Contact
(Tel) 206.310.5323

Click here to see all recent news from this company

Filed Under: Facilities And Providers

ExamWorks Group, Inc. Announces Pricing of Its Initial Public Offering

Posted on October 28, 2010 Written by Annalyn Frame

SOURCE: ExamWorks Group, Inc.

Common Stock Will Begin Trading on NYSE

ATLANTA, GA–(Marketwire – October 28, 2010) –  ExamWorks Group, Inc. (NYSE: EXAM), a leading provider of independent medical examinations (IMEs), peer reviews, bill reviews and related services for the insurance and legal industries, today announced the pricing of its initial public offering of 10,300,000 shares of its common stock at a price to the public of $16.00 per share. Of the 10,300,000 shares being offered to the public 7,745,114 shares are being offered by ExamWorks Group and 2,554,886 shares are being offered by selling stockholders. In addition, the underwriters have a 30-day option to purchase up to an additional 1,545,000 shares from the company.

ExamWorks Group’s common stock is expected to begin trading on the New York Stock Exchange under the symbol “EXAM” on October 28, 2010. To celebrate the company’s IPO and NYSE listing, ExamWorks Group, led by Richard E. Perlman, Executive Chairman and James K. Price, Chief Executive Officer, will ring the NYSE Opening Bell.

Goldman, Sachs & Co., Credit Suisse and Barclays Capital are joint book runners for the offering. William Blair & Company and Needham & Company LLC are acting as co-managers of the offering.

A registration statement relating to this offering was declared effective by the U.S. Securities and Exchange Commission on October 27, 2010. This offering is being made solely by means of a prospectus. A copy of the prospectus relating to this offering may be obtained from Goldman, Sachs & Co., 200 West Street, New York, New York 10282-2198, Attention: Prospectus Department, telephone (866) 471-2526; or from Credit Suisse Securities (USA) LLC, 11 Madison Avenue, New York, New York 10010, Attention: Prospectus Department, telephone (800) 221-1037.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About ExamWorks Group

ExamWorks Group, Inc. is a leading provider of independent medical examinations, or “IMEs”, peer and bill reviews, and related services, which include, litigation support services, administrative support services, and medical record retrieval services, and which we collectively refer to as IME services or the IME industry. We provide these IME services through our medical panel of independently contracted, credentialed physicians and other medical providers. Our clients include property and casualty insurance carriers, law firms, third-party claim administrators and government agencies that use independent services to confirm the veracity of claims by sick or injured individuals for workers’ compensation, automotive, personal injury liability and disability insurance coverage. We help our clients manage costs and enhance their risk management processes by verifying the validity, nature, cause and extent of claims, identifying fraud and providing fast, efficient and quality IME services. ExamWorks is focused on providing carriers with the national presence they need and with the local service that they have come to expect.

ExamWorks Group, Inc.
J. Miguel Fernandez de Castro
404-952-2400
Senior Vice President and Chief Financial Officer
[email protected]

Filed Under: Facilities And Providers

Sun Healthcare Group, Inc. Reports Third-Quarter Operating Results; Meets Analyst Expectations for Diluted Earnings per Share From Continuing…

Posted on October 27, 2010 Written by Annalyn Frame

SOURCE: Sun Healthcare Group, Inc.

IRVINE, CA–(Marketwire – October 27, 2010) – Sun Healthcare Group, Inc. (NASDAQ: SUNH) today
announced its operating results for the third quarter ended Sept. 30, 2010.

Normalized results for the third-quarter period ended Sept. 30, 2010:

--  consolidated revenues rose 1.1 percent to $476.0 million, compared to
    the same period in 2009;
    --  increased patient acuity resulted in solid reimbursement rates in
        quarter;
    --  hospice and rehabilitation therapy businesses showed revenue
        growth;
--  consolidated adjusted EBITDAR was $60.6 million and adjusted EBITDAR
    margin was 12.7 percent;
--  diluted earnings per share from continuing operations (after giving
    effect to the issuance of 30.76 million shares in the Company's equity
    offering) were $0.18;
--  diluted earnings per share from continuing operations would have been
    $0.23 based on shares outstanding prior to the issuance of
    30.76 million shares in the Company's August equity offering and before
    the application of the offering proceeds, which equals the mean of
    diluted earnings per share from continuing operations estimates for the
    third quarter from analysts who publish on First Call;
--  free cash flow was $21.3 million for the quarter; and
--  results have been normalized to exclude the impact of $4.7 million for
    transaction costs associated with the separation transaction described
    in further detail below in this press release.

Commenting on the Company’s third-quarter results, Richard K. Matros, Sun’s
chairman and chief executive officer, remarked, “Although our sector
continues to experience a tough operating environment, I am pleased with
our ability to turn in a solid quarter, with normalized adjusted EBITDAR
comparable to that achieved in last year’s third quarter.”

Matros added, “With respect to the previously announced separation of our
operating assets and real estate assets, we have completed debt financings
for both the operating company and the real estate company and have
received all necessary regulatory approvals. We look forward to our
stockholders’ meeting on November 4 and to completing the separation
transaction on November 15.”

Segment Updates

On a year-over-year basis for the quarter, revenue growth in Sun’s
inpatient services business totaled $3.8 million, or 0.9 percent, due
principally to revenue growth in its hospice business, SolAmor. SolAmor’s
revenues increased from $7.2 million to $11.3 million, due to census
expansion derived from same store census growth as well as an October 2009
acquisition. SolAmor contributed $2.5 million of adjusted EBITDA for the
quarter and an adjusted EBITDA margin of 22.3 percent. In the quarter,
revenues from SunBridge’s nursing center operations were flat on a
year-over-year basis due to declines in nursing center customer base and
the lingering effect of the October 2009 Medicare rate reduction, partially
offset by acuity-driven rate growth. SunBridge’s acuity growth was
evidenced by its Medicare Rehab RUG use of 91.2 percent, which was up 250
basis points year-over-year, and its Medicare REX utilization of 44.4
percent, which was up 240 basis points year-over-year. On an overall basis,
the inpatient services business reported adjusted EBITDAR of $69.0 million
for the quarter, with an adjusted EBITDAR margin of 16.3 percent.

SunDance, Sun’s rehabilitation therapy services business, experienced
revenue growth of $6.8 million, or 15.0 percent, in the quarter on the
strength of growth in revenue per contract of 8.5 percent and growth in
total non-affiliated contracts of 4.9 percent. Given the strong revenue
results, adjusted EBITDA margin also expanded in the quarter by 190 basis
points, producing an 8.0 percent adjusted EBITDA margin.

Industry demand for temporary medical staffing continues to be down as a
result of the slow economy. Accordingly, revenues from CareerStaff, Sun’s
medical staffing services business, were down compared to revenues in the
same quarter of 2009, resulting in adjusted EBITDA margin of 6.2 percent
for the quarter.

Bill Mathies, president and chief operating officer of SunBridge and chief
operating officer over Sun’s operating subsidiaries, commented on the
segment results: “Our early assessment of the implementation of RUG IV, the
changes to concurrent therapy and the elimination of the look-back period
is that they are neutral on a consolidated basis, with the market basket
rate increases we received on October 1 being accretive to our results. Our
experience to date affirms our positive view of the opportunity that these
changes in the reimbursement system afford us, given our strategy of
serving
clinically-complex patients, as well as the savings the changes will
achieve for the Medicare program. Continuing our focus on short-stay
high-acuity patients requires the expansion of our portfolio of Rehab
Recovery Suites® (RRS). At the end of the quarter, our RRS centers
aggregated 1,647 beds, an increase of 44.6 percent over the number of RRS
beds in service in the third quarter of 2009. Our rehabilitation business
achieved solid revenue growth in the quarter, driven by the increase in
contracts as well as the increase in revenue per contract. Our hospice
business continues to perform consistently with our expectations. Our
medical staffing business, as noted, continued to show a decline in
revenues, EBITDA, and margins but the revenue decline has slowed and
billable hours were actually up for the quarter.”

Conference Call

As previously announced, investors and the general public are invited to
listen to a conference call with Sun’s senior management on Thursday, Oct.
28, 2010, at 10 a.m. Pacific / 1 p.m. Eastern to discuss the Company’s
earnings for the third quarter of 2010.

To listen to the conference call, dial (888) 437-9364 and refer to Sun
Healthcare Group. A recording of the call will be available from 4 p.m.
Eastern on Oct. 28, 2010, until midnight Eastern on Nov. 28, 2010, by
calling (888) 203-1112 and using access code 4118106.

About Sun Healthcare Group, Inc.

Sun Healthcare Group, Inc.’s (NASDAQ: SUNH) subsidiaries provide nursing,
rehabilitative and related specialty healthcare services principally to the
senior population in the United States. Sun’s core business is providing,
through its subsidiaries, inpatient services, primarily through 166 skilled
nursing centers, 16 combined skilled nursing, assisted and independent
living centers, 10 assisted living centers, two independent living centers
and eight mental health centers. On a consolidated basis, Sun has annual
revenues of $1.9 billion and approximately 30,000 employees in 46 states.
At Oct. 1, 2010, SunBridge centers had 23,189 licensed beds located in 25
states, of which 22,407 were available for occupancy. Sun also provides
rehabilitation therapy services to affiliated and non-affiliated centers
through its SunDance subsidiary, medical staffing services through its
CareerStaff Unlimited subsidiary and hospice services through its SolAmor
subsidiary.

In May 2010, Sun announced a plan to restructure its business by separating
its real estate assets and its operating assets into two separate,
publicly-traded companies (the “Separation”), subject to the approval of
stockholders and other conditions. The Separation will be accomplished by
distributing to stockholders the stock of SHG Services, Inc., a Sun
subsidiary that will own and operate the operating subsidiaries.
Substantially all of Sun’s owned real estate assets will continue to be
owned by Sun, which will, after the Separation, merge into its subsidiary,
Sabra Health Care REIT, Inc. Following this merger, SHG Services, Inc. will
change its name to Sun Healthcare Group, Inc. The common stock of both
companies is expected to trade on the NASDAQ Global Select Market. The
Separation is expected to be completed on Nov. 15, 2010.

Forward-looking Statement

Statements made in this release that are not historical facts are
“forward-looking” statements (as defined in the Private Securities
Litigation Reform Act of 1995) that involve risks and uncertainties and are
subject to change at any time. These forward-looking statements may
include, but are not limited to, statements containing words such as
“anticipate,” “believe,” “plan,” “estimate,” “expect,” “hope,” “intend,”
“may” and similar expressions. Forward-looking statements in this release
include all statements regarding the Company’s expected future financial
position and results of operations, business strategy, the impact of
reductions in reimbursements and other changes in government reimbursement
programs, the timing and impact of the Separation and transactions related
thereto, growth opportunities and plans and objectives of management for
future operations. Factors that could cause actual results to differ are
identified in the public filings made by the Company with the Securities
and Exchange Commission and include changes in Medicare and Medicaid
reimbursements; the impact that any healthcare reform legislation will have
on the Company’s business; the ability to maintain the occupancy rates and
payor mix at the Company’s healthcare centers; potential liability for
losses not covered by, or in excess of, the insurance; the effects of
government regulations and investigations; the significant amount of the
Company’s indebtedness; covenants in debt agreements that may restrict the
Company’s activities, including the Company’s ability to make acquisitions,
incur more indebtedness and refinance indebtedness on favorable terms;
Sun’s ability to accomplish the Separation and the transactions related
thereto; the impact of the current economic downturn on the business;
increasing labor costs and the shortage of qualified healthcare personnel;
and the Company’s ability to receive increases in reimbursement rates from
government payors to cover increased costs. More information on factors
that could affect the Company’s business and financial results are included
in Sun’s public filings made with the Securities and Exchange Commission,
including its Annual Report on Forms 10-K and Quarterly Reports on Form
10-Q, copies of which are available on Sun’s web site, www.sunh.com. There
may be additional risks of which the Company is presently unaware or that
it currently deems immaterial.

The forward-looking statements involve known and unknown risks,
uncertainties and other factors that are, in some cases, beyond the
Company’s control. Sun cautions investors that any forward-looking
statements made by Sun are not guarantees of future performance and are
only made as of the date of this release. Sun disclaims any obligation to
update any such factors or to announce publicly the results of any
revisions to any of the forward-looking statements to reflect future events
or developments.

Adjusted EBITDA, adjusted EBITDAR and free cash flow, as used in this press
release and in the accompanying tables, which are non-GAAP financial
measures, are each reconciled to their respective GAAP-recognized financial
measures in the accompanying tables. In addition, the normalizing
adjustments to adjusted EBITDAR and earnings per share as discussed in this
press release and shown, together with normalizing adjustments to other
financial measures, in the accompanying tables, are non-GAAP adjustments,
and are reconciled to GAAP financial measures in the accompanying tables.

Additional Information

In connection with the Separation, SHG Services, Inc. has filed with the
SEC a Registration Statement on Form S-1 and Sabra Health Care REIT, Inc.
has filed with the SEC a Registration Statement on Form S-4, each
containing an identical proxy statement/prospectus for the special meeting
of stockholders to be held on Nov. 4, 2010. The definitive proxy
statement/prospectus was mailed to Sun stockholders on or about Oct. 4,
2010. Before making any voting or investment decision, Sun stockholders and
investors are urged to read the proxy statement/prospectus and other
documents filed with the SEC carefully and in their entirety because they
contain important information about the proposed transactions.
Stockholders will be able to obtain these documents free of charge at the
SEC’s website at www.sec.gov. In addition, investors and stockholders of
Sun may obtain free copies of the documents filed with the SEC by
contacting Sun’s investor relations department at (505) 468-2341 (TDD
users, please call (505) 468-4458) or by sending a written request to
Investor Relations, Sun Healthcare Group, Inc. 101 Sun Avenue N.E.,
Albuquerque, N.M. 87109. Investors and stockholders may also obtain a copy
of these documents by requesting them in writing from Sun’s proxy
solicitation agent, Innisfree M&A, at 501 Madison Avenue, New York, NY
10022, or by telephone at (212) 750-5833.

Sun and its directors and executive officers and other members of its
management and employees may be deemed participants in the solicitation of
proxies from the stockholders of Sun in connection with the transactions
described in this release. Information about the directors and executive
officers of Sun and their ownership of shares of Sun common stock are set
forth in the Annual Report on Form 10-K for the year ended Dec. 31, 2009,
filed with the SEC on March 5, 2010, and in the definitive proxy
statement/prospectus for the special meeting of stockholders filed with the
SEC on Sept. 29, 2010. These documents may be obtained free of charge from
the sources indicated above. Additional information regarding the interests
of these participants is also included in the definitive proxy
statement/prospectus for the special meeting.


                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                       KEY INCOME STATEMENT FIGURES
                               CONSOLIDATED
                  (in thousands, except per share data)


                                           For the            For the
                                         Three Months       Three Months
                                             Ended              Ended
                                         September 30,      September 30,
                                             2010               2009
                                       ----------------   ----------------

Revenue                                $        475,997   $        470,644

Depreciation and amortization                    12,733             11,457

Interest expense, net                            10,614             12,231

Pre-tax income                                   13,557             17,759

Income tax expense                                5,559              7,220

Income from continuing operations                 7,998             10,539

Loss from discontinued operations                  (442)              (881)
                                       ----------------   ----------------

Net income                             $          7,556   $          9,658
                                       ================   ================


Diluted earnings per share             $           0.13   $           0.22
                                       ================   ================


Adjusted EBITDAR                       $         55,858   $         60,509
Margin - Adjusted EBITDAR                          11.7%              12.9%

Adjusted EBITDAR normalized            $         60,605   $         60,509
Margin - Adjusted EBITDAR normalized               12.7%              12.9%


Adjusted EBITDA                        $         36,904   $         42,319
Margin - Adjusted EBITDA                            7.8%               9.0%

Adjusted EBITDA normalized             $         41,651   $         42,319
Margin - Adjusted EBITDA normalized                 8.8%               9.0%


Pre-tax income continuing operations -
 normalized                            $         18,304   $         18,631

Income tax expense - normalized        $          7,505   $          7,578

Income from continuing operations -
 normalized                            $         10,799   $         11,053

Diluted earnings per share from
 continuing operations - normalized    $           0.18   $           0.25

Net income - normalized                $         10,357   $         10,172

Diluted earnings per share -
 normalized                            $           0.17   $           0.23


See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
"Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

See normalizing adjustments in the table "Normalizing Adjustments -
Quarter Comparison."





                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                       KEY INCOME STATEMENT FIGURES
                               CONSOLIDATED
                  (in thousands, except per share data)


                                           For the            For the
                                         Nine Months        Nine Months
                                             Ended              Ended
                                         September 30,      September 30,
                                             2010               2009
                                       ----------------   ----------------

Revenue                                $      1,423,443   $      1,406,949

Depreciation and amortization                    37,732             33,329

Interest expense, net                            34,366             37,422

Pre-tax income                                   49,205             56,066

Income tax expense                               19,990             22,795

Income from continuing operations                29,215             33,271

Loss from discontinued operations                (1,488)            (3,275)
                                       ----------------   ----------------

Net income                             $         27,727   $         29,996
                                       ================   ================


Diluted earnings per share             $           0.55   $           0.68
                                       ================   ================


Adjusted EBITDAR                       $        177,609   $        182,485
Margin - Adjusted EBITDAR                          12.5%              13.0%

Adjusted EBITDAR normalized            $        184,604   $        186,785
Margin - Adjusted EBITDAR normalized               13.0%              13.3%


Adjusted EBITDA                        $        121,303   $        127,730
Margin - Adjusted EBITDA                            8.5%               9.1%

Adjusted EBITDA normalized             $        128,298   $        132,030
Margin - Adjusted EBITDA normalized                 9.0%               9.4%


Pre-tax income continuing operations -
 normalized                            $         56,200   $         61,238

Income tax expense - normalized        $         22,858   $         24,916

Income from continuing operations -
 normalized                            $         33,342   $         36,322

Diluted earnings per share from
 continuing operations - normalized    $           0.66   $           0.83

Net income - normalized                $         31,854   $         33,395

Diluted earnings per share -
 normalized                            $           0.63   $           0.76


See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
"Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

See normalizing adjustments in the table "Normalizing Adjustments -
Quarter Comparison."





                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                        CONSOLIDATED BALANCE SHEETS
                    (in thousands, except share data)



                                         September 30,      December 31,
                                             2010               2009
                                       ----------------   ----------------
                                          (unaudited)        (unaudited)
                ASSETS

Current assets:
  Cash and cash equivalents            $        138,350   $        104,483
  Restricted cash                                21,961             24,034
  Accounts receivable, net                      216,391            220,319
  Prepaid expenses and other assets              15,093             21,757
  Deferred tax assets                            71,940             68,415
                                       ----------------   ----------------
    Total current assets                        463,735            439,008

Property and equipment, net                     622,355            622,682
Intangible assets, net                           51,428             53,931
Goodwill                                        338,364            338,296
Restricted cash, non-current                        350              3,317
Deferred tax assets                              89,818            108,999
Other assets                                      5,157              4,961
                                       ----------------   ---------------- 
    Total assets                       $      1,571,207   $      1,571,194
                                       ================   ================


 LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
  Accounts payable                     $         47,799   $         57,109
  Accrued compensation and benefits              60,898             58,953
  Accrued self-insurance obligations,
   current                                       45,610             45,661
  Income taxes payable                            1,605                  -
  Other accrued liabilities                      58,234             55,265
  Current portion of long-term debt and
   capital lease obligations                     39,796             46,416
                                       ----------------   ----------------
  Total current liabilities                     253,942            263,404

Accrued self-insurance obligations,
 net of current portion                         127,040            121,948
Long-term debt and capital lease
 obligations, net of current portion            410,145            654,132
Unfavorable lease obligations, net               10,518             12,663
Other long-term liabilities                      60,016             69,983
                                       ----------------   ----------------
  Total liabilities                             861,661          1,122,130


Stockholders' equity:
  Preferred stock of $.01 par value,
   authorized 10,000,000 shares, no
   shares were issued and outstanding
   as of September 30, 2010 and
   December 31, 2009                                  -                  -
  Common stock of $.01 par value,
   authorized 125,000,000 shares,
   74,788,448 and 43,764,240 shares
   issued and outstanding as of
   September 30, 2010 and
   December 31, 2009, respectively                  748                438
  Additional paid-in capital                    885,083            655,667
  Accumulated deficit                          (176,285)          (204,012)
  Accumulated other comprehensive loss,
   net                                                -             (3,029)
                                       ----------------   ----------------
                                                709,546            449,064
                                       ----------------   ----------------
    Total liabilities and
     stockholders' equity              $      1,571,207   $      1,571,194
                                       ================   ================





                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                      CONSOLIDATED INCOME STATEMENTS
                  (in thousands, except per share data)


                                           For the            For the
                                         Three Months       Three Months
                                             Ended              Ended
                                         September 30,      September 30,
                                             2010               2009
                                       ----------------   ----------------
                                         (unaudited)        (unaudited)

Total net revenues                     $        475,997   $        470,644
                                       ----------------   ----------------
Costs and expenses:
  Operating salaries and benefits               270,052            265,597
  Self-insurance for workers'
   compensation and general and
   professional liability insurance              14,621             14,162
  Operating administrative costs                 13,343             12,462
  Other operating costs                          98,089             97,015
  Center rent expense                            18,954             18,190
  General and administrative expenses            14,146             15,586
  Depreciation and amortization                  12,733             11,457
  Provision for losses on accounts
   receivable                                     5,141              5,313
  Interest, net of interest income of
   $59 and $106, respectively                    10,614             12,231
  Transaction costs                               4,747                  -
  Restructuring costs                                 -                872
                                       ----------------   ----------------
Total costs and expenses                        462,440            452,885
                                       ----------------   ----------------

Income before income taxes and
 discontinued operations                         13,557             17,759
Income tax expense                                5,559              7,220
                                       ----------------   ----------------
Income from continuing operations                 7,998             10,539
                                       ----------------   ----------------

Discontinued operations:
  Loss from discontinued operations,
   net of related taxes                            (442)              (862)
  Loss on disposal of discontinued
   operations, net of related taxes                   -                (19)
                                       ----------------   ----------------
Loss from discontinued operations, net             (442)              (881)
                                       ----------------   ----------------

Net income                             $          7,556   $          9,658
                                       ================   ================


Basic income per common and common
 equivalent share:
  Income from continuing operations    $           0.13   $           0.24
  Loss from discontinued operations,
   net                                                -              (0.02)
                                       ----------------   ----------------
Net income                             $           0.13   $           0.22
                                       ================   ================

Diluted income per common and common
 equivalent share:
  Income from continuing operations    $           0.13   $           0.24
  Loss from discontinued operations,
   net                                                -              (0.02)
                                       ----------------   ----------------
Net income                             $           0.13   $           0.22
                                       ================   ================

Weighted average number of common and
 common equivalent shares outstanding:
  Basic                                          59,516             43,923
  Diluted                                        59,538             44,015





                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                      CONSOLIDATED INCOME STATEMENTS
                  (in thousands, except per share data)


                                           For the            For the
                                         Nine Months        Nine Months
                                             Ended              Ended
                                         September 30,      September 30,
                                             2010               2009
                                       ----------------   ----------------
                                          (unaudited)       (unaudited)

Total net revenues                     $      1,423,443   $      1,406,949
                                       ----------------   ----------------
Costs and expenses:
  Operating salaries and benefits               804,302            789,744
  Self-insurance for workers'
   compensation and general and
   professional liability insurance              43,702             45,617
  Operating administrative costs                 38,932             38,231
  Other operating costs                         291,348            287,233
  Center rent expense                            56,306             54,755
  General and administrative expenses            44,570             48,057
  Depreciation and amortization                  37,732             33,329
  Provision for losses on accounts
   receivable                                    15,985             15,582
  Interest, net of interest income of
   $222 and $310, respectively                   34,366             37,422
  Transaction costs                               6,995                  -
  Loss on sale of assets, net                         -                 41
  Restructuring costs                                 -                872
                                       ----------------   ----------------
Total costs and expenses                      1,374,238          1,350,883
                                       ----------------   ----------------

Income before income taxes and
 discontinued operations                         49,205             56,066
Income tax expense                               19,990             22,795
                                       ----------------   ----------------
Income from continuing operations                29,215             33,271
                                       ----------------   ----------------

Discontinued operations:
  Loss from discontinued operations,
   net of related taxes                          (1,488)            (2,941)
  Loss on disposal of discontinued
   operations, net of related taxes                   -               (334)
                                       ----------------   ----------------
Loss from discontinued operations, net           (1,488)            (3,275)
                                       ----------------   ----------------

Net income                             $         27,727   $         29,996
                                       ================   ================


Basic income per common and common
 equivalent share:
  Income from continuing operations    $           0.58   $           0.76
  Loss from discontinued operations,
   net                                            (0.03)             (0.08)
                                       ----------------   ----------------
Net income                             $           0.55   $           0.68
                                       ================   ================

Diluted income per common and common
 equivalent share:
  Income from continuing operations    $           0.58   $           0.76
  Loss from discontinued operations,
   net                                            (0.03)             (0.08)
                                       ----------------   ----------------
Net Income                             $           0.55   $           0.68
                                       ================   ================

Weighted average number of common and
 common equivalent shares outstanding:
  Basic                                          50,184             43,807
  Diluted                                        50,251             43,926





                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                  CONSOLIDATED STATEMENTS OF CASH FLOWS
                              (in thousands)


                                           For the            For the
                                         Three Months       Three Months
                                             Ended              Ended
                                         September 30,      September 30,
                                             2010               2009
                                       ----------------   ----------------
                                         (unaudited)        (unaudited)

Cash flows from operating activities:
  Net income                           $          7,556   $          9,658
  Adjustments to reconcile net income
   to net cash provided by operating
   activities, including discontinued
   operations:
     Depreciation and amortization               12,736             11,460
     Amortization of favorable and
      unfavorable lease intangibles                (504)              (474)
     Provision for losses on accounts
      receivable                                  5,289              5,318
     Loss on sale of assets, including
      discontinued operations, net                    -                 31
     Stock-based compensation expense             1,661              1,476
     Deferred taxes                               3,286              5,500
  Changes in operating assets and
   liabilities, net of acquisitions:
     Accounts receivable                         (1,307)             1,079
     Restricted cash                              2,769               (710)
     Prepaid expenses and other assets            5,399                382
     Accounts payable                            (4,909)            (6,762)
     Accrued compensation and benefits           (2,117)             4,561
     Accrued self-insurance obligations             199                  4
     Income taxes payable                         1,267                  -
     Other accrued liabilities                    4,429              9,355
     Other long-term liabilities                   (676)            (1,004)
                                       ----------------   ----------------
       Net cash provided by operating
        activities                               35,078             39,874
                                       ----------------   ----------------

Cash flows from investing activities:
  Capital expenditures                          (13,774)           (16,456)
                                       ----------------   ----------------
     Net cash used for investing
      activities                                (13,774)           (16,456)
                                       ----------------   ----------------

Cash flows from financing activities:
  Borrowings of long-term debt                   20,500             20,822
  Principal repayments of long-term
   debt and capital lease obligations          (234,116)           (22,562)
  Proceeds from issuance of common
   stock                                        226,001                 55
  Deferred financing costs                       (2,312)                 -
                                       ----------------   ----------------
     Net cash used for financing
      activities                                 10,073             (1,685)
                                       ----------------   ----------------

Net (decrease) increase in cash and
 cash equivalents                                31,377             21,733
Cash and cash equivalents at beginning
 of period                                      106,973             95,672
                                       ----------------   ----------------
Cash and cash equivalents at end of
 period                                $        138,350   $        117,405
                                       ================   ================

Reconciliation of net cash provided by
 operating activities to free cash
 flow:

  Net cash provided by operating
   activities                          $         35,078   $         39,874
  Capital expenditures                          (13,774)           (16,456)
                                       ----------------   ----------------
    Free cash flow                     $         21,304   $         23,418
                                       ================   ================

Free cash flow is defined as net cash flow provided by operating activities
less cash used for capital expenditures.  Free cash flow is used by
management to evaluate discretionary cash flow potentially available for
debt service and other financing activities.





                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                  CONSOLIDATED STATEMENTS OF CASH FLOWS
                              (in thousands)


                                           For the            For the
                                         Nine Months        Nine Months
                                             Ended              Ended
                                         September 30,      September 30,
                                             2010               2009
                                       ----------------   ----------------
                                         (unaudited)        (unaudited)

Cash flows from operating activities:
  Net income                           $         27,727   $         29,996
  Adjustments to reconcile net income
   to net cash provided by operating
   activities, including discontinued
   operations:
     Depreciation and amortization               37,744             33,336
     Amortization of favorable and
      unfavorable lease intangibles              (1,452)            (1,350)
     Provision for losses on accounts
      receivable                                 16,428             15,599
     Loss on sale of assets, including
      discontinued operations, net                    -                607
     Stock-based compensation expense             4,748              4,385
     Deferred taxes                              14,976             18,019
  Changes in operating assets and
   liabilities, net of acquisitions:
     Accounts receivable                        (12,500)           (20,588)
     Restricted cash                              5,040              8,811
     Prepaid expenses and other assets            8,012                144
     Accounts payable                            (3,628)           (11,825)
     Accrued compensation and benefits            1,945              4,927
     Accrued self-insurance obligations           5,041              1,255
     Income taxes payable                         1,605                  -
     Other accrued liabilities                    4,442              8,530
     Other long-term liabilities                 (5,775)               177
                                       ----------------   ----------------
       Net cash provided by operating
        activities                              104,353             92,023
                                       ----------------   ----------------

Cash flows from investing activities:
  Capital expenditures                          (41,488)           (41,458)
  Purchase of leased real estate                      -             (3,275)
  Proceeds from sale of assets held for
   sale                                               -              2,174
                                       ----------------   ----------------
     Net cash used for investing
      activities                                (41,488)           (42,559)
                                       ----------------   ----------------

Cash flows from financing activities:
  Borrowings of long-term debt                   20,500             20,822
  Principal repayments of long-term
   debt and capital lease obligations          (271,093)           (44,249)
  Payment to non-controlling interest            (2,025)              (311)
  Distribution to non-controlling
   interest                                         (69)              (549)
  Proceeds from issuance of common
   stock                                        226,001                 75
  Deferred financing costs                       (2,312)                 -
                                       ----------------   ----------------
     Net cash used for financing
      activities                                (28,998)           (24,212)
                                       ----------------   ----------------

Net increase in cash and cash
 equivalents                                     33,867             25,252
Cash and cash equivalents at beginning
 of period                                      104,483             92,153
                                       ----------------   ----------------
Cash and cash equivalents at end of
 period                                $        138,350   $        117,405
                                       ================   ================

Reconciliation of net cash provided by
 operating activities to free cash
 flow:

  Net cash provided by operating
   activities                          $        104,353   $         92,023
  Capital expenditures                          (41,488)           (41,458)
                                       ----------------   ----------------
    Free cash flow                     $         62,865   $         50,565
                                       ================   ================

Free cash flow is defined as net cash flow provided by operating activities
less cash used for capital expenditures.  Free cash flow is used by
management to evaluate discretionary cash flow potentially available for
debt service and other financing activities.





                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

            RECONCILIATION OF NET INCOME TO EBITDA and EBITDAR
                              (in thousands)


                                           For the           For the
                                         Three Months      Three Months
                                             Ended            Ended
                                         September 30,    September 30,
                                             2010              2009
                                       ----------------   ----------------
                                          (unaudited)        (unaudited)

  Total net revenues                   $        475,997   $        470,644
                                       ----------------   ----------------

  Net income                           $          7,556   $          9,658
                                       ----------------   ----------------


    Income from continuing operations             7,998             10,539

    Income tax expense                            5,559              7,220

    Interest, net                                10,614             12,231

    Depreciation and amortization                12,733             11,457
                                       ----------------   ----------------

  EBITDA                               $         36,904   $         41,447

    Restructuring costs                               -                872
                                       ----------------   ----------------

  Adjusted EBITDA                      $         36,904   $         42,319


    Center rent expense                          18,954             18,190
                                       ----------------   ----------------

  Adjusted EBITDAR                     $         55,858   $         60,509
                                       ================   ================

EBITDA is defined as earnings before loss on discontinued operations,
income taxes, interest, net, depreciation and amortization.  Adjusted
EBITDA is defined as EBITDA before restructuring costs and loss on sale of
assets, net.  Adjusted EBITDAR is defined as Adjusted EBITDA before center
rent expense.  Adjusted EBITDA and Adjusted EBITDAR are used by management
to evaluate financial performance and resource allocation for each entity
within the operating units and for the Company as a whole.  Adjusted EBITDA
and Adjusted EBITDAR are commonly used as analytical indicators within the 
healthcare industry and also serve as measures of leverage capacity and
debt service ability.  Adjusted EBITDA and Adjusted EBITDAR should not be
considered as measures of financial performance under generally accepted
accounting principles.  As the items excluded from Adjusted EBITDA and
Adjusted EBITDAR are significant components in understanding and assessing
finance performance, Adjusted EBITDA and Adjusted EBITDAR should not be
considered in isolation or as alternatives to net income, cash flows
generated by or used in operating, investing or financing activities or
other financial statement data presented in the consolidated financial
statements as indicators of financial performance or liquidity.  Because
Adjusted EBITDA and Adjusted EBTIDAR are not measurements determined in
accordance with U.S. generally accepted accounting principles and are thus
susceptible to varying calculations.  Adjusted EBITDA and Adjusted EBITDAR
as presented may not be comparable to other similarly titled measures of
other companies.





                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

   RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA and ADJUSTED EBITDAR
                              (in thousands)


                                           For the            For the
                                         Nine Months        Nine Months
                                             Ended             Ended
                                         September 30,     September 30,
                                             2010               2009
                                       ----------------   ----------------
                                          (unaudited)        (unaudited)

  Total net revenues                   $      1,423,443   $      1,406,949
                                       ----------------   ----------------

  Net income                           $         27,727   $         29,996
                                       ----------------   ----------------


    Income from continuing operations            29,215             33,271

    Income tax expense                           19,990             22,795

    Interest, net                                34,366             37,422

    Depreciation and amortization                37,732             33,329
                                       ----------------   ----------------

  EBITDA                               $        121,303   $        126,817

    Loss on sale of assets, net                       -                 41

    Restructuring costs                               -                872
                                       ----------------   ----------------

  Adjusted EBITDA                      $        121,303   $        127,730


    Center rent expense                          56,306             54,755
                                       ----------------   ----------------

  Adjusted EBITDAR                     $        177,609   $        182,485
                                       ================   ================

EBITDA is defined as earnings before loss on discontinued operations,
income taxes, interest, net, depreciation and amortization.  Adjusted
EBITDA is defined as EBITDA before restructuring costs and loss on sale of
assets, net.  Adjusted EBITDAR is defined as Adjusted EBITDA before center
rent expense.  Adjusted EBITDA and Adjusted EBITDAR are used by management
to evaluate financial performance and resource allocation for each entity
within the operating units and for the Company as a whole.  Adjusted EBITDA
and Adjusted EBITDAR are commonly used as analytical indicators within the
healthcare industry and also serve as measures of leverage capacity and
debt service ability.  Adjusted EBITDA and Adjusted EBITDAR should not be
considered as measures of financial performance under generally accepted
accounting principles.  As the items excluded from Adjusted EBITDA and
Adjusted EBITDAR are significant components in understanding and assessing
finance performance, Adjusted EBITDA and Adjusted EBITDAR should not be
considered in isolation or as alternatives to net income, cash flows
generated by or used in operating, investing or financing activities or
other financial statement data presented in the consolidated financial
statements as indicators of financial performance or liquidity.  Because
Adjusted EBITDA and Adjusted EBTIDAR are not measurements determined in
accordance with U.S. generally accepted accounting principles and are thus
susceptible to varying calculations.  Adjusted EBITDA and Adjusted EBITDAR
as presented may not be comparable to other similarly titled measures of
other companies.








                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

  RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED
                        EBITDA and ADJUSTED EBITDAR
                             ($ in thousands)

              For the Three Months Ended September 30, 2010
                                (unaudited)



                          Rehabil-                    Elimination
                          itation   Medical                of
               Inpatient  Therapy   Staffing  Other &  Affiliated  Consoli-
                Services  Services  Services  Corp Seg  Revenue     dated
                --------  --------  --------  --------  --------  --------
Nonaffiliated
 revenue        $424,160  $ 30,342  $ 21,481  $     14  $      -  $475,997
Affiliated
 revenue               -    21,397       724         -   (22,121)        -
                --------  --------  --------  --------  --------  --------
  Total revenue $424,160  $ 51,739  $ 22,205  $     14  $(22,121) $475,997
                --------  --------  --------  --------  --------  --------

Income (loss)
 from
 continuing
 operations     $ 36,134  $  3,961  $  1,195  $(33,292) $      -  $  7,998
Income tax
 expense               -         -         -     5,559         -     5,559
Interest, net      2,570         -         -     8,044         -    10,614
Depreciation
 and
 amortization     11,630       173       181       749         -    12,733
                --------  --------  --------  --------  --------  --------

  EBITDA        $ 50,334  $  4,134  $  1,376  $(18,940) $      -  $ 36,904

Restructuring
 costs                 -         -         -         -         -         -
                --------  --------  --------  --------  --------  --------

  Adjusted
   EBITDA       $ 50,334  $  4,134  $  1,376  $(18,940) $      -  $ 36,904

Center rent
 expense          18,629       123       202         -         -    18,954
                --------  --------  --------  --------  --------  --------

  Adjusted
   EBITDAR      $ 68,963  $  4,257  $  1,578  $(18,940) $      -  $ 55,858
                ========  ========  ========  ========  ========  ========

  Normalized
   Adjusted
   EBITDA       $ 50,334  $  4,134  $  1,376  $(14,193) $      -  $ 41,651
  Normalized
   Adjusted
   EBITDAR      $ 68,963  $  4,257  $  1,578  $(14,193) $      -  $ 60,605


Adjusted EBITDA
         margin     11.9%      8.0%      6.2%                          7.8%
       Adjusted
 EBITDAR margin     16.3%      8.2%      7.1%                         11.7%
     Normalized
       Adjusted
  EBITDA margin     11.9%      8.0%      6.2%                          8.8%
     Normalized
       Adjusted
 EBITDAR margin     16.3%      8.2%      7.1%                         12.7%

   See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
   "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."
   See normalizing adjustments in the table "Normalizing Adjustments -
   Quarter Comparison."









                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

  RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED
                        EBITDA and ADJUSTED EBITDAR
                             ($ in thousands)

               For the Nine Months Ended September 30, 2010
                                (unaudited)



                       Rehabil-                     Elimination
                       itation   Medical                 of
           Inpatient   Therapy   Staffing   Other &  Affiliated
            Services   Services  Services  Corp Seg   Revenue  Consolidated
           ----------  --------  --------  ---------  --------  ----------
Nonaffiliated
 revenue   $1,265,980  $ 89,723  $ 67,712  $      28  $      -  $1,423,443
Affiliated
 revenue            -    63,584     1,364          -   (64,948)          -
           ----------  --------  --------  ---------  --------  ----------
  Total
   revenue $1,265,980  $153,307  $ 69,076  $      28  $(64,948) $1,423,443
           ----------  --------  --------  ---------  --------  ----------

Income
 (loss)
 from
 continuing
 opera-
 tions     $  113,355  $ 11,757  $  4,479  $(100,376) $      -  $   29,215
Income tax
 expense            -         -         -     19,990         -      19,990
Interest,
 net            8,087         -        (1)    26,280         -      34,366
Depreciation
 and
 amortization  34,320       484       543      2,385         -      37,732
           ----------  --------  --------  ---------  --------  ----------

  EBITDA   $  155,762  $ 12,241  $  5,021  $ (51,721) $      -  $  121,303

Loss on
 sale of
 assets,
 net                -         -         -          -         -           -
Restructuring
 costs              -         -         -          -         -           -
           ----------  --------  --------  ---------  --------  ----------

  Adjusted
   EBITDA  $  155,762  $ 12,241  $  5,021  $ (51,721) $      -  $  121,303

Center
 rent
 expense       55,326       364       616          -         -      56,306
           ----------  --------  --------  ---------  --------  ----------

  Adjusted
   EBITDAR $  211,088  $ 12,605  $  5,637  $ (51,721) $      -  $  177,609
           ==========  ========  ========  =========  ========  ==========

  Normalized
   Adjusted
   EBITDA  $  155,762  $ 12,241  $  5,021  $ (44,726) $      -  $  128,298
  Normalized
   Adjusted
   EBITDAR $  211,088  $ 12,605  $  5,637  $ (44,726) $      -  $  184,604


  Adjusted
    EBITDA
    margin       12.3%      8.0%      7.3%                             8.5%
  Adjusted
   EBITDAR
    margin       16.7%      8.2%      8.2%                            12.5%
Normalized
  Adjusted
    EBITDA
    margin       12.3%      8.0%      7.3%                             9.0%
Normalized
  Adjusted
   EBITDAR
    margin       16.7%      8.2%      8.2%                            13.0%

   See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
   "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."
   See normalizing adjustments in the table "Normalizing Adjustments -
   Quarter Comparison."










                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

  RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED
                        EBITDA and ADJUSTED EBITDAR
                             ($ in thousands)

              For the Three Months Ended September 30, 2009
                                (unaudited)


                          Rehabil-                    Elimination
                          itation   Medical                of
               Inpatient  Therapy   Staffing  Other &  Affiliated  Consoli-
                Services  Services  Services  Corp Seg  Revenue     dated
                --------  --------  --------  --------  --------  --------
Nonaffiliated
 revenue        $420,374  $ 26,394  $ 23,864  $     12  $      -  $470,644
Affiliated
 revenue               -    18,592       545         -   (19,137)        -
                --------  --------  --------  --------  --------  --------
  Total revenue $420,374  $ 44,986  $ 24,409  $     12  $(19,137) $470,644
                --------  --------  --------  --------  --------  --------

Income (loss)
 from
 continuing
 operations     $ 39,481  $  2,606  $  2,091  $(33,639) $      -  $ 10,539
Income tax
 expense               -         -         -     7,220         -     7,220
Interest, net      3,024         -        (1)    9,208         -    12,231
Depreciation
 and
 amortization     10,480       140       179       658         -    11,457
                --------  --------  --------  --------  --------  --------

  EBITDA        $ 52,985  $  2,746  $  2,269  $(16,553) $      -  $ 41,447

Restructuring
 costs                 -         -         -       872         -       872
                --------  --------  --------  --------  --------  --------

  Adjusted
   EBITDA       $ 52,985  $  2,746  $  2,269  $(15,681) $      -  $ 42,319
Center rent
 expense          17,848       119       223         -         -    18,190
                --------  --------  --------  --------  --------  --------

  Adjusted
   EBITDAR      $ 70,833  $  2,865  $  2,492  $(15,681) $      -  $ 60,509
                ========  ========  ========  ========  ========  ========

  Normalized
   Adjusted
   EBITDA       $ 52,985  $  2,746  $  2,269  $(15,681) $      -  $ 42,319
  Normalized
   Adjusted
   EBITDAR      $ 70,833  $  2,865  $  2,492  $(15,681) $      -  $ 60,509


Adjusted EBITDA
         margin     12.6%      6.1%      9.3%                          9.0%
       Adjusted
 EBITDAR margin     16.8%      6.4%     10.2%                         12.9%
     Normalized
       Adjusted
  EBITDA margin     12.6%      6.1%      9.3%                          9.0%
     Normalized
       Adjusted
 EBITDAR margin     16.8%      6.4%     10.2%                         12.9%

   See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
   "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."
   See normalizing adjustments in the table "Normalizing Adjustments -
   Quarter Comparison."







                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

  RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED
                        EBITDA and ADJUSTED EBITDAR
                             ($ in thousands)

               For the Nine Months Ended September 30, 2009
                                (unaudited)


                       Rehabil-                       Elimina-
                       itation   Medical              tion of
           Inpatient   Therapy   Staffing   Other &   Affiliated
            Services   Services  Services  Corp Seg    Revenue
Consolidated
           ----------  --------  --------  ---------  --------  ----------
Nonaffiliated
 revenue   $1,251,524  $ 78,063  $ 77,335  $      27  $      -  $1,406,949
Affiliated
 revenue            -    55,168     1,668          -   (56,836)          -
           ----------  --------  --------  ---------  --------  ----------
  Total
   revenue $1,251,524  $133,231  $ 79,003  $      27  $(56,836) $1,406,949
           ----------  --------  --------  ---------  --------  ----------

Income
 (loss)
 from
 continuing
 opera-
 tions     $  120,395  $  8,572  $  6,401  $(102,097) $      -  $   33,271
Income tax
 expense            -         -         -     22,795         -      22,795
Interest,
 net            9,345        (2)       (1)    28,080         -      37,422
Depreciation
 and
 amortization  30,323       399       601      2,006         -      33,329
           ----------  --------  --------  ---------  --------  ----------

  EBITDA   $  160,063  $  8,969  $  7,001  $ (49,216) $      -  $  126,817

Loss on sale
 of assets,
 net                7        34         -          -         -          41
Restructuring
 costs              -         -         -        872         -         872
           ----------  --------  --------  ---------  --------  ----------

  Adjusted
   EBITDA  $  160,070  $  9,003  $  7,001  $ (48,344) $      -  $  127,730
Center
 rent
 expense       53,707       348       700          -         -      54,755
           ----------  --------  --------  ---------  --------  ----------

  Adjusted
   EBITDAR $  213,777  $  9,351  $  7,701  $ (48,344) $      -  $  182,485
           ==========  ========  ========  =========  ========  ==========

  Normalized
   Adjusted
   EBITDA  $  164,370  $  9,003  $  7,001  $ (48,344) $      -  $  132,030
  Normalized
   Adjusted
   EBITDAR $  218,077  $  9,351  $  7,701  $ (48,344) $      -  $  186,785


  Adjusted
    EBITDA
    margin       12.8%      6.8%      8.9%                             9.1%
  Adjusted
   EBITDAR
    margin       17.1%      7.0%      9.7%                            13.0%
Normalized
  Adjusted
    EBITDA
    margin       13.1%      6.8%      8.9%                             9.4%
Normalized
  Adjusted
   EBITDAR
    margin       17.4%      7.0%      9.7%                            13.3%

   See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
   "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."
   See normalizing adjustments in the table "Normalizing Adjustments -
   Quarter Comparison."






                Sun Healthcare Group, Inc. and Subsidiaries
                      Selected Operating Statistics
                          Continuing Operations


                    For the                         For the
              Three Months Ended               Nine Months Ended
                 September 30,                   September 30,
            -----------------------       ---------------------------
              2010           2009            2010             2009
Consolidated
 Company
            --------       --------       ----------       ----------
Revenues -
 Non-
 affiliated
 (in
 thousands)
  Skilled
   Nursing
   and
   similar
   facilit-
   ies      $412,295       $412,550        1,230,684        1,230,551
  Hospice     11,277          7,242           33,633           19,249
  Other -
   Inpatient
   Services      588            582            1,663            1,724
            --------       --------       ----------       ----------
   Inpatient
    Services 424,160        420,374        1,265,980        1,251,524
  Rehabili-
   tation
   Therapy
   Services   30,342         26,394           89,723           78,063
  Medical
   Staffing
   Services   21,481         23,864           67,712           77,335
  Other -
   non-core
   businesses     14             12               28               27
            --------       --------       ----------       ----------
    Total   $475,997       $470,644       $1,423,443       $1,406,949
            ========       ========       ==========       ==========


Revenue Mix
 -
 Non-
 affiliated
 (in
 thousands)
  Medicare  $138,125   29% $137,857   29%    421,398   30%    417,059   30%
  Medicaid   194,936   41%  189,878   40%    574,856   40%    559,358   40%
  Private
   and
   Other     113,610   24%  114,143   25%    339,492   24%    341,424   24%
  Managed
   Care /
   Insurance  24,178    5%   24,393    5%     72,636    5%     76,591    5%
  Veterans     5,148    1%    4,373    1%     15,061    1%     12,517    1%
            --------  ---  --------  ---  ----------  ---  ----------  ---
    Total   $475,997  100% $470,644  100% $1,423,443  100% $1,406,949  100%
            ========  ===  ========  ===  ==========  ===  ==========  ===


Inpatient
 Services
 Stats
 Number of
  centers:       202            202              202              202
 Number of
  available
  beds:       22,407         22,331           22,407           22,331
 Occupancy
  %:            86.9%          88.1%            87.1%            88.3%


 Payor Mix
  % based
  on
  patient
  days:
   Medicare
    - SNF
    Beds        14.7%          15.3%            15.2%            15.8%
   Managed
    care /
    Ins. -
    SNF
    Beds         3.9%           3.9%             4.0%             4.1%
            --------       --------       ----------       ----------
     Total
      SNF
      skilled
      mix       18.6%          19.2%            19.2%            19.9%
            --------       --------       ----------       ----------
  Medicare      13.4%          14.0%            13.9%            14.4%
  Medicaid      62.5%          60.6%            62.2%            60.4%
  Private
   and
   Other        19.4%          20.8%            19.1%            20.4%
  Managed
   Care /
   Insurance     3.5%           3.6%             3.6%             3.8%
  Veterans       1.2%           1.0%             1.2%             1.0%

 Revenue
  Mix % of
  revenues:
   Medicare
    - SNF
    Beds        31.1%          32.2%            31.9%            32.9%
   Managed
    care /
    Ins. -
    SNF
    Beds         6.0%           6.1%             6.0%             6.4%
            --------       --------       ----------       ----------
     Total
      SNF
      skilled
      mix       37.1%          38.3%            37.9%            39.3%
            --------       --------       ----------       ----------
  Medicare      31.4%          31.9%            32.2%            32.4%
  Medicaid      46.0%          45.2%            45.4%            44.7%
  Private
   and
   Other        15.8%          16.1%            15.5%            15.8%
  Managed
   Care /
   Insurance     5.6%           5.8%             5.7%             6.1%
  Veterans       1.2%           1.0%             1.2%             1.0%


 Revenues
  PPD:
  LTC only
   Medicare
   (Part A) $ 463.36       $ 457.79       $   464.46       $   454.15
  Medicare
   Blended
   Rate
   (Part A
   & B)     $ 505.73       $ 496.11       $   504.05       $   491.94
  Medicaid  $ 173.49       $ 172.06       $   173.29       $   170.86
  Private
   and
   Other    $ 182.95       $ 175.29       $   184.95       $   175.82
  Managed
   Care /
   Insurance$ 375.76       $ 371.09       $   369.09       $   373.86
  Veterans  $ 238.74       $ 234.74       $   241.44       $   229.95

Rehab
 contracts
Affiliated       132            121              132              121
Non-affiliated   344            328              344              328

Average
 Qtrly
 Revenue
 per
 Contract
 (in thou-
 sands)     $    109       $    100       $      107       $       99






                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

               NORMALIZING ADJUSTMENTS - QUARTER COMPARISON
                  (in thousands, except per share data)

                             AS REPORTED - 3rd QUARTER 2010
             -------------------------------------------------------------
                                                  Income
                                                   from
                     Adjusted  Adjusted         Continuing  Disc     Net
             Revenue  EBITDAR   EBITDA  Pre-tax Operations   Ops    Income
             -------- -------  -------  -------  -------  -------  -------

As Reported
 3rd QUARTER
 2010        $475,997 $55,858  $36,904  $13,557  $ 7,998  $  (442) $ 7,556
  Percent of
     Revenue             11.7%     7.8%     2.8%     1.7%    -0.1%     1.6%
Normalizing
 Adjustments:

 REIT
  separation
  transaction
  costs             -   4,747    4,747    4,747    2,801        -    2,801
             -------- -------  -------  -------  -------  -------  -------

Normalized
 As Reported
 - 3rd
 QUARTER
 2010        $475,997 $60,605  $41,651  $18,304  $10,799  $  (442) $10,357
             ======== =======  =======  =======  =======  =======  =======
  Percent of
     Revenue             12.7%     8.8%     3.8%     2.3%    -0.1%     2.2%

Diluted EPS:
 As Reported                                     $  0.13  $     -  $  0.13
 As Normalized                                   $  0.18  $ (0.01) $  0.17



Weighted average
 number of common
 and common
 equivalent
 shares
 outstanding
 on a diluted                                                      Diluted
 basis:                                                             Shares
                                                                   -------

 As Reported
  / As
  Normalized
  diluted
  shares                                                            59,538
 Stock
  offering
  impact on
  diluted
  shares                                                           (15,412)
                                                                   -------

 As Adjusted
  diluted
  shares                                                            44,126
                                                                   =======






                             AS REPORTED - 3rd QUARTER 2009
             -------------------------------------------------------------
                                                  Income
                                                   from
                     Adjusted  Adjusted         Continuing  Disc     Net
             Revenue  EBITDAR   EBITDA  Pre-tax Operations   Ops    Income
             -------- -------  -------  -------  -------  -------  -------

As Reported
 - 3rd
 QUARTER
 2009        $470,644 $60,509  $42,319  $17,759  $10,539  $  (881) $ 9,658
Percent of
 Revenue                 12.9%     9.0%     3.8%     2.2%    -0.2%     2.1%
Normalizing
 Adjustments:

 Restructuring
  costs             -       -        -      872      514        -      514
             -------- -------  -------  -------  -------  -------  -------

Normalized
 As Reported
 - 3rd
 QUARTER
 2009        $470,644 $60,509  $42,319  $18,631  $11,053  $  (881) $10,172
             ======== =======  =======  =======  =======  =======  =======
  Percent of
     Revenue             12.9%     9.0%     4.0%     2.3%    -0.2%     2.2%

Diluted EPS:
 As Reported                                     $  0.24  $ (0.02) $  0.22
 As Normalized                                   $  0.25  $ (0.02) $  0.23





See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
"Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

Normalizing adjustments are transactions or adjustments not related to
ongoing operations and consist of REIT separation transaction costs and
restructuring costs.

Normalizing adjustments do not include any adjustment for the August 2010
equity offering or the use of proceeds to pay down debt, avoiding interest
expense.

Since normalizing adjustments are not measurements determined in
accordance with U.S. generally accepted accounting principles and are thus
susceptible to varying calculations and interpretations, the information
presented herein may not be comparable to other similarly described
information of other companies.









                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

            NORMALIZING ADJUSTMENTS - YEAR TO DATE COMPARISON
                  (in thousands, except per share data)

                             AS REPORTED -NINE MONTHS 2010
             -------------------------------------------------------------
                                                    Income
                                                     from
                                                  Continuing
                        Adjusted  Adjusted   Pre-   Opera-   Disc     Net
              Revenue   EBITDAR    EBITDA     tax   tions     Ops   Income
             ---------- --------  --------  ------  ------  ------  ------

As Reported
 - Nine
 Months 2010 $1,423,443 $177,609  $121,303 $49,205 $29,215 $(1,488)$27,727
  Percent of
     Revenue                12.5%      8.5%    3.5%    2.1%   -0.1%    1.9%

Normalizing
 Adjustments:

 REIT
  separation
  transaction
  costs               -    6,995     6,995   6,995   4,127       -   4,127
             ---------- --------  --------  ------  ------  ------  ------

Normalized
 As Reported
 - Nine
 Months 2010 $1,423,443 $184,604  $128,298 $56,200 $33,342 $(1,488)$31,854
             ========== ========  ========  ======  ======  ======  ======
  Percent of
     Revenue                13.0%      9.0%    3.9%    2.3%   -0.1%    2.2%

Diluted EPS:
 As Reported                                        $ 0.58  $(0.03) $ 0.55
 As
  Normalized                                        $ 0.66  $(0.03) $ 0.63




Weighted average
 number of common and
 common equivalent
 shares
 outstanding
 on a diluted                                                      Diluted
 basis:                                                             Shares
                                                                    ------

 As Reported
  / As
  Normalized
  diluted
  shares                                                            50,251
 Stock
  offering
  impact on
  diluted
  shares                                                            (5,879)
                                                                    ------

 As Adjusted
  diluted
  shares                                                            44,372
                                                                    ======





                             AS REPORTED - NINE MONTHS 2009
             -------------------------------------------------------------
                                                    Income
                                                     from
                                                  Continuing
                        Adjusted  Adjusted   Pre-   Opera-   Disc     Net
              Revenue   EBITDAR    EBITDA     tax   tions     Ops   Income
             ---------- --------  --------  ------  ------  ------  ------

As Reported
 - Nine
 Months 2009 $1,406,949 $182,485  $127,730 $56,066 $33,271 $(3,275)$29,996
  Percent of
     Revenue                13.0%      9.1%    4.0%    2.4%   -0.2%    2.1%

Normalizing
 Adjustments:

 Restructuring
  costs               -        -         -     872     514       -     514
 Prior
  periods'
  self-
  insurance
  costs               -    4,300     4,300   4,300   2,537     348   2,885
             ---------- --------  --------  ------  ------  ------  ------

Normalized
 As Reported
 - Nine
 Months 2009 $1,406,949 $186,785  $132,030 $61,238 $36,322 $(2,927)$33,395
             ========== ========  ========  ======  ======  ======  ======
  Percent of
     Revenue                13.3%      9.4%    4.4%    2.6%   -0.2%    2.4%

Diluted EPS:
 As Reported                                        $ 0.76  $(0.08) $ 0.68
 As Normalized                                      $ 0.83  $(0.07) $ 0.76



See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
"Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

Normalizing adjustments are transactions or adjustments not related to
ongoing operations and consist of REIT separation transaction costs,
restructuring costs and prior periods' self-insurance costs.

Normalizing adjustments do not include any adjustment for the August 2010
equity offering or the use of proceeds to pay down debt, avoiding interest
expense.

Since normalizing adjustments are not measurements determined in
accordance with U.S. generally accepted accounting principles and are thus
susceptible to varying calculations and interpretations, the information
presented herein may not be comparable to other similarly described
information of other companies.

Contact:

Investor Inquiries
(505) 468-2341

Media Inquiries
(505) 468-4582

Filed Under: Facilities And Providers

TomoTherapy Announces Third Quarter Financial Results

Posted on October 27, 2010 Written by Annalyn Frame

SOURCE: TomoTherapy

Reports $43.6 Million of Revenue and $35.0 Million of Equipment Orders; Raises 2010 Revenue Guidance

MADISON, WI–(Marketwire – October 27, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, today
released financial results for the third quarter ended September 30, 2010.

Third Quarter Results

Third quarter 2010 revenue was $43.6 million, an increase of 27% from $34.4
million in the third quarter of 2009. Revenue from product sales was $29.8
million in the third quarter of 2010, up 23% compared to the same quarter
last year, and revenue from service and other was $13.8 million in the
third quarter of 2010, up 37% compared to the same quarter last year. The
company reported a third quarter 2010 loss from operations of $14.6
million, a 10% decrease from the $16.1 million loss from operations for the
same period last year.

The company incurred a net loss attributable to shareholders of $10.9
million, or $0.21 per share, for the third quarter of 2010, compared to a
net loss of $13.9 million, or $0.27 per share, for the third quarter of
2009.

As of September 30, 2010, the company had $140.0 million of cash, cash
equivalents and short-term investments, representing a $5.6 million
decrease from June 30, 2010. There were no borrowings against the
company’s credit facility during the quarter.

As of September 30, 2010, the company had a revenue backlog of $146.4
million, a 5% increase from the $139.2 million backlog as of June 30, 2010.
The backlog includes $35.0 million of equipment orders received during the
third quarter of 2010. Backlog includes firm orders that the company
believes are likely to ship within the next two years, as well as the
minimum payments for system rental contracts. Backlog does not include any
revenue from service contracts, which represents a growing portion of the
company’s overall revenue.

“We are encouraged by our third quarter financial performance, which
reflects substantial improvement from the same period last year and
demonstrates that our efforts on several key fronts are yielding results,”
said Fred Robertson, TomoTherapy’s CEO. “Importantly, our year-over-year
revenue growth is attributable to strength in product sales as well as
service. On the product side, we have increased our backlog for two
consecutive quarters as a result of a stronger, more integrated global
sales and marketing efforts combined with the market’s demand for our new,
more diverse product offerings. Service and other sales also continued to
grow at a significant rate in comparison to the prior year, and at the same
time, we maintained leading customer service rankings. We are focused on
driving product sales in the geographic regions we have targeted, while
simultaneously continuing to improve the reliability of our systems,
including enhancing machine uptime and reducing maintenance required, as we
continue on our path to return to profitability.”

Nine-Month Results

For the nine months ended September 30, 2010, revenue was $133.3 million, a
26% increase from $106.1 million for the nine months ended September 30,
2009. Revenue from product sales was $93.2 million in the first nine
months of 2010, up 23% compared to the first nine months of 2009, and
revenue from service and other was $40.1 million in the first nine months
of 2010, up 33% compared to the first nine months of 2009.

The company reported a year-to-date 2010 loss from operations of $28.9
million, a 27% decrease from the loss from operations of $39.8 million
during the first nine months of 2009. The company incurred a net loss
attributable to shareholders of $22.5 million, or $0.43 per share, for the
nine months ended September 30, 2010, compared to a net loss attributable
to shareholders of $34.0 million, or $0.67 per share, for the same period
last year.

During the first nine months of 2010, the company’s cash, cash equivalents
and short-term investments decreased by $14.3 million. In the same period,
the company’s backlog increased by $10.6 million, from $135.8 million as of
December 31, 2009 to $146.4 million as of September 30, 2010.

Outlook

The company is revising upward its revenue guidance for full-year 2010.
Management now expects 2010 revenue to be $175 million to $185 million, as
compared to the previous range of $160 million to $180 million.
Additionally, the net loss attributable to shareholders is now projected to
be in the range of $0.65 to $0.75 per share, as compared to the previous
projection of $0.65 to $0.85 per share.

Robertson concluded, “Our year-to-date results continue to show improving
revenue and margins. Coupled with our backlog growth, we now expect
stronger top-line results than we had anticipated earlier in the year.
While global market conditions remain difficult to assess, there have been
positive indications recently that demand is stabilizing. We are seeing
strong indications of interest in our new product offerings throughout
North America, Europe and the Asia Pacific region and continue to believe
there are significant growth opportunities across these geographies.
Moreover, based on many published reports regarding TomoTherapy treatment,
we believe that the market is increasingly recognizing the benefits of this
radiation therapy approach.”

Investor Conference Call

TomoTherapy will conduct a conference call regarding its third quarter 2010
results at 5:00 p.m. ET today, October 27, 2010 (4:00 p.m. CT). To hear a
live Webcast or replay of the call, visit the Investor Relations page at TomoTherapy.com, where it will
be archived for two weeks. To access the call via telephone, dial
1-800-638-4817 from inside the United States or 1-617-614-3943 from outside
the United States, and enter pass code 19539609. The replay can be
accessed by dialing
1-888-286-8010 from inside the United States or
1-617-801-6888 from outside the United States and entering pass code
40905886. The telephone replay will be available through 10:59 p.m. CT on
November 3, 2010.

About TomoTherapy Incorporated

TomoTherapy Incorporated develops, markets and sells advanced radiation
therapy solutions that can be used to efficiently treat a wide variety of
cancers, from the most common to the most complex. The ring gantry-based
TomoTherapy® platform combines integrated CT imaging with conformal
radiation therapy to deliver sophisticated radiation treatments with speed
and precision while reducing radiation exposure to surrounding healthy
tissue. TomoTherapy’s suite of solutions includes its flagship Hi-Art®
treatment system, which has been used to deliver more than three million
CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment
fractions; the TomoHD™ treatment system, designed to enable cancer centers
to treat a broader patient population with a single device; and the
TomoMobile™ relocatable radiation therapy solution, designed to improve
access and availability of state-of-the-art cancer care. TomoTherapy’s
stock is traded on the NASDAQ Global Select Market under the symbol “TOMO.”
To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Statements
concerning market acceptance of the company’s technology; growth drivers;
the company’s orders, revenue, backlog or earnings growth; future financial
results and any statements using the terms “should,” “believe,” “outlook,”
“expect,” “anticipate” or similar statements are forward-looking statements
that involve risks and uncertainties that could cause the company’s actual
results to differ materially from those anticipated. Such risks and
uncertainties include: demand for the company’s products; impact of sales
cycles and competitive products and pricing; the effect of economic
conditions and currency exchange rates; the company’s ability to develop
and commercialize new products; its reliance on sole or limited-source
suppliers; its ability to increase gross margins; the company’s ability to
meet U.S. Food and Drug Administration (FDA) and other regulatory agency
product clearance and compliance requirements; the possibility that
material product liability claims could harm future revenue or require the
company to pay uninsured claims; the company’s ability to protect its
intellectual property; the impact of managed care initiatives, other health
care reforms and/or third-party reimbursement levels for cancer care;
potential loss of key distributors or key personnel; risk of interruptions
to the company’s operations due to terrorism, disease or other events
beyond the company’s control; and the other risks listed from time to time
in the company’s filings with the U.S. Securities and Exchange Commission,
which by this reference are incorporated herein. TomoTherapy assumes no
obligation to update or revise the forward-looking statements in this
release because of new information, future events or otherwise.

                TOMOTHERAPY INCORPORATED AND SUBSIDIARIES

              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                  (In thousands, except per share data)
                                (unaudited)



                                 Three Months Ended     Nine Months Ended
                                    September 30,         September 30,
                                --------------------  --------------------
                                  2010       2009       2010       2009
                                ---------  ---------  ---------  ---------
Revenue:
 Product                        $  29,759  $  24,252  $  93,230  $  75,937
 Service and other                 13,823     10,126     40,062     30,144
                                ---------  ---------  ---------  ---------
  Total revenue                    43,582     34,378    133,292    106,081
                                ---------  ---------  ---------  ---------
Cost of revenue:
 Product                           16,233     13,782     46,372     39,779
 Service and other                 20,339     17,038     54,848     51,690
                                ---------  ---------  ---------  ---------
  Total cost of revenue            36,572     30,820    101,220     91,469
                                ---------  ---------  ---------  ---------
   Gross profit                     7,010      3,558     32,072     14,612
                                ---------  ---------  ---------  ---------
Operating expenses:
  Research and development          8,228      7,218     24,728     20,086
  Selling, general and
   administrative                  13,342     12,470     36,286     34,347
                                ---------  ---------  ---------  ---------
   Total operating expenses        21,570     19,688     61,014     54,433
                                ---------  ---------  ---------  ---------
Loss from operations              (14,560)   (16,130)   (28,942)   (39,821)
Other income (expense):
  Interest income                     342        617      1,289      2,009
  Interest expense                     (4)       (18)       (27)       (47)
  Other income (expense), net       1,539        105        513       (258)
                                ---------  ---------  ---------  ---------
   Total other income (expense)     1,877        704      1,775      1,704
                                ---------  ---------  ---------  ---------
Loss before income tax and
 noncontrolling interests         (12,683)   (15,426)   (27,167)   (38,117)
  Income tax expense (benefit)         47        256         13       (162)
                                ---------  ---------  ---------  ---------
Net loss                          (12,730)   (15,682)   (27,180)   (37,955)
  Noncontrolling interests          1,842      1,802      4,691      3,953
                                ---------  ---------  ---------  ---------
Net loss attributable to
 shareholders                   $ (10,888) $ (13,880) $ (22,489) $ (34,002)
                                =========  =========  =========  =========

Weighted-average common shares
 outstanding -
 basic and diluted                 51,934     50,748     51,739     50,645
                                =========  =========  =========  =========

Loss per common share - basic
 and diluted                    $   (0.21) $   (0.27) $   (0.43) $   (0.67)
                                =========  =========  =========  =========



                TOMOTHERAPY INCORPORATED AND SUBSIDIARIES

                  CONDENSED CONSOLIDATED BALANCE SHEETS
                              (In thousands)
                                (unaudited)

                                                 September 30, December 31,
                                                      2010         2009
                                                  ------------ ------------
                   ASSETS
Cash and cash equivalents                         $    110,424 $     76,108
Short-term investments                                  29,612       78,225
Receivables, net                                        34,454       33,559
Inventories, net                                        53,014       47,669
Prepaid expenses and other current assets                3,352        3,633
                                                  ------------ ------------
  Total current assets                                 230,856      239,194
Property and equipment, net                             21,305       18,628
Other non-current assets, net                           11,168       12,429
                                                  ------------ ------------
 TOTAL ASSETS                                     $    263,329 $    270,251
                                                  ============ ============


           LIABILITIES AND EQUITY
Accounts payable                                  $     14,095 $      6,269
Accrued expenses                                        23,415       19,588
Accrued warranty                                         4,115        4,173
Deferred revenue                                        30,877       34,145
Customer deposits                                       14,801       13,266
                                                  ------------ ------------
  Total current liabilities                             87,303       77,441
Other non-current liabilities                            3,213        5,475
                                                  ------------ ------------
  TOTAL LIABILITIES                                     90,516       82,916

Total shareholders' equity                             167,007      183,424
Noncontrolling interests                                 5,806        3,911
                                                  ------------ ------------
  TOTAL EQUITY                                         172,813      187,335
                                                  ------------ ------------
  TOTAL LIABILITIES AND EQUITY                    $    263,329 $    270,251
                                                  ============ ============

Filed Under: Facilities And Providers

New Study: Saints Mary and Elizabeth Medical Center Ranks in Top 5 Percent for Stroke, Gastrointestinal Surgery/Care

Posted on October 27, 2010 Written by Annalyn Frame

SOURCE: Resurrection Health Care

CHICAGO, IL–(Marketwire – October 27, 2010) –  Saints Mary and Elizabeth Medical Center (SMEMC) is among the top 5 percent of U.S. hospitals for stroke care, gastrointestinal surgery and gastrointestinal care, according to a newly published health care study.

SMEMC ranks fifth in the state for gastrointestinal surgery and gastrointestinal care.

The nation’s nearly 5,000 hospitals were included in this sweeping study, which examined mortality rates and complication rates. The 13th Annual HealthGrades Hospital Quality in America study, the largest annual report of its kind, analyzed patient outcomes from nearly 40 million Medicare hospitalization records from 2007 to 2009. HealthGrades, an independent ratings company, conducted the study.

For 2011, SMEMC was recognized with nine clinical achievements:

  • HealthGrades Stroke Care Excellence Award™ (second year in a row)
  • HealthGrades Gastrointestinal Surgery Excellence Award™
  • HealthGrades Gastrointestinal Care Excellence Award™
  • Five-star ratings, the highest level, in six areas — heart attack, pneumonia, sepsis (complication of a serious bacterial infection), gastrointestinal bleed, bowel obstruction and cholecystectomy (gall bladder removal)

“Our mission — since we opened our doors 123 years ago — is to provide patients with the highest level of quality care,” said Margaret McDermott, executive vice president/chief executive officer, SMEMC. “I am proud of our entire health care team for their commitment to delivering excellent care with excellent results.”

McDermott said patients are increasingly seeking independent information on hospital quality performance. “I hope this study will help guide individuals confronted with important health care decisions,” she said.

According to the study, top-performing hospitals had dramatically lower mortality rates than other hospitals. HealthGrades analyzed mortality rates for 17 procedures and diagnoses. Results showed that patients at hospitals ranking in the top 5 percent had a 72 percent lower chance of dying when compared with the lowest-performing hospitals, and a 53 percent lower chance of dying when compared to the U.S. national average.

HealthGrades rates hospitals independently based on data that hospitals submit to the Centers for Medicare and Medicaid services, part of the U.S. Department of Health and Human Services.

To read the full study and FAQ, visit http://www.reshealth.org/sub_smemc/about/healthgrades/default.cfm.

About SMEMC
Part of Resurrection Health Care, SMEMC is an award-winning medical center on Chicago’s near northwest side and includes two campuses: Saint Mary Campus, 2233 W. Division St., and Saint Elizabeth Campus, 1431 North Claremont Ave. Visit smemc.reshealthcare.org.

Contact:
Russell Milligan
Saints Mary and Elizabeth Medical Center
312-770-2225
Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

MTA and University Richmond Partner for Medical Tourism Certification

Posted on October 27, 2010 Written by Annalyn Frame

WEST PALM BEACH, FLORIDA–(Marketwire – Oct. 27, 2010) – The Medical Tourism Association and the University of Richmond have launched a “Medical Tourism Certification” program, which will officially launch in 2011. The University of Richmond’s School of Continuing Studies will work in partnership with the Medical Tourism Association in creating a curriculum and selecting instructors.

The professional certificate program will require six courses to complete, and each course will be available in both English and Spanish. The courses will be offered completely online, allowing the program to reach an international audience. Each course will cost $199 and will take four weeks to complete. Students will be able to participate in these courses anywhere, at any time, and at their own pace during the four-week period.

In the online classroom, students will be able to view lectures and presentations, read articles, engage in discussions with other students and faculty, answer questions and take quizzes.

In addition to earning the Professional Studies Certificate from the University of Richmond, students will also earn Continuing Education Units, or CEUs, for each class they complete. Courses can be taken individually, or as part the entire certificate program. The Medical Tourism Certification will provide a standard of best practices for those who work in this field.

“This is the first certification program for medical tourism taught by an established and leading university and educational system. This program will be a great opportunity for those individuals in the industry who are looking for advanced education and to set them apart,” said, Renée-Marie Stephano, President of the Medical Tourism Association and Chief Editor of the Medical Tourism Magazine.

“We are very excited to partner with the Medical Tourism Association, who has clearly established itself as the leader in the industry. We feel this program will be invaluable to potential students from around the world who are looking for certification in medical tourism,” said Stephanie Bowlin, Non-Credit Program Manager at the University of Richmond. “We are looking forward to working with the MTA to put together a cutting edge curriculum and schedule and bringing in some of the leaders in medical tourism and international healthcare as professors and teachers for this online certificate program.” 

About the Medical Tourism Association

The Medical Tourism Association™ (Global Healthcare Association) is the international non-profit trade association for the medical tourism and global healthcare industry made up of the top international hospitals, healthcare providers, medical travel facilitators, insurance companies, and other affiliated companies and members with the common goal of promoting the highest level of quality of healthcare to patients in a global environment. Our Association promotes the interests of its healthcare provider and medical tourism facilitator members. The Medical Tourism Association™ (Global Healthcare Association) has three tenets: Transparency in Quality and Pricing, Communication and Education.

For more information about the MTA http://www.medicaltourismassociation.com.

About the University of Richmond

The University of Richmond is a highly selective, liberal arts university located on a 350-acre suburban campus located in Richmond, Virginia. Founded in 1830, the University of Richmond provides a learning environment unlike any other in higher education, offering students an extraordinary combination of the liberal arts with law, business, leadership studies, and continuing education. The School of Continuing Studies primarily serves non-traditional students, offering a variety of undergraduate and graduate degrees for adults as well as non-credit certification and professional development programs.

For More Information on University of Richmond: http://scs.richmond.edu/medical-tourism. 

For More Information about this Medical Tourism Certification or to request an opportunity to provide curriculum for the program, please contact:

Gaby Vicuña

Global Program Coordinator

[email protected]

US 561-791-2000

Filed Under: Facilities And Providers

ISSYS Inc. Awarded Another Patent for Wireless, Batteryless, Implantable Sensors

Posted on October 27, 2010 Written by Annalyn Frame

SOURCE: Integrated Sensing Systems

YPSILANTI, MI–(Marketwire – October 27, 2010) –  Integrated Sensing Systems, Inc. (ISSYS) announced that the U.S Patent Office has granted a patent titled “Wireless Device and System for Monitoring Physiological Parameters” (US Patent No. 7,686,762) which covers the overall structure of ISSYS’ miniature, wireless, batteryless, implantable sensors for non-invasive monitoring of biological pressures for the effective management of chronic diseases.

ISSYS has also developed accompanying anchors and delivery systems that allow its wireless, batteryless, sensors to be implanted within the body via 3 distinct approaches: transcatheter delivery, open heart surgery, and minimally invasive surgery. 

Dr. Nader Najafi, ISSYS CEO, stated that “ISSYS’ intellectual properties (patents, know how, and trade secrets) cover a wide spectrum including MEMS pressure sensor, the overall system, delivery and anchoring, and a variety of medical applications. Another major competitive advantage for ISSYS is its newly expanded manufacturing facility that is capable of producing tens of thousands of the miniature implants per year. The particular targets of ISSYS products are cardiovascular disease, especially congestive heart failure (CHF), hydrocephalus (high brain pressure), and traumatic brain injuries (TBI). ISSYS plans to start its cardiovascular clinical studies in 2011.”

Company Background: ISSYS is a leader in advanced MEMS technologies for industrial, medical, microfluidic and scientific analytical sensing applications. Founded in 1995, ISSYS is one of the oldest independent MEMS companies in the US. ISSYS operates a comprehensive, state-of-the-art MEMS fabrication facility located near Ann Arbor, Michigan. ISSYS is currently ISO 9001:2008 certified and compliant to EN13980:2002 for its ATEX (intrinsically safe) and CE approved products. ISSYS Quality System is also designed to meet the ISO13485:2003 standard. ISSYS is a vertically integrated company dedicated to developing and manufacturing system-level products based on MEMS technology (MEMS Inside), please visit: http://www.mems-issys.com/

Contact:
Dr. Nader Najafi
Integrated Sensing Systems Inc. (ISSYS)
391 Airport Industrial Dr., Ypsilanti, MI 48198
Tel: (734) 547-9896 Ext. 103
Fax: (734) 547-9964
Email: [email protected]

Filed Under: Facilities And Providers

Advanced Pain Management Selects the SRS Hybrid EMR for Its 7 Providers Across Multiple Office Locations

Posted on October 27, 2010 Written by Annalyn Frame

SOURCE: SRSsoft

Unparalleled, Enthusiastic Recommendations Are Validated Within First Days of Implementation

MONTVALE, NJ–(Marketwire – October 27, 2010) –  SRS, the leading provider of productivity-enhancing technology and services for high-performance specialty practices, today announced that Advanced Pain Management has selected the SRS Hybrid EMR for its high-volume practice. Advanced Pain Management is headquartered in Annapolis, MD, with additional office locations throughout central and southern Maryland, and the eastern shore of Maryland.

“For over two years, we performed our due diligence and conducted site visits to find the EMR that would fulfill our practice needs,” says Dr. Paul W. Davies, managing partner & President, Advanced Pain Management. “The resulting reluctance to proceed was based on the reports of drastic productivity loss from virtually every physician we spoke with, even those at vendor-selected sites. The physicians also noted that using their EMR systems required so much attention that they could not give patients the time they needed. Even when vendor representatives were present, we were hard-pressed to find any physicians willing to make positive comments about the usability of their EMR. Our SRS site visit was dramatically different — it was the first time that we saw providers genuinely excited to share their experience. Physicians of all ages and levels of technological proficiency were uniformly delighted with the SRS Hybrid EMR, and the entire office staff was highly enthusiastic — they made these comments even when no one from SRS was present! Physicians reported no downtime during implementation and training, and no loss in productivity. Our own implementation went flawlessly and we are already enjoying the clinical and business benefits that we were anticipating.”

“Our hospital was offering its EMR product to practices whose members were on the medical staff, but we knew it would not meet our needs,” says Bill Hughes, Chief Operating Officer, Advanced Pain Management. “We know that we made the right choice — if we had any doubt at all, attending our first SRS User Summit has erased it completely. I have never seen so many satisfied and happy customers at any company-sponsored event.”

“We are seeing firsthand how, in an era of declining reimbursements and increased costs, physicians are using SRS to efficiently and cost-effectively manage their practices,” says Evan Steele, CEO of SRSsoft. “Advanced Pain Management adopted the SRS Hybrid EMR because they value both the clinical and business improvements for which SRS is recognized.”

About SRS
SRS is the leading provider of productivity-enhancing EMR technology and services for high-performance specialty practices — with a successful adoption rate unparalleled in the industry. Offered via the Unified Desktop™, the robust SRS Hybrid EMR, SRS CareTracker PM, and SRS PACS increase speed, free physicians’ time, boost revenue, and heighten patient care and satisfaction. For more information on SRS, visit www.srssoft.com, e-mail [email protected], fax 201.802.1301, or call 800.288.8369.

About Advanced Pain Management
Advanced Pain Management has assembled the top specialists in their region to offer the most advanced, minimally invasive treatments for spine pain. While they are experienced with all types of chronic pain, they specialize in neck and spine related conditions, the most common and often debilitating ailments affecting so many today. For more information, visit www.mypainspecialist.com.

Media Contact
Jeremy Duca
SRSsoft
800.288.8369
Email Contact

Filed Under: Facilities And Providers

DM-199 Validated by Significantly Increasing Insulin Sensitivity by 122%

Posted on October 27, 2010 Written by Annalyn Frame

WINNIPEG, MANITOBA–(Marketwire – Oct. 27, 2010) – DiaMedica (TSX VENTURE:DMA) today announces that DM-199 has been validated by demonstrating significantly increased insulin sensitivity in animals using the hyperinsulemic euglycemic clamp model. Type 2 diabetes is a severely debilitating condition characterized by high blood sugar primarily due to a decrease in insulin sensitivity, which results in a number health problems including cardiovascular disease. 

The amount of glucose being processed in an animal model of type 2 diabetes with DM-199 was measured using the hyperinsulinemic euglycemic clamp, the gold standard method for characterizing the actions of insulin. Animals treated with a single dose of DM-199 had a 122% increase in maximal glucose infusion rate. This enabled animals to process 77% more total glucose compared to untreated animals. In a second study, DM-199 also had a pronounced anti-hypertensive effect on systolic blood pressure. This is important as approximately 70% of type 2 diabetes patients take multiple medications to treat high blood pressure.

“The clamp study clearly shows that treatment with DM-199 results in a major increase in insulin sensitivity in an animal model of type 2 diabetes. It is notable that the results of these studies actually provide an underestimate of the true effectiveness of DM-199. This is because the potency of DM-199 was so great that it was difficult to maintain the euglycemic clamp.” stated Dr. David Wasserman, Ron Santo Chair in Diabetes Research & Professor molecular physiology and biophysics at Vanderbilt University. “I very much look forward to seeing the future development of DM-199.”

“The results from both studies provide further validation of DM-199, our next generation form of DM-99, as a potential treatment for type 1 diabetes, type 2 diabetes and other diseases,” said Mr. Rick Pauls, CEO of DiaMedica. “This DM-199 data builds on compelling earlier animal and human proof of concept data with DM-99, and gives us confidence in moving forward with this very promising recombinant protein,” continued Mr. Pauls. “The dual benefits shown by DM-199 to increase the body’s ability to metabolize glucose and its positive effect on lowering systolic blood pressure may ultimately alleviate the need for diabetics to take multiple drugs for diabetes and hypertension.”

About DiaMedica

DiaMedica is a biopharmaceutical company focused on developing novel treatments for type 1 diabetes, type 2 diabetes and other disorders. DiaMedica has completed two successful proof-of-concept Phase II studies with DM-71 and DM-99, which demonstrated human efficacy in lowering blood glucose levels in patients with type 2 diabetes.

DiaMedica’s lead product DM-199 is a novel recombinant next generation form of DM-99, which has shown the potential to increase insulin sensitivity, reduce the autoimmune attack and trigger proliferation of pancreatic beta cells, neural stem cells and bone marrow cells. DiaMedica is listed on the TSX Venture Exchange under the trading symbol “DMA”. For further information please visit www.diamedica.com.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the “forward-looking statements“). These forward-looking statements relate to, among other things, DiaMedica’s objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Specifically, this press release contains forward-looking statements regarding matters such as, but not limited to, the anticipated use of proceeds from the Offering, management’s assessment of DiaMedica’s future plans, information with respect to the advancement of DiaMedica’s research and development programs, and DiaMedica’s other estimates and expectations. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to our research and development programs, the availability of additional financing, risks and uncertainties relating to the anticipated use of proceeds, changes in debt and equity markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, the cost and supply of raw materials, management of growth, effects of insurers’ willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters.

Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading “Risk Factors” contained in DiaMedica’s 2009 annual information form. DiaMedica cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on DiaMedica’s forward-looking statements to make decisions with respect to DiaMedica, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions, which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of additional financing for research and development companies, and general business and economic conditions. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, DiaMedica cannot provide assurance that actual results will be consistent with these forward-looking statements. DiaMedica undertakes no obligation to update or revise any forward-looking statement. 

Filed Under: Facilities And Providers

Medagate and InComm Launch OTCNetwork(TM), the First National OTC Benefits Disbursement & Redemption Network for Medicare Advantage Plan Members

Posted on October 27, 2010 Written by Annalyn Frame

SOURCE: Medagate

Leading Medicare Advantage Plans, Health Plus Elite and Access Medicare, Leverage New OTCMedicareTM Prepaid Card to Reduce Member Healthcare Costs

REDWOOD CITY, CA–(Marketwire – October 27, 2010) –  Medagate Corporation, a leading provider of over-the-counter (OTC) health care benefit platform solutions and services, in partnership with InComm, the leader in sales and marketing of prepaid products and innovator of transaction processing, today launched OTCNetwork™, the first national Over-The-Counter (OTC) benefits program for Medicare Advantage plans and their members. OTCNetwork features patented and patent pending technology with acceptance at national, regional, and local retailers. Initial retailer rollout will start immediately in New York, with expanded national rollout slated for early 2011, comprising in total 20,000 retail locations in all 50 states. Health Plus Elite and Access Medicare will be the first to leverage Medagate’s new OTCMedicare™ branded health benefits card to make OTC Medicare benefits more accessible to their Medicare Advantage members for use in self-care, and in an effort to increase member satisfaction and reduce member healthcare costs.

“Over 11 million Americans are enrolled in Medicare Advantage plans, which provide $5.5 billion in OTC Medicare benefits annually. Yet, only four percent of those benefits are actually consumed each year because plan members do not have convenient access to their benefits for use in self-care,” said Devin Wade, President & Founder of Medagate. “This lack of OTC benefit access costs Medicare billions of dollars in unnecessary doctor and hospital visits, resulting from patients seeking care for less serious ailments treatable with OTC medications or for ailments that go untreated and later require urgent care. Increasing member overall health and self-care through OTC items dramatically reduces healthcare costs, and increases member satisfaction and re-enrollment rates.”

“Our retailers recognize the future of healthcare will include a heavy dose of self-care programs in an effort to improve general health and reduce costs,” said Mark Leonard, EVP of InComm. “With an increasing demand for more convenient access to OTC items, Medagate is a key partner for InComm, offering this retail OTC benefits program not just for our drug channel retail partners but also for our extensive network of discount, grocery, and convenience store retail locations nationally. For the first time, Medicare Advantage plan members will be able to use their benefits for self-care via OTC items when they need them.”

“We are extremely pleased to be able to offer our Medicare Advantage plan members more convenient access to their OTC Medicare benefits via the OTCMedicare benefits card,” said Dr. Clifford D. Marbut, Chief Medical Officer of Health Plus Elite. “This will empower our members with the ability to maintain better health to treat non-serious health ailments immediately and reduce patient doctor visits.”

Deployed for acceptance at leading retailers nationally, OTCNetwork is the first national OTC benefits program for Medicare Advantage plans and their members. Medicare Advantage plans load monthly OTC Medicare benefits onto OTCMedicare branded, re-loadable benefit cards, which plans distribute to their members. Medicare Advantage plan members can then access their benefits via participating retailers nationally using their OTCMedicare benefits card, which is restricted to the purchase of OTC Medicare eligible items only for use in self-care.

About InComm:
InComm is the industry leading marketer, distributor and technology innovator of stored-value gift and prepaid products using its state-of-the-art point-of-sale transaction technology to revolutionize retail product sales and customer experiences. With nearly $10 billion in retail sales transactions processed in 2009, InComm is the nation’s largest provider of gift cards, prepaid wireless products, reloadable debit cards, digital music downloads, content, games, software and bill payment solutions. InComm partners with consumer brand leaders around the world to provide more than 225,000 retail locations the products and services their customers demand. Since 1992, InComm’s patented technologies have made the buying process easier for consumers while streamlining the selling process for product and retail partners. InComm is headquartered in Atlanta, GA with offices in Australia/New Zealand, Canada, Japan, Mexico, Puerto Rico, the United Kingdom, Arkansas, California, Colorado, Florida, Georgia, Minnesota, Oregon, and Texas. To learn more about InComm, visit www.incomm.com or call 1.800.352.3084.

About Medagate Corporation:
Medagate Corporation is a leading provider of health care benefit platform solutions and services. Medagate’s innovative technology, products, and services empower consumers with greater access to health care benefits for use in self-care. Medagate powers the OTCNetwork™ in partnership with InComm — the leading issuer and processor of gift cards, processing over $15 billion in transactions annually. OTCNetwork acceptance is today integrated into front-of-store Point-Of-Sale (POS) terminals at over 20,000 retail locations in all 50 states. Medagate’s OTCMedicare™ branded re-loadable prepaid cards are the first to restrict spending exclusively to OTC Medicare benefits eligible items. For information on Medagate, OTCMedicare prepaid cards, and the OTCNetwork, please visit: www.otcnetwork.com.

Media Contacts:

Mark Hall
EGOEAST Inc.
(media only)
Email Contact
609-477-3475

Donny Tye
Medagate
Email Contact
408-694-8673

Jenn Boutwell
InComm
Email Contact
1-770-882-2240

id=”nav_links”>

Filed Under: Facilities And Providers

Articulate Technologies Launches Speech Buddies, a New Consumer Medical Device to Help Children With Speech Disorders

Posted on October 27, 2010 Written by Annalyn Frame

SOURCE: Articulate Technologies, Inc.

SAN FRANCISCO, CA–(Marketwire – October 27, 2010) –  Speech therapy is an industry that has historically shown limited adoption of technology, unlike most health care fields. The inability to produce speech sounds correctly affects approximately 6% of school age children. Articulate Technologies, Inc., has just launched Speech Buddies — a new line of products to help young children overcome speaking disorders. Speech Buddies (www.speechbuddy.com) are a new kind of helper: a family of practical, handheld devices that accelerate learning with the hardest problem sounds: R, S, L, CH, and SH.

Speech Buddies work by providing targets inside the mouth for children to feel correct tongue placement when attempting to pronounce problem sounds. Speech Buddies can quickly help children turn their Wabbits into Rabbits, Wessons into Lessons, and Thocks into Socks. This tactile feedback within the mouth is often just what kids need to achieve learning breakthroughs.

Parents can choose to use Speech Buddies at home with their child or bring their Buddy to speech therapy lessons with the goal of accelerating learning and correcting problem sounds.

“Parents and children have been thrilled about Speech Buddies and this new approach has been well received by the professional community,” says Gordy Rogers, M.S. CCC-SLP, speech therapist and Chief Scientific Officer of Articulate Technologies. “For years, speech professionals have not had the benefit of technology in their treatment of speech disorders and have used household items like coffee stirrers, spoons, and peanut butter to try and help their clients. Speech Buddies are more sophisticated, produce better outcomes, and are applicable to a wide variety of cases. Getting parents involved in the learning process either on their own at home or in combination with traditional therapy, gives families a sense of empowerment as they see improvement quickly.”

Speech Buddies were invented by a pair of high school classmates who put together an interdisciplinary team of MIT engineers and speech therapists across the country to help develop the solution. After hundreds of prototypes and refinements over the course of several years, the first-in-class system is finally accessible to both parents and speech therapists. Prices range from $149 for single Speech Buddies (R, S, L, CH or SH) to $299 for the Professional Set of all five Speech Buddies.

A clinical trial, INTACT (Intra-Oral Tactile Biofeedback), is currently underway to examine the efficacy of Speech Buddies in children aged 5-8 years old. It is a randomized, controlled, single blind clinical study; preliminary results are extremely encouraging and peer reviewed publication is pending.

Visit www.speechbuddy.com for information and videos on how Speech Buddies work.

Contact:
Alexey Salamini
Chief Executive Officer
415-997-9038
Email Contact

Filed Under: Facilities And Providers

University Radiotherapy Center of Antwerp to Install Industry’s First TomoHD(TM) Treatment System

Posted on October 27, 2010 Written by Annalyn Frame

SOURCE: TomoTherapy

TomoTherapy’s Comprehensive Radiation Therapy System Offers Single, Efficient Solution for Treating Common and Complex Cancers

MADISON, WI–(Marketwire – October 27, 2010) –  TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, announced today that University Radiotherapy Center of Antwerp, Belgium, has begun installation of the world’s first TomoTherapy® TomoHD™ treatment system, a comprehensive radiation therapy system that enables cancer centers to efficiently handle both common and complex tumors with a single device. University Radiotherapy Center Antwerp is a collaboration between the Antwerp University Hospital and the Antwerp Hospital Network (ZNA).

The TomoHD treatment system combines technologies previously only available as options to TomoTherapy’s flagship system, as well as beamline components redesigned for enhanced performance.

Specifically, the TomoHD system includes TomoHelical™ and TomoDirect™ delivery modes. The TomoHelical technique enables continuous 360-degree treatment delivery for targeting complex volumes, while TomoDirect offers a discrete-angle delivery option to support highly efficient intensity-modulated radiation therapy (IMRT) and 3D conformal radiation therapy (3D CRT) for more routine cases. In addition, the TomoHD treatment system offers standard 1 cm beam commissioning for enhanced stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) capabilities.

The TomoHD system also includes the Tomo Quality Assurance (TQA™) application, which simplifies collection and analysis of system performance information and provides trending and reporting tools for monitoring machine performance.

“We were interested in adding a TomoTherapy system at our center, but waited for the TomoHD system because we recognize that this integrated solution will enable us to improve the efficiency with which we are able to treat patients with high quality radiation therapy. And the integration of the TomoDirect technique provides us a way to bring the benefits of IG-IMRT to a broader patient base with a single system,” said Prof. Dr. Danielle Van den Weyngaert, head of the department at University Radiotherapy Center. “More importantly, we believe that TomoHD will be the platform we need for supporting future advancements in radiation therapy.”

Patient treatments are expected to commence using the TomoHD treatment system in December. This is the third TomoTherapy system purchased by University Radiotherapy Center. The first two systems were installed in 2007 and have been used to treat patients with advanced image-guided IMRT, and to train TomoTherapy users from institutions across Europe.

With the TomoHD treatment system, University Radiotherapy Center will be able to advance its ability to treat patients with head and neck tumors, particularly those extending into the ocular region, as well as those in the abdominal and lung region where healthy tissue and organs are at risk to radiation exposure. Additionally, the TomoDirect technique will expand the center’s ability to address breast cancer with a fixed angle radiation delivery mode.

“We are pleased to announce that the first TomoHD treatment system installation has begun, less than a year after its commercial introduction to the market,” said TomoTherapy CEO Fred Robertson. “We are honored to work with University Radiotherapy Center of Antwerp to bring this advanced treatment solution to patients in Belgium and beyond.”

The TomoHD treatment system will be on display in the TomoTherapy booth (#3101) at the 52nd annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego, Calif., Oct. 31 – Nov. 4, 2010.

About University Radiotherapy Center of Antwerp
The University Radiotherapy Center Antwerp is a collaboration between the Antwerp University Hospital and the Antwerp Hospital Network (ZNA). Both hospitals offer comprehensive care for patients with complex disorders. Together, the hospitals treat in excess of 300,000 patients every year. The Radiotherapy Center treats patients in two major locations in Antwerp. TomoTherapy® technology has mainly been used used to treat cancers of the head and neck. The radiotherapy center is also being used as the European TomoTherapy® training center for physicists and engineers working with the system.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements
Statements in this release regarding future products or product capabilities, events, expectations and other similar matters, including but not limited to statements using the terms “believe,” “may,” “should,” “suggests” or “expects” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to integrate acquired assets, ability to protect intellectual property, risks of interruption due to events beyond the company’s control, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoHD, Hi·Art, TomoHelical, TomoDirect, TQA, and the TomoTherapy logo are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

Investor Contact:
Thomas E. Powell
Chief Financial Officer
608.824.2800
Email Contact

Media Contacts:
Kevin O’Malley
Manager, Corporate Communications
608.824.3384
Email Contact

Susan Lehman
Rockpoint Public Relations
510.832.6006
Email Contact

Filed Under: Facilities And Providers

ONRAD Announces Turnkey Radiology Peer Review Program

Posted on October 27, 2010 Written by Annalyn Frame

SOURCE: ONRAD, Inc.

National Radiology Provider Now Offering Expanded Quality Assurance Radiology Services to Customers

RIVERSIDE, CA–(Marketwire – October 27, 2010) – ONRAD, Inc., a leading radiology services provider, is now expanding the scope of its quality assurance program to include a complete Turnkey Radiology Peer Review Solution for hospitals. Radiology departments of any size could benefit from ONRAD’s Peer Review Program, including small hospitals that do not currently have an established program, or larger hospitals that want to utilize ONRAD’s independent third-party system. As a Joint Commission Accredited facility, customers can trust that ONRAD adheres to the strictest quality standards. 

“Delivering quality interpretations is extremely important to our physician group,” said Dr. Alix Vincent, CEO, ONRAD Medical Group, and member of ONRAD Quality Assurance Committee, a group chaired by Dr. Samuel Salen, CEO, ONRAD, Inc. To ensure a rich clinical knowledge base, the other five committee seats rotate on a yearly basis. 

“The goal for the Committee is to make sure that all of our radiologists continue to learn and expand their clinical expertise,” said Dr. Vincent of the group’s commitment to continuing education.

For Turnkey Solution customers, a random sample of reports will be reviewed by the Quality Assurance Committee on a quarterly basis. After an internal evaluation of the physician group performance and individual physician quality, the results will be reviewed by the hospital’s Quality Assurance Committee via physician-to-physician communication. Potential issues will be handled directly by ONRAD physicians in a proactive manner.

As a provider of services to such a large, diverse customer base, ONRAD is uniquely positioned to receive a wide variety of challenging cases. Difficult diagnoses, unusual findings, or potential teaching files are distributed to the physician group as a tool for learning. 

For more information on ONRAD Inc. visit www.onradinc.com. For more on this topic, visit: http://www.onradinc.com/?page_id=2220.

About ONRAD

ONRAD is a full service physician-owned radiology provider offering customized radiology services including teleradiology services and solutions, on-site radiology, subspecialty teleradiology interpretations, and quality assurance programs. As a partner, ONRAD helps its customers be more competitive in their local markets by complementing and expanding the radiology services already in place, or providing a comprehensive solution.

Contact:
Elizabeth Perley
Phone: 800-848-5876 x2310
Email: [email protected]

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

AdCare Health Systems Closes $11,050,000 Convertible Note Offering

Posted on October 26, 2010 Written by Annalyn Frame

SOURCE: AdCare

SPRINGFIELD, OH–(Marketwire – October 26, 2010) – AdCare Health Systems, Inc. (NYSE Amex: ADK), a recognized innovator in senior living and health care facility management, has closed a private placement of $11,050,000 of unsecured subordinated convertible notes due October 2013 to certain accredited investors.

The notes, which are unsecured and subordinated in right of payment to existing and future senior indebtedness, will pay interest quarterly at an annual rate of 10.0% and are convertible into shares of common stock of AdCare at an initial conversion price of $4.13 per share, which is equal to an initial conversion rate of 242.13 shares per $1,000 principal amount of the notes. The initial conversion price, which is equal to 115% of the 15-day volume-weighted average price of AdCare’s common stock prior to the closing of the transaction, is subject to full-ratchet anti-dilution protection, subject to customary exclusions as set forth in the notes.

If after six (6) months from the closing of the transaction, AdCare’s common stock trades at or above 200% of the conversion price for 20 out of 30 consecutive trading days, with an average daily trading volume of over 50,000 shares, then AdCare may, subject to the satisfaction of certain other conditions, redeem the notes in cash at a price equal to the sum of (i) 100% of the principal being redeemed plus (ii) any accrued and unpaid interest on the principal, plus late charges, if any.

Approximately $3.5 million in principal amount of the notes were issued in exchange for, and as a result of the cancellation of, an equal principal amount of promissory notes previously issued on September 30, 2010, as reported by AdCare in a Form 8-K filed with the Securities and Exchange Commission on October 6, 2010. 

AdCare expects to use the proceeds from this financing for general corporate purposes, including the acquisition of two nursing home facilities in Alabama, and general and administrative expenses.

C. K. Cooper & Company acted as lead placement agent for the offering, with GVC Capital, LLC and Cantone Research Partners serving as co-placement agents.

The notes were offered and issued only to accredited investors in a private placement transaction under Section 4(2) under the Securities Act of 1933 and the rules and regulations promulgated thereunder. Accordingly, the securities offered in this placement have not been registered under the Securities Act of 1933 or state securities laws, and cannot be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements. As part of the transaction, AdCare has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock to be issued upon conversion of the notes.

This news release is neither an offer to sell nor a solicitation of an offer to buy any of the securities discussed herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any state.

About AdCare Health Systems
AdCare Health Systems, Inc. (NYSE Amex: ADK) is a recognized innovator in senior living and health care facility management. AdCare develops, owns and manages assisted living facilities, nursing homes and retirement communities, as well as provides home health care services. Since its inception in 1988, AdCare’s mission has been to provide the highest quality of healthcare services to the elderly. For more information about AdCare, visit www.adcarehealth.com.

Forward-Looking Statements Disclaimer
Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of federal law. Such forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available to management, and involve known and unknown risks, results, performance or achievements of the company which may differ materially from those expressed or implied in such statements. Such factors are identified in the public filings made by the company with the Securities and Exchange Commission and include, among others, the company’s ability to secure lines of credit and/or an acquisition credit facility, find suitable acquisition properties at favorable terms, changes in the health care industry because of political and economic influences, changes in regulations governing the industry, changes in reimbursement levels including those under the Medicare and Medicaid programs and changes in the competitive marketplace. There can be no assurance that such factors or other factors will not affect the accuracy of such forward-looking statements. Except where required by law, AdCare undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Company Contacts
David A. Tenwick
Chairman
Tel (740) 549-0400, or
Chris Brogdon
Vice Chairman and CAO
Tel (937) 964-8974
AdCare Health Systems, Inc.
Email Contact

Investor Relations
Scott Liolios or Ron Both
Liolios Group, Inc.
Tel (949) 574-3860
Email: Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

SCI Solutions Completes Fiscal Year With Record New Contract Sales

Posted on October 26, 2010 Written by Annalyn Frame

SOURCE: SCI Solutions

Web-Based Access Management Company Expands Self-Service Capabilities

LOS GATOS, CA–(Marketwire – October 26, 2010) – SCI Solutions, the premier Access Management solution provider for healthcare, today announced it has completed its 2010 fiscal year with another record-setting sales period. SCI Solutions signed 42 new customer contracts representing 86 hospitals, for its award-winning Access Management Solutions: Order Facilitator®, Schedule Maximizer®, Revenue Accelerator® and Consumer and Provider self-scheduling Portals. Schedule Maximizer is an Internet-based, enterprise Access Management solution that combines sophisticated workflow technology to streamline a hospital’s complex patient and resource scheduling requirements. Order Facilitator is an Internet-based web solution for automating outpatient orders for hospital services from community physicians. Revenue Accelerator is a revenue cycle workflow system that streamlines pre-registration, prepares patients for arrival and expedites service delivery. SCI’s self-service scheduling portals provide 24×7 self-service scheduling options to both consumers and physicians.

Founded in 1999, SCI Solutions, then known as scheduling.com, brought web-native technology and a dramatically new business model to healthcare. With a focus on improving the increasingly complex nature of scheduling healthcare services and procedures, SCI was the first to offer effective, mission-critical, enterprise solutions via the Internet. Over the past ten years, SCI has demonstrated how a focus on efficient, effective, patient access processes can generate significant benefits for integrated delivery networks and healthcare communities. SCI’s current customer base is comprised of over 390 healthcare delivery systems dedicated to improving customer service, maximizing resources, ensuring accurate data collection, and improving overall access to care.

According to Stuart Hammond, SCI’s Senior Vice President of Sales, “Despite the economic challenges faced by the healthcare industry this year, SCI has successfully proven the value of advanced healthcare Access Management solutions.” He continued, “Our new and existing customers truly understand how the impact of improved access and revenue cycle directly affects the profitability and overall health of their organization.”

“SCI’s customer base ranges from Alaska to Florida encompassing many of the 50 states,” stated John Holton, SCI’s President and CEO. He continued, “This is a testament to the range of healthcare facilities nationwide that have turned to advanced Access Management solutions to honor their commitment to organizational and financial improvements.”

About SCI Solutions
SCI Solutions is transforming healthcare Access Management with products and services that facilitate the efficient and secure exchange of clinical and financial information between patients, physicians and healthcare facilities. SCI provides a variety of products and self-service portals that help physicians and patients interact easily and at their convenience for many of their access-related needs. From a hospital’s clinical departments, to its financial executives, to its physicians, SCI improves their effectiveness while making the patient’s service experience first class.

SCI Solutions is headquartered in Los Gatos, CA with additional offices in Tucson, AZ, Pensacola, FL and employees throughout the United States. For more information about SCI Solutions visit www.scisolutions.com.

Executive Contact:
Cindy Dullea
Senior VP, Marketing
408.378.0262 ext. 522
Email Contact

Marketing Contact:
Cheryl Monahan
Marketing Support Specialist
408.378.0262 ext. 530
Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

CoverageForAll.org Lanza en Español La Edición En-Línea de un Directorio de Programas Públicos y Privados para los 50 Estados

Posted on October 26, 2010 Written by Annalyn Frame

SOURCE: Foundation for Health Coverage Education

Beca de La Fundación Aetna hace posible este Nuevo servicio

SAN JOSE, CA–(Marketwire – October 26, 2010) – Esfuerzos para educar a los norteamericanos
sin seguro médico que no están conscientes de los programas de salud
actuales financiados por el gobierno y de bajo costo han recibido un
impulso con La Fundación para la Educación sobre Cobertura de Salud
(conocido por sus siglas en ingles FHCE) con el lanzamiento de una edición
en español de su sitio pionero www.CoverageForAll.org.

Esta organización sin fines de lucro fue capaz de traducir
CoverageForAll.org y así ampliar su alcance a la comunidad hispana con el
apoyo monetario de $ 30,000 de la Fundación Aetna, la rama filantrópica
independiente de Aetna Inc. La versión en español
http://espanol.coverageforall.org proporcionará a los visitantes de habla
hispana el mismo contenido que se encuentra en el directorio de programas
de cobertura públicos y privados de FHCE de estado por estado, el cual ha
educado norteamericanos sin seguro medico sobre sus opciones de cobertura
desde el 2004.

“En un momento en que la legislación de reforma de salud requiere que la
gente tenga cobertura de seguro de salud, tenemos que avanzar con mayor
urgencia para romper las barreras, como el lenguaje, para informar sobre
los programas de bajo costo o programas financiados por el gobierno,” dijo
Anne C. Beal, M.D., M.P.H., presidente de la Fundación Aetna. “Nos alienta
que la nueva versión en español de CoverageForAll.org permitirá a un
importante segmento de la población de norteamericanos tener un acceso a
nuestro sistema de salud. El establecimiento de condiciones equitativas
para todos los grupos raciales y étnicos para obtener una buena atención
médica es un área de programas prioritarios de la Fundación Aetna.”

Con este nuevo realce, los visitantes de CoverageForAll.org simplemente
podrán hacer clic en http://espanol.coverageforall.org y aprender sus
opciones de seguro de salud en español a través de un cuestionario de
elegibilidad de FHCE de 5 preguntas o pueden llamar 24/7 a la multilingüe
Línea de Ayuda Nacional (1-800-234-1317) para personas sin seguro medico y
hablar con un especialista de seguros médico, de habla hispana que va
ayudar a revisar las preguntas con ellos. Esta revisión de elegibilidad es
un punto de partida para los consejeros del centro de llamadas con sede en
Fresno, California, quienes guían a cada persona que llama a través de sus
opciones y los dirigen a los programas apropiados por el Estado. Además de
tomar el cuestionario de elegibilidad, los visitantes también tienen la
oportunidad de aprender acerca de la cobertura de COBRA a través de la
versión en español de COBRA con el folleto de FHCE o puede descargar el
Matrix de Opciones de Atención, una guía amistosa del consumidor fácil de
usar para todos los programas de cobertura médica en su estado.

El propósito de FHCE de traducir el sitio fue para ampliar su misión de
reducir las filas de las personas sin seguro, específicamente alcanzar al
32% de norteamericanos hispanos que muestra el Censo de EE.UU. viven si
cobertura de salud. La donación de la Fundación Aetna abrió una
oportunidad aún mayor para ayudar a la lista de socios colaboradores
actuales de FHCE, la Asociación Americana del Cáncer, la Asociación
Americana del Corazón, la Asociación Americana de los Pulmones, la
Asociación Americana de Diabetes, y el Departamento de Desarrollo de
Empleados de California y el Departamento de Seguros en ayudar su población
de hispanos.

“FHCE ha ayudado a mas de dos millones de personas a encontrar cobertura
medica a través de CoverageForAll.org y nuestra Línea de Ayuda Nacional,”
dijo Ankeny Minoux, presidente de FHCE. “Con los fondos recibidos de la
Fundación Aetna para una versión en Español de CoverageForAll.org, podemos
seguir proporcionando a norteamericanos sin seguro médico una forma fácil y
eficiente de tener acceso a la información sobre sus opciones de cobertura
medica en su propia lengua.

Acera de la Fundación Aetna :

La Fundación Aetna es la rama caritativa y filantrópica independiente de
Aetna Inc. Desde 1980, Aetna y la Fundación Aetna han contribuido con más
de $379 millones, incluyendo más de $20 millones en el 2009. Siendo una
fundación nacional de salud, promovemos el bienestar, la salud y el acceso
a la atención medica de alta calidad para todos. Esta labor se ve
reforzada por el compromiso y tiempo de los empleados de Aetna, que han
ofrecido casi dos millones de horas desde 2003. Nuestras donaciones
actuales se centran en hacer frente a la creciente tasa de obesidad
infantil y de adultos en los estadounidenses, en promover la igualdad
racial y étnica en el cuidado de salud y avanzar en el tratamiento
integrado de salud. Para mas información visite nuestra página
www.AetnaFoundation.org.

Acerca de La Fundación para la Educación sobre Cobertura de Salud:

La Fundación para la Educación sobre Cobertura de Salud es una organización
sin fines de lucro 501 (c) 3 organización con la misión de ayudar a
simplificar la información de acceso de elegibilidad de seguros públicos y
privados para que mas personas sin seguro tengan acceso a cobertura. Además
de su Línea Nacional de Ayuda para personas sin seguro (800) 234-1317 y su
pagina www.CoverageForAll.org, FHCE ofrece guías gratuitas a los
consumidores, tales como el Matrix de Opciones de Atención el cual está
disponible para todos los 50 estados

Contactos de Prensa:

Fundación para la Educación sobre Cobertura de Salud
Marilyn Haese/Bobbi Rubinstein
(310) 556-9612
[email protected]

Fundación Aetna
Susan Millerick
860-273-0536
[email protected]

Filed Under: Facilities And Providers

Sun Healthcare Group, Inc. Announces Anticipated Record and Distribution Dates in Connection With Its Restructuring Plan

Posted on October 26, 2010 Written by Annalyn Frame

SOURCE: Sun Healthcare Group, Inc.

IRVINE, CA–(Marketwire – October 26, 2010) –  Sun Healthcare Group, Inc. (NASDAQ: SUNH) today announced details concerning the anticipated timing of Sun’s previously announced plan to restructure its business by separating its operating assets and its real estate assets into two separate publicly-traded companies. As previously described, the separation of Sun’s operating assets will occur by means of a spin-off transaction pursuant to which Sun will distribute to its stockholders on a pro rata basis (the “Distribution”) all of the outstanding shares of common stock of its wholly-owned subsidiary, SHG Services, Inc. (“New Sun”). Following the Distribution, Sun will merge with and into its wholly-owned subsidiary, Sabra Health Care REIT, Inc., a Maryland corporation (“Sabra”). Immediately following completion of both transactions, New Sun will be renamed Sun Healthcare Group, Inc. and will own all of Sun’s operating subsidiaries, while Sabra, through its subsidiaries, will own substantially all of Sun’s currently owned real property assets. 

Sun expects to make the Distribution on Nov. 15, 2010 to its stockholders of record at the close of business on Nov. 5, 2010. At the same time as it makes the Distribution, Sun also intends to make a cash distribution to the same stockholders of record. The amount of the cash distribution is currently expected to equal approximately $0.17 per share (for an aggregate cash distribution to Sun’s stockholders of approximately $13 million), although the actual amount of the cash distribution will not be determined until the time the Distribution is declared by Sun’s board of directors. The merger of Sun with and into Sabra (the “REIT Conversion Merger”) is expected to be completed on Nov. 15, 2010, following the Distribution.

The actual record and distribution dates for the Distribution and cash distribution, and the actual amount of the cash distribution, are subject to approval and declaration by Sun’s board of directors, which is currently expected to occur on Nov. 4, 2010, subject to the satisfaction of certain conditions, including approval of the Distribution and REIT Conversion Merger by Sun’s stockholders at a special meeting of stockholders to be held on Nov. 4, 2010.

Commenting on the restructuring plan, Richard K. Matros, Sun’s chairman and chief executive officer, remarked, “The management teams of both Sabra and New Sun look forward to the completion of the transactions and the opportunity to enhance stockholder value through the growth of both companies.”

In connection with the Distribution, each Sun stockholder will receive one share of New Sun common stock for every three shares of Sun common stock held at the close of business on the record date for the Distribution. In addition, in connection with the REIT Conversion Merger, each Sun stockholder will receive one share of Sabra common stock in exchange for every three shares of Sun common stock held at the effective time of the REIT Conversion Merger. Sun stockholders will receive cash in lieu of any fractional shares of New Sun common stock and Sabra common stock to which such stockholders would otherwise have been entitled.

Shares of Sun common stock will continue to trade “regular way” on the NASDAQ Global Select Market under the symbol “SUNH” through the distribution date for the Distribution. Any holders of Sun common stock who sell their Sun shares regular way on or before the distribution date will also be selling their right to receive shares of New Sun common stock in connection with the Distribution and the additional cash distribution. Holders of Sun common stock also will not be entitled to receive shares of Sabra common stock in connection with the REIT Conversion Merger if they do not own Sun common stock at the effective time of the merger. Shares of Sun common stock will cease trading on the NASDAQ Global Select Market at the close of business on the date of the Distribution and REIT Conversion Merger. Investors are encouraged to consult with their financial advisors regarding the specific implications of buying or selling Sun common stock prior to this time.

New Sun common stock is expected to begin trading on a “when-issued” basis on the NASDAQ Global Select Market under the symbol “SUNHV” beginning on Nov. 8, 2010, the first business day after the record date for the Distribution. When-issued trading of New Sun common stock is expected to end and “regular-way” trading under the symbol “SUNHD” is expected to begin on Nov. 16, 2010, the first business day after the distribution date for the Distribution. Trading of New Sun common stock under the symbol “SUNHD” is expected to continue for approximately 20 trading days following the date of the Distribution. After this time, New Sun common stock will trade on the NASDAQ Global Select Market under the symbol “SUNH.”

Sabra common stock also is expected to begin trading on a “when-issued” basis on the NASDAQ Global Select Market under the symbol “SBRAV” beginning on Nov. 8, 2010. When-issued trading of Sabra common stock is expected to end and “regular-way” trading under the symbol “SBRA” is expected to begin on Nov. 16, 2010, the first business day after the REIT Conversion Merger. 

About Sun Healthcare Group, Inc.

Sun Healthcare Group, Inc.’s (NASDAQ: SUNH) subsidiaries provide nursing, rehabilitative and related specialty healthcare services principally to the senior population in the United States. Sun’s core business is providing, through its subsidiaries, inpatient services, primarily through 166 skilled nursing centers, 16 combined skilled nursing, assisted and independent living centers, 10 assisted living centers, two independent living centers and eight mental health centers. On a consolidated basis, Sun has annual revenues of $1.9 billion and approximately 30,000 employees in 46 states. At Oct. 1, 2010, SunBridge centers had 23,189 licensed beds located in 25 states, of which 22,407 were available for occupancy. Sun also provides rehabilitation therapy services to affiliated and non-affiliated centers through its SunDance subsidiary, medical staffing services through its CareerStaff Unlimited subsidiary and hospice services through its SolAmor subsidiary.

Forward-Looking Statements 

Statements made in this release that are not historical facts are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995) that involve risks and uncertainties and are subject to change at any time. These forward-looking statements may include, but are not limited to, statements containing words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “hope,” “intend,” “may” and similar expressions. Factors that could cause actual results to differ are identified in the public filings made by Sun with the Securities and Exchange Commission (“SEC”) and include Sun’s ability to complete the Distribution and REIT Conversion Merger on terms and conditions satisfactory to Sun or at all, as well as other risks and uncertainties, including those detailed from time to time in Sun’s SEC Commission filings. More information on factors that could affect the business and financial results are included in Sun’s public filings made with the SEC, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available on Sun’s web site, www.sunh.com. The forward-looking statements involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Sun’s control. Investors are cautioned that any forward-looking statements made by Sun are not guarantees of future performance. Sun disclaims any obligation to update any such factors or to announce publicly the results of any revisions to any of the forward-looking statements to reflect future events or developments.

Additional Information

In connection with the transactions described in this release, SHG Services, Inc. has filed with the SEC a Registration Statement on Form S-1 and Sabra Health Care REIT, Inc. has filed with the SEC a Registration Statement on Form S-4, each containing an identical prospectus and proxy statement for the special meeting. The definitive proxy statement/prospectus was mailed to Sun stockholders on Oct. 4, 2010. Before making any voting or investment decision, Sun stockholders and investors are urged to read the proxy statement/prospectus and other documents filed with the SEC carefully and in their entirety when they become available because they will contain important information about the proposed transactions. Stockholders will be able to obtain these documents free of charge at the SEC’s web site at www.sec.gov. In addition, investors and stockholders of Sun may obtain free copies of the documents filed with the SEC by contacting Sun’s investor relations department at (505) 468-2341 (TDD users, please call (505) 468-4458) or by sending a written request to Investor Relations, Sun Healthcare Group, Inc. 101 Sun Avenue N.E., Albuquerque, N.M. 87109. Investors and stockholders may also obtain a copy of these documents by requesting them in writing from Sun’s proxy solicitation agent, Innisfree M&A, at 501 Madison Avenue, New York, NY 10022, or by telephone at
(212) 750-5833.

Sun and its directors and executive officers and other members of its management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of Sun in connection with the transactions described in this release. Information about the directors and executive officers of Sun and their ownership of shares of Sun common stock are set forth in the definitive proxy statement/prospectus for the special meeting.

Contact:
Investor Inquiries
(505) 468-2341

Media Inquiries
(505) 468-4582

Filed Under: Facilities And Providers

VHA Hires David J. Robertson to Lead Regional Hospital Network

Posted on October 26, 2010 Written by Annalyn Frame

SOURCE: VHA

IRVING, TX–(Marketwire – October 26, 2010) –  VHA Inc., the national health care network, has hired David J. Robertson as senior vice president and executive officer over its Oklahoma and Arkansas region. The VHA Oklahoma/Arkansas office coordinates and directs VHA efforts to serve 43 member hospitals and hundreds of non-acute care organizations in the two states. 

Robertson assumes his new duties at VHA on Feb. 1, 2011. He currently serves as president and chief executive officer of Monongalia Health System in Monogalia, W.V., a position he’s held since January 2003. Prior to that, for 18 years he served as CEO of Duncan Regional Hospital in Duncan, Okla., after spending five years as CEO of Shelby County Myrtue Hospital in Harlan, Iowa.

“Dave brings to this position more than 30 years of experience as a hospital leader, and his extensive knowledge of hospital priorities and challenges gives him a solid platform to direct VHA resources to have the maximum benefit for members in the region,” said Gary Ford, group senior vice president at VHA.

Robertson holds a master’s degree in public health with a concentration in health administration and a master’s degree in business administration with an emphasis in marketing, obtaining both degrees from the University of Missouri in Columbia. He earned his bachelor’s degree in health care administration from Wichita State University in Wichita, Kan. He is the recipient of numerous awards in the health care industry, including being named the outstanding young health care administrator in Iowa and Oklahoma.

The VHA Oklahoma/Arkansas region, with offices in Little Rock and Oklahoma City, deploys staff to help members implement supply chain efficiency strategies, improve clinical performance and accelerate knowledge transfer to improve health care operations overall. The region also supports AROK, a regional supply network; and LifeCare Health Services, a regional business that provides employee benefit management services, a nurse advice line, a managed care consultancy and clinical and operational risk management support services. 

About VHA
VHA Inc., based in Irving, Texas, is a national network of not-for-profit health care organizations that work together to drive maximum savings in the supply chain arena, set new levels of clinical performance and identify and implement best practices to improve operational efficiency and clinical outcomes. Formed in 1977, through its 16 regional offices, VHA serves 1,400 hospitals and more than 30,000 non-acute care providers nationwide. VHA was ranked by Modern Healthcare as the 7th best place to work in health care in 2009.

Media Contact:
Lynn Gentry
Email Contact

Filed Under: Facilities And Providers

Future of European Flu Vaccine Market Rife With Innovation

Posted on October 26, 2010 Written by Annalyn Frame

SOURCE: Kalorama Information

NEW YORK, NY–(Marketwire – October 26, 2010) –  In 2009, the adult in flu vaccine market in Europe reached new heights with nearly $1.6 billion in revenues, up a whopping 81.4% from the prior year. According to healthcare market research publisher Kalorama Information’s newly published “European Vaccine Markets,” this surge in flu vaccine sales was due to products developed to address the H1N1 flu pandemic.

Influenza vaccines are responsible for almost half of the adult vaccine market in 2010. Although Kalorama does not foresee the same kind of growth witnessed in 2009, the publisher expects strong demand for flu vaccines to continue, tempered by a near term decrease in demand for pandemic vaccines. Flu vaccine revenues should reach $2.6 billion by 2014, supported by an aging population and expanded recommendations for adult influenza vaccinations.

“The swine flu pandemic of 2009 prompted a flurry of activity in the flu vaccines market around the world, with a resulting surge in revenues,” says Bruce Carlson, publisher of Kalorama Information. “This growth is unlikely to continue as governments overestimated the demand for H1N1 flu vaccines and found themselves with excess stock. Current development initiatives focus on products that protect against pandemic outbreaks, specific strains of influenza and alternative administration routes.”

In May 2008, GlaxoSmithKline received European approval for Prepandrix and Pandemrix; each contains the H5N1 (avian flu) inactivated split, monovalent virus. Prepandrix is designed to be given before or at the onset of a declared influenza pandemic to prevent influenza caused by H5N1. It is formulated with a novel proprietary adjuvant system, which is designed to achieve a high immune response at a low dose of antigen, and to be long-lasting and active against a broad range of H5N1 strains. Pandemrix is approved for use when an H5N1 influenza pandemic has been officially declared by the WHO or European Union.

In December 2008, the European Medicines Agency (EMEA) issued a positive opinion for Baxter’s CELVAPAN, the first cell culture-based H5N1 pandemic vaccine, in the European Union. CELVAPAN is made using Baxter’s proprietary Vero cell technology, which speeds up the manufacturing process due to its ability to use the native virus which does not need to be modified in order to grow in chicken eggs. The shorter production time is critical in accelerating vaccine supply in response to an influenza pandemic.

Also of note are advancing efforts to develop a universal flu vaccine which would protect against multiple influenza strains, thereby significantly increasing effectiveness. While many companies over the years have investigated methods to achieve this, U.K.-based Immune Targeting Systems, with funding from a broad range of investors including Novartis’s venture capital group, is expected to begin studies of a product candidate in 2010.

More information on flu and other types of vaccines in the European market can be found in Kalorama Information’s “European Vaccine Markets.” This report presents market estimates and forecasts, product reviews and pipelines, issues and trends, and company profiles for pediatric and adult vaccines. The report can be found at: http://www.kaloramainformation.com/redirect.asp?progid=79864&productid=2833006.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

Click here to see all recent news from this company

Filed Under: Facilities And Providers

PDC’s PermaPrint(R) Technology Outperforms Standard Direct Thermal Wristbands and Tags

Posted on October 26, 2010 Written by Annalyn Frame

SOURCE: Precision Dynamics Corporation

Patented PermaPrint® Provides Best Imprint Quality and Resistance to Solvents in Laboratory Testing

SAN FERNANDO, CA–(Marketwire – October 26, 2010) –  Precision Dynamics Corporation, the global leader in healthcare identification solutions, announced today that all of its direct thermal bar code ID products now feature its patented PermaPrint surface technology. Unlike traditional direct thermal patient wristbands and tags, PDC PermaPrint products provide optimized thermal heat transfer, which results in higher quality images when printing. It also provides stronger resistance to solvents and harsh storage environments, which can corrupt patient data.

“In talking to hospital staff, a common challenge with thermal printing is the consistency of the imprint,” said Kim Canchola, Product Manager for PDC. “Traditional thermal ID products have a layer of varnish that absorbs heat and disperses it unevenly along the wristband. With PDC’s PermaPrint wristbands and tags, heat is transferred evenly and consistently along the surface, resulting in higher quality images and more accurate readings versus standard thermal ID products.” Also, unlike traditional thermal ID products, PDC’s PermaPrint surface can be imprinted within a wide range of print head temperatures without compromising the quality of the imprint. This helps meet the needs of hospitals that use a variety of printers.

The PermaPrint surface is also designed to resist moisture and chemicals, which can blemish the surface of traditional direct thermal ID products, leading to potential patient misidentification. During laboratory testing at PDC, hand sanitizer was rubbed on the surface of the PDC Scanband® wristband and two competitor direct thermal wristbands. “While the competitor wristbands immediately became blemished, discoloring the wristband data, the PDC Scanband was unaffected,” said Canchola. The PermaPrint surface withstands hand sanitizer, as well as other chemicals including betadine iodine, isopropyl alcohol, hand lotion, and sunscreen.

“Having a wristband that stands up to moisture and chemicals during the full duration of the patient’s hospital stay protects patients and hospitals by preventing critical misidentification errors,” said Canchola.

In addition to solvents, product transport and storage conditions can also affect the quality and legibility of direct thermal products, which can be vulnerable to higher exposure to heat, direct sunlight, and humidity. Based in side-by-side product testing in more extreme heat and humidity conditions, standard direct thermal products became discolored, corrupting the data on the wristbands and tags, while PDC’s PermaPrint products showed no signs of discoloring or blemishing.

The PDC PermaPrint surface can also increase the lifespan of the printer’s print head. Traditional thermal ID products can transfer varnish to the print head, which can cause damage and lead to costly replacement. Print head longevity is also enhanced because PermaPrint requires less heat to print an image.

Printer speed can also impact the performance of direct thermal wristbands and tags, which have higher sensitivity compared to PDC PermaPrint products. This can affect the quality of the imprint when printing at high speeds. Because PermaPrint has a lower sensitivity, its imprint quality is unaffected by printer speed.

PDC PermaPrint Direct Thermal ID products meet current Joint Commission, AHA, and HIPAA requirements.
For more information, please visit: www.pdcorp.com/healthcare or contact PDC Customer Care at 800-772-1122.

About Precision Dynamics Corporation:
The Leading Provider of Positive ID and Positive Outcomes™
With more than 50 years of experience, Precision Dynamics provides accurate, reliable, and easy-to-use healthcare ID solutions that empower the flawless delivery of care and enhance outcomes across all major hospital functions. Our products are used in all of the leading hospitals worldwide and comprise a comprehensive range of wristband and labeling systems that provide positive ID and positive clinical outcomes.

Precision Dynamics products meet important guidelines of The Joint Commission, World Healthcare Organization, FDA, AHA, and HIPAA. As the developer of the first single-piece patient wristband, the first bar code wristband system, and the first Smart Band® RFID wristband system, Precision Dynamics solutions are an integral part of some of the most successful patient safety initiatives. As an ISO 9001 certified company, Precision Dynamics follows a systematic, world-standard approach to ensure superior product design, manufacturing, and customer support services.

MEDIA CONTACT:
Daniel Hobin
Precision Dynamics Corporation
818.897.1111 x 1340
Email Contact

Filed Under: Facilities And Providers

Dean Evans & Associates Completes First Facilities and Services Benchmark Survey of Its Kind

Posted on October 26, 2010 Written by Annalyn Frame

SOURCE: Dean Evans & Associates, Inc.

Free Executive Summary Highlights Stats and Trends

DENVER, CO–(Marketwire – October 26, 2010) – Dean Evans & Associates, Inc. (www.dea.com), maker of the EMS line of facility and resource scheduling software, has completed an ambitious benchmarking survey initiative that will provide participants with valuable metrics on their meeting and event management operations.

More than 150 customers filled out the inaugural Facilities and Services Benchmark Survey, which is believed to be the first cross-industry survey of its kind, as it provides comparison data both within the participant’s industry and across the many industries that DEA serves. While detailed results will only be sent to participants, an Executive Summary is available to the public.

“We deeply appreciate the eagerness participants showed and the time they invested in answering the benchmark survey questions. As a result, we’re able to offer important data to our current and future customers,” said Kevin Raasch, vice president of Dean Evans & Associates. “Each participant can use their customized survey report as a yardstick to measure their performance and identify areas for improvement.”

The survey compared individual organizations’ key metrics, such as bookings-to-scheduling staff ratios, overall space utilization and service order numbers with their industry standards as well as with responses across all industries, generating powerful insights into facility scheduling best practices.

“Individual measurements such as number of bookings per year, number of staff members by job function and average hours of operation per day can be very helpful in and of themselves,” said Raasch. “But combining two or more of those numbers to get stats like the number of hours per day that your scheduling staff spends making reservations or the average number of service orders that each of your catering staff members is involved in each day can be very enlightening — especially when compared to other organizations in your industry.”

The survey also asked a number of subjective questions including some designed to identify trends. Event volume expectations, desired software integrations and anticipated shifts in technology were among them.

The 2011 Facilities and Services Benchmark Survey will be sent to customers and selected prospective customers next spring. To request a free copy of the Executive Summary from this year’s survey, please visit www.dea.com and click Benchmark Survey Summary under Quick Links.

Media Contacts:

Jennifer O’Connell
DEA Communications Coordinator
(303) 740-4838
[email protected]

Filed Under: Facilities And Providers

MMRGlobal to Link to U.S. Vets With www.MyBlueButton.org Website

Posted on October 26, 2010 Written by Annalyn Frame

SOURCE: MMRGlobal, Inc.

LOS ANGELES, CA–(Marketwire – October 26, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (MMR) announced today it plans to offer U.S. Veterans the opportunity to maintain all their medical records and personal health information directly in a MyMedicalRecords Personal Health Record (PHR) located at www.MyBlueButton.org. The service will be provided at no cost for the first year as a thank you for their service to our country. Each account will cover the Veteran and up to nine additional family members to securely store personal health information, medical records and medical images in addition to any important document needed in an emergency.

On August 2, President Obama announced the “Blue Button” initiative (http://www4.va.gov/bluebutton) that allows U.S. Veterans to download their personal health information from their My HealtheVet account. On April 30, 2011, at a special event at the Playboy Mansion honoring Veterans and Operation Mend at the UCLA Health System Medical Center, MMRGlobal will launch its www.MyBlueButton.org website linking to its MyMedicalRecords Personal Health Record. The Company’s PHR can store the full range of medical records, from lab reports and doctor’s notes to immunizations and X-rays and other medical images, and also includes multiple special “lockbox” folders with secondary passwords for other important documents such as military discharge papers, gun permits, passports, birth and marriage certificates, insurance policies and deeds of trusts.

“We appreciate the sacrifices made for our safety and security by the brave men and women of our armed forces,” said Robert H. Lorsch, Chairman and CEO of MMRGlobal. “Although no commercial enterprise can fully repay them, we want to offer Vets the opportunity to use their ‘Blue Button’ to store their most important records with the safety and security of our advanced patented technologies on our www.MyBlueButton.org site. This way, Veterans can be assured that their records can be shared in any emergency with doctors in or out of the VA system from any Internet-connected computer anywhere in the world. At the same time, our system ensures the highest level of privacy because users maintain control over who has access to their records and the Company does not use third party intermediaries to retrieve data. And unlike any other product of its kind, users are protected by a one million dollar Cyber Liability policy protecting their important information.”

MMR’s MyBlueButton.org program rides on the back of the government’s “Blue Button” initiative and branding and augments the Administration’s national calling for all Americans to have a Personal Health Record by 2014. Delivering the most comprehensive PHR product in the marketplace today, the MyMedicalRecords system is built on an integrated telecommunications platform incorporating Internet, fax and phone to transmit and store personal health information and other important data in one central secure online account with a single sign-on. This provides for the ultimate flexibility in communicating and accessing information which the Company believes is necessary to accelerate widespread adoption of Personal Health Records by 2014.

The MyMedicalRecords PHR also offers other valuable tools to help Vets and their families have greater control over their health and better manage their lives overall. In addition to its ease-of-use and availability in both English and Spanish, the system includes a family health history, a drug database and drug interaction tool that can automatically check for interactions between over 20,000 medications and also food allergies, and a reference center containing information on 3,000 conditions and diseases. Importantly, there is a separate Emergency Login that medical personnel and authorized users can access to retrieve potentially life-saving information in a crisis situation; and each account also comes with its own inbound and outbound e-fax capability which further expands the options for quickly and easily sharing information.

According to Lorsch, “The service will be free for a year and then additional years’ subscriptions will be provided by our Company at prices well below the cost of the personalized voice fax telecommunications services embedded in every account. Our numbers show that 99 percent of all MyMedicalRecords users do not cancel the service after the initial period. I also plan to work through the Robert H. Lorsch Foundation Trust to identify non-profits that can underwrite services for Veterans and their families in subsequent years.”

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (MMR), provides secure and easy-to-use online Personal Health Records (PHRs) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. MMRGlobal’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMRGlobal, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements, and some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” “help” and “continue,” or the negative of such terms and other comparable terminology. MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.’s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related but not limited to changes in MMRGlobal, Inc.’s business prospects, its results of operations or financial condition, government regulation and changes in healthcare initiatives, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

CONTACT:

Michael Selsman
Public Communications Co.
(310) 553-5732
[email protected]

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Eating Recovery Center to Open Innovative Eating Disorders Hospital for Children and Adolescents

Posted on October 26, 2010 Written by Annalyn Frame

SOURCE: Eating Recovery Center

World-Renowned Expert, Dr. Ovidio Bermudez, to Lead the New Treatment Center

DENVER, CO–(Marketwire – October 26, 2010) –  Eating Recovery Center (www.EatingRecoveryCenter.com), a national eating disorders recovery program providing comprehensive treatment for anorexia and bulimia, today announced that it will open a new behavioral hospital specifically designed to provide eating disorders care to children and adolescents. The hospital is slated to open in late November in Denver’s Lowry neighborhood. 

Eating Recovery Center’s newest treatment program will be led by a world-renowned expert in child and adolescent eating disorders, Ovidio Bermudez, MD, FAAP, FSAM, FAED, CEDS. Dr. Bermudez will serve as the hospital’s new medical director. It will operate under the direction of the treatment center’s CEO and co-founder, Kenneth L. Weiner, MD, CEDS, and its chief clinical officer, Craig Johnson, PhD, FAED, CEDS. 

“The child and adolescent hospital will offer comprehensive treatment for eating disorders for children and adolescents, males and females. Our comprehensive treatment model will blend traditional approaches like medical stabilization, psychiatric stabilization and nutritional rehabilitation with new approaches like Behavioral Family Therapy in the partial hospitalization phase of the treatment experience,” explains Dr. Bermudez. “We have carefully chosen an outstanding staff and, in addition, will use technologies to enhance patient care. Our goal is to be a center of excellence and to offer the best treatment to the patients and families we care for.”

The child and adolescent facility will offer a full spectrum of treatment options for children and adolescents ages 10 to 17, including inpatient, residential, partial hospitalization, intensive outpatient and outpatient services. In addition to treating eating disorders, such as anorexia and bulimia, the treatment center will address “eating disturbances,” which include such behaviors as extreme pickiness, food fears and food avoidance.

Eating Recovery Center’s multidisciplinary treatment team will work closely with families and referring professionals to collaborate on traditional treatment experiences such as nutritional rehabilitation, medical care and psychotherapy. Eating Recovery Center will also introduce such innovative approaches as:

  • Utilizing technology, such as heart monitoring, movement monitoring and biofeedback, to monitor for overactive behaviors and manage anxiety in children and adolescents.
  • Introducing Behavioral Family Therapy at a later point in the treatment continuum — after a traditional phase of treatment in 24-hour care — to allow patients to manage nutritional deficiencies and medical issues prior to collaboration with family.

“Recent studies have shown that the involvement of family in the treatment process has a positive impact on recovery,” explains Dr. Weiner. “We will work closely with families to integrate recovery-focused behaviors and sustainable changes into family life, enabling family members and loved ones to become agents of change for our patients.”

Eating Recovery Center’s child and adolescent hospital will be located at 8140 E. 5th Ave., Denver, Colo., and is now accepting patients from across the country.

About Eating Recovery Center
Eating Recovery Center is a national center for eating disorders recovery providing comprehensive treatment for anorexia and bulimia. Denver-based facilities include a licensed behavioral hospital treating adults, an outpatient office and a facility treating children and adolescents scheduled to open in November 2010. Under the personal guidance and care of Drs. Weiner and Bishop, and the newest additions to our leadership team — Drs. Craig Johnson and Ovidio Bermudez, our collaborative programs provide a full spectrum of services for children, adolescents and adults. Our integrated program offers patients from across the country a continuum of care that includes inpatient, residential, partial hospitalization, intensive outpatient and outpatient services. Our compassionate team of professionals collaborates with treating professionals and loved ones to cultivate lasting behavioral change. For more information please contact us at 877-218-1344 or [email protected] or confidentially chat live on our website at www.EatingRecoveryCenter.com.

Contact:
Shannon Fern
CSG|PR
303.433.7020
Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Medical Professionals Increasingly Adopting the SHAPE Guidelines

Posted on October 26, 2010 Written by Annalyn Frame

SOURCE: Society for Heart Attack Prevention and Eradication

Effort to Detect and Treat Heart Attack Risk in Apparently Healthy People Gains Foothold in Lebanon

HOUSTON, TX–(Marketwire – October 26, 2010) –  SHAPE, The Society for Heart Attack Prevention and Eradication (http://www.shapesociety.org), a nonprofit organization that promotes the early detection and treatment of heart attack risk in apparently healthy people, today awarded SHAPE Provider Certification to 10 medical providers from around the world. The newly certified providers include nine physicians in Lebanon and one registered nurse in Arizona.

“SHAPE Provider Certification focuses on best practices for reducing the incidence of acute coronary events and deaths from coronary artery disease, and we are pleased that medical providers around the world are finding it to be a valuable resource,” said JoAnne Zawitoski, chair of the SHAPE Board of Directors. “Through a rigorous process of training and examination, the program teaches how to identify clinically appropriate patients for non-invasive screening for coronary artery disease, which advances our mission of promoting the early detection of CAD.”

The nine newly certified physicians in Lebanon participated in a course facilitated by Hussain Isma’eel, M.D.

SHAPE Provider Certification adheres to the First SHAPE Guideline for screening to identify hidden CAD in apparently healthy patients. The SHAPE II Task Force will convene at the American Heart Association (AHA) Scientific Sessions 2010 on November 13th and is expected to recommend updates that incorporate what has been learned through research and medical practice during the four years since the First SHAPE Guideline was introduced.

In addition to SHAPE Provider Certification, SHAPE encourages best practices in heart attack screening through SHAPE Certified Centers of Excellence. Unlike traditional cardiovascular clinics that are primarily focused on preventing a second heart attack, SHAPE Certified Centers of Excellence focus on the prevention of a first heart attack.

SHAPE’s exhibit at the AHA Scientific Sessions 2010 (Booth #1708) will showcase updates to the SHAPE Guideline as well as the SHAPE Certified Centers of Excellence program and SHAPE Provider Certification initiative.

SHAPE Certified Providers

United States

Kelly Coracides, RN
Mercy Gilbert Medical Center
Gilbert, AZ

Lebanon

Mohammad Dghaili, MD
Alaeedine Hospital
Sarafand, Lebanon

Mohammad Sleiman, MD
Beirut, Lebanon

Samir Arnaout, MD
Beirut, Lebanon

Adel Dimassi, MD
Beirut, Lebanon

Ali Jaffal, MD
Nabatieh, Lebanon

Imad Marji, MD
Beirut, Lebanon

Jihad Chebbo, MD
Saida, Lebanon

Ali Mansour, MD
Beirut, Lebanon

Gilbert Abi Nader, MD
Beirut, Lebanon

About SHAPE
Based in Houston, the Society for Heart Attack Prevention and Eradication (SHAPE) is a non-profit organization that promotes education and research related to prevention, detection, and treatment of heart attacks. SHAPE is committed to raising public awareness about revolutionary discoveries that are opening exciting avenues to prevent heart attacks. SHAPE’s mission is to eradicate heart attacks in the 21st century. Additional information is available on the organization’s Web site at www.shapesociety.org.

Contact:
Daniel Keeney, APR
DPK Public Relations
832.467.2904
Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Accentus Inc.: New Services Help Healthcare Organizations Create and Manage Electronic Health Records

Posted on October 26, 2010 Written by Annalyn Frame

OTTAWA, CANADA–(Marketwire – Oct. 26, 2010) – Accentus Inc. the leading provider of Transcription Services for the Canadian healthcare industry announced today that it is launching two new services – Document Imaging and Remote Coding. These new services together with the company’s well entrenched Transcription Service will allow Accentus to offer a completely Integrated Medical Document Management Solution.

“Accessibility, availability, and usability of patient health information are of paramount importance to providing the best possible healthcare,” said Stephen Rogers, Chief Executive Officer, Accentus Inc. “Our services help healthcare organizations electronically capture and manage patient data from multiple sources and make it available at the click of a button to healthcare professionals facilitating more immediate diagnosis and more timely access to data for trending and funding activities.”

Accentus will offer archival, near real-time and real-time document imaging services bringing significant efficiency gains to each step in the document imaging process to save clients time and money. Using patented software Accentus Document Imaging Services automate otherwise manual processes in the document preparation and scanning stages greatly reducing man-hours and human-error. Accentus will also take a multi-tiered approach supported by industry-leading logic and intelligence software to fully automate image processing. Many functions such as content understanding, indexing, forms recognition, electronic content separation and sorting, content identification and/or extraction, rules based workflow management, and, exception handling will be carried out electronically.

Through Accentus Remote Coding Services healthcare organizations will have access to a team of certified Health Information Management professionals fully trained on the ICD-10-CA coding standard, as well as, coding tools such as computer assisted coding and auditing software and regulatory compliance functionality with submission interface.

Accentus’ multifunctional document management platform, eDoc, will support both new services. eDoc’s, integrated electronic content management (ECM) functionality allows for easy search and retrieval of scanned images, the extraction and use of information contained within those images, secure web enabled remote or shared access to documents, and easy management of chart content deficiencies. It can greatly enhance existing hospital electronic health records systems that are image-enabled or can be integrated with those that are not.

Business Process Management software further enhances eDoc’s ECM capability. Healthcare organizations can improve efficiency and productivity by fully automating and streamlining business processes, electronically distributing tasks, implementing and enforcing business rules, documenting and measuring performance, and accessing data for real-time and historical reporting.

Accentus offers a transactional fee structure, partial to full outsourcing flexibility, a highly skilled workforce, end-to-end workflow management, comprehensive reporting, SaaS based technology platform to support services, strict adherence to both provincial and national (PIPEDA) standards, and a strong commitment to quality.

About Accentus Inc.

Accentus provides Integrated Medical Document Management Solutions for the creation of electronic health records. Leading hospitals, medical clinics, and independent physicians across Canada rely on Accentus to capture accurate and timely patient health information. Combining state-of-the-art technology, human resources, industry knowledge, and value-add services, Accentus, delivers outsourced or co-sourced medical document management solutions based on a pay- and scale- as-you-go business model. Accentus Enterprise Services meet the needs of hospitals and large clinics and Accentus MD, is a hospital calibre transcription service specifically tailored to meet the needs of individual doctors and group practices. Accentus was founded in 2001, is headquartered in Ottawa, Canada, and privately funded.

Filed Under: Facilities And Providers

Gemino Healthcare Finance Receives Rating Upgrade; Extends Credit Facility

Posted on October 26, 2010 Written by Annalyn Frame

SOURCE: Gemino Healthcare Finance

PHILADELPHIA, PA–(Marketwire – October 26, 2010) –  Gemino Healthcare Finance (“Gemino”) today announced it has received a rating upgrade from rating agency DBRS to A from BBB. The rating change was based upon the historical performance of the loan portfolio, underlying collateral pools and the structural integrity of the transactions.

Mike Gervais, Chief Executive Officer of Gemino, said, “Obtaining the upgrade to A was another milestone for Gemino. It validates the quality of our clients, credit team, and overall business. We have funded over 40 deals since we launched Gemino in 2007 and are very focused on continuing to expand our business.”

Gemino Extends WestLB Credit Facility
Gemino also announced that it has received a two year extension on its credit facility with WestLB.

“We are excited about extending our facility with WestLB and having them continue to support the growth of our business. They have been a valuable partner the last three years through a difficult lending environment,” said Stacy Allen, Vice President of Operations and Treasurer for Gemino.

Matt Tallo, Executive Director for WestLB, said, “WestLB is happy to continue to support Gemino. We have an extensive history with the team and look forward to working with them as they grow their business.”

About Gemino Healthcare Finance (www.gemino.com)
Gemino, a privately held commercial finance company, provides senior loans to healthcare service providers throughout the U.S., with typical financing needs ranging from $2 million and up in the form of revolving lines of credit and term loans.

Based in Philadelphia, with offices in Atlanta, Dallas and Los Angeles, Gemino provides loans to growing healthcare companies for working capital, recapitalizations, acquisitions and other general corporate purposes.

About WestLB Structured Finance
WestLB develops sophisticated structured solutions through a team of highly experienced investment banking professionals. WestLB has a long-standing presence in the corporate, structured and project financing sectors supporting clients’ needs with capital commitments, advisory services and innovative financing solutions. The bank’s global relationships, coupled with its unique understanding of local economies, industries and cultures, help WestLB bankers consistently deliver high quality advice and service. For more information, please visit www.westlb.com.

About WestLB
WestLB AG is one of Germany´s leading financial services providers and offers the full range of products and services of a universal bank, focusing on lending, corporate and structured finance, capital market and private equity products and transaction services. WestLB has total assets of EUR 251.2 billion, as of June 30, 2010. For more information, please visit www.westlb.com.

In the United States, certain securities, trading, brokerage and advisory services are provided by WestLB’s wholly owned subsidiary WestLB Securities Inc., a registered broker-dealer and member of the NASD and SIPC.

CONTACT:
Joni Miller
770-321-4033
Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Laura’s Journeys, an Organization Supporting Travel Therapy, Awards 3 Vacations to Cancer Patients at St. Luke’s-Roosevelt Hospital

Posted on October 26, 2010 Written by Annalyn Frame

SOURCE: Laura’s Journeys

Grand Prize Winner Chosen by Lance Armstrong During Surprise Visit to Infusion Suite

NEW YORK, NY–(Marketwire – October 26, 2010) –  Patients undergoing treatment for cancer at St. Luke’s-Roosevelt Hospital were recently treated to a vacation giveaway and a surprise visit by seven-time Tour de France winner Lance Armstrong.

The renowned cancer survivor and founder of LIVESTRONG was joined by LIVESTRONG President and CEO Doug Ulman and American Cancer Society CEO Dr. John Seffrin on a tour of the hospital’s chemotherapy infusion suite. In addition to personally interacting with the patients, the prominent visitors gained first-hand knowledge of the hospital’s quality-of-life initiatives for cancer patients. These include art, music, and massage therapy programs funded by the Helen Sawaya Fund, as well as the travel therapy program funded by Laura’s Journeys (www.laurasjourneys.org).

During the Sept. 22nd visit, three vacations were awarded in the latest raffle from Laura’s Journeys, a support program for cancer patients at St. Luke’s-Roosevelt and other institutions within the Continuum Health Partners network, designed to encourage and facilitate recreational travel for patients along with their family members or friends. The three winners and a runner-up were drawn by Messrs. Armstrong, Ulman, Seffrin and previous Laura’s Journeys winner Rodney Carroll from over 80 entrants, all currently undergoing chemotherapy or radiation treatments. Prior to the drawing, Mr. Carroll told patients and others in the infusion suite about the life-changing impact of his family’s week-long visit to Greece in late-spring.

The latest drawing’s grand prize went to Aida George, 41, a resident of Yonkers, N.Y. being treated for breast cancer. Ms. George won accommodations for seven nights in a fully-furnished, five-bedroom, three-bath vacation home, complete with a private swimming pool and hot tub. The accommodations were donated by Pytha Realty Group of Merritt Island, http://www.pytharealty.com. The winner will travel to Merritt Island with her husband, three children, and her mother, later this fall. In addition to relaxing at the house and beach, the family plans to travel to nearby Orlando, where they will go to Disney World and other theme parks, and visit with family members who live in that area. Laura’s Journeys is providing funding for the family’s travel expenses.

The second winner, who requested privacy, is a 58-year-old male from Westchester County undergoing treatment for colorectal cancer. He will travel with his wife this fall to the Berkshire Mountains for a two-night stay at The Summer White House, a bed & breakfast in Lenox, Mass. 

The third winner, Jean Scheller, a 44-year old resident of Weehawken, N.J. being treated for ovarian cancer, also won a two-night stay at the Summer White House, where she will travel with a friend this fall. In addition to the accommodations, Laura’s Journeys is providing both Berkshires trip winners with funds for meals and local attractions. 

Laura’s Journeys was created by Aberdeen, N.J. resident Bill Parness in memory of his wife Laura, who passed away in November 2008 at the age of 54 after a courageous battle with breast cancer. He developed the program based on the therapeutic benefits he and Laura derived from their extensive travels during the six years she was being treated for advanced breast cancer. Since its inception in late 2009, Laura’s Journeys has sent St. Luke’s-Roosevelt Hospital patients on week-long cruises to the Caribbean and New England/Canada; week-long stays in Greece and Florida; and weekend getaways to the Berkshires. With these three latest trips, the program will have awarded nine vacations to patients in the space of a year. 

Laura Parness was a patient of Gabriel A. Sara, M.D., Medical Director of the Chemotherapy Infusion Suite and Executive Director of the Patient Services Initiative at Continuum Cancer Centers of New York, located at Roosevelt Hospital. As he was with Laura, Dr. Sara is a strong advocate for therapeutic travel for his patients.

“The benefits of our philanthropy programs — including Laura’s Journeys and the music, art and massage therapy programs funded by the Helen Sawaya Fund — are so immense that today, I can hardly imagine running the chemotherapy infusion suite without them,” said Dr. Sara. “Patients’ journeys are transformed as they feel they can play, dream and feel alive, all over again. The fact that LIVESTRONG and ACS chose to visit our unit because of our philanthropy program validates and reaffirms the power of our work. I hope it will help drum up financial support so we can continue to offer this life-altering support to our patients.”

He added: “Lance Armstrong’s visit was a very emotional experience for all of us. During his visit, he interacted with all of us and heard the testimonies of Fuad Sawaya and Bill Parness about their late wives, Helen and Laura, respectively. Lance was very engaged and curious to know more about these programs and how they have transformed the experience of patients and staff alike. During Lance’s interactions with every patient in our infusion suite, you could just feel that this was familiar territory and that he had been there, done that and survived a similar experience. It was touching to see him look into the patients’ eyes and inquire about their feelings. The patients, of course, were so moved. But the highlight of the visit was undeniably the Laura’s Journeys travel raffle. We always start by creating a certain atmosphere of festivity and playfulness. We gave out percussion instruments, and our music therapist played a Beatles song in the middle of the chemo suite, as guests, staff, patients and everyone began to sing. No one could believe this was a chemo suite in which 18 patients were receiving treatment.” 

In early 2010, LIVESTRONG announced they would recognize The Creative Center, a Manhattan-based group that runs the art therapy program at St. Luke’s-Roosevelt and 19 other New York area hospitals, as a “Model Program” and would work with them to expand their Artist in Residence program to 20 new cities across the U.S. This commitment makes LIVESTRONG the largest funder of the program and was the driving force behind Mr. Armstrong’s visit.

“The Creative Center provides patients with a connection to the things they like to spend time doing,” said Mr. Armstrong. “Being exposed to art and music has created a community among the patients that is inspirational. It has been amazing to see the result of LIVESTRONG‘s funding affecting patients in such an overwhelmingly positive way.”

Filed Under: Facilities And Providers

Prolitec Names Bhandari Director of Business Development

Posted on October 26, 2010 Written by Annalyn Frame

SOURCE: Prolitec

MILWAUKEE, WI–(Marketwire – October 26, 2010) –  Prolitec Inc., a leading developer of air treatment and air care technologies, today announced the appointment of Suresh Bhandari, 45, as Director of Business Development.

 In his new position, Mr. Bhandari, who is based in the Washington, D.C. area, will be responsible for managing the company’s government sales effort nationwide.

Bhandari comes to Prolitec from First American Corporation, a Fortune 500 company and the leader in providing nationwide property information and analytics in support of the financial and real estate sectors, where he served as Director, Federal Solutions since 2007. In that capacity, he was responsible for managing sales, marketing and GSA/GWAC functions for the company’s federal business unit. 

 Prior to that, Bhandari established the Federal Practice for Global Consultants, a $200 million IT solutions and staffing company based in Herndon, Va. As General Manager, he directed all phases of the Federal Practice’s strategy, marketing, sales, operations, and client relationships.

Earlier in his career, Bhandari worked in sales and marketing at several software and information systems companies. He began his career in 1996 as a regional sales manager for Upspring Software, Inc., Lexington, Mass., and went on to serve as vice president of sales and marketing at Rjay Consultants, Inc., Sterling, Va.; director of marketing and strategic alliances at Invertix Corporation, Alexandria, Va.; and vice president, strategic relations, Artech Information Systems, McLean, Va., before joining Global Consultants in 2004.

Mr. Bhandari, a resident of Oakton, Va., earned a Master of Science degree in computer science from Arizona State University, Tempe, Ariz.; a Bachelor of Engineering in computer engineering and science from Bangalore University, Bangalore; and, concurrently, a Diploma in Commerce, with emphasis on marketing & sales, commerce, accounting and mercantile law from Davars College of Commerce, Bangalore. 

About Prolitec
Prolitec (www.prolitec.com) develops and deploys air-treatment and air care technologies for healthcare facilities, hotels, casinos, and other institutional and commercial facilities in the U.S. and 46 countries around the world. The company’s Aerobiology and Infection Control division is engaged in the development and deployment of airborne and surface antimicrobial systems to inhibit disease transmission. 

Filed Under: Facilities And Providers

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 12
  • Next Page »

Search Our Site

Categories

  • AARP
  • Blue Cross Blue Shield
  • Canadian Health Care System
  • CIGNA HealthCare
  • COVID-19
  • Facilities And Providers
  • FDA
  • Health Clinics
  • Healthcare Companies
  • Healthcare Plan News
  • Humana
  • MedBasics
  • Medical And Healthcare
  • Medical Malpractice
  • Medicare
  • Senior News
  • The SCOOTER Store

Our Partners

Portal of Dallas
Auto News Review
OSS News Review
Holly Bushes
Rose Bushes
SatelliteDish.Net
I Go Cars
Bad School Photos
Canonical Tag
Check A Domain
Idaho Resorts
iWannaBeFamous
Mabank Online
Stockyards
TravelXL

Pages

  • 1199 National Benefit Fund
  • A Little about Drug Preparation and Formulation Development
  • About Us
  • Achieve Your Weight Goals with Advanced Thermogenic with NMN
  • Affordable Health Insurance
  • Anavar: A Deep Dive into Athletic Benefits, Potential Side Effects, and Weight Loss Applications
    • Anavar Cycle: Benefits, Dosages, and Side Effects
      • Anavar Cycle: Benefits, Dosages, and Side Effects
    • Deca Durabolin vs Anavar: Comparing Performance Enhancers
  • B12 Elite Elixir: Vitalizing Your Health and Energy Levels
  • Benefits of Hiring a Senior Caregiving Service
  • Catastrophic Health Insurance
  • Cheap Health Insurance
  • Cheap Health Insurance Plans
  • Child Health Insurance Plans
  • Choosing a Health Insurance Plan
  • Christian Health Insurance
  • Dental Assistants and Their Future
  • Disclaimer
  • Dr. Howard Bellin: Questions about Rhinoplasty
  • Elite Health Online Dual Stack approach: Unlock your weight loss potential
  • Elite Thermogenic Formula: A Game-Changer in Weight Management and Metabolic Health
  • Finding the Right Dentist
  • Get Your Winks in Blink
  • Harnessing the Power of HGH for Vitality and Youthfulness
  • Health Insurance
  • Health Insurance Plans For Family
  • Health Sharing Plans
  • Healthcare and Hospitals: Disinfection is Key
  • High Deductible Health Plans
  • Home Care Employment in Arizona
  • Hormone Replacement Therapy
    • Harmonizing Body and Spirit: Navigating through Hormone Replacement Therapy
    • Hormone Replacement Therapy (HRT) – A Double-Edged Sword
    • Hormone Replacement Therapy (HRT): A Guide to Rebalancing Hormones
    • Hormone Replacement Therapy (HRT): Balancing the Benefits, Side Effects, and Menopausal Relief
    • Hormone Replacement Therapy: Benefits & Considerations
  • Hot ROCS: The Ultimate Solution for Enhanced Energy and Metabolism
  • How A Medical Weight Loss Plan Can Help You Get The Figure You Want
  • How Ketamine Therapy Helps Fight Depression
  • How Orthotic Insoles Improve Your Health
  • Individual Health Insurance Plans
  • Ketamine Uses and Benefits
  • List of Health Insurance Companies
  • Low Income Health Insurance
  • Medical Device CROs: The Role in Research and Development
  • Medical Malpractice
  • Medical Research Consultants
  • Menopause and HRT
  • Mounjaro (Tirzepatide): A Breakthrough in Diabetes and Obesity Management
  • Nicotinamide Adenine Dinucleotide – Unleashing Vital Molecule Power for Optimal health
    • Unlocking the Power of NMN in Our Advanced Thermogenic and NMN Formula
  • Oxytocin Benefits
    • Oxytocin: The Love Hormone Decoded
    • Oxytocin: The Love Hormone’s Role in Bonding and Beyond
  • Oxytocin Benefits and Hormone Therapy
  • Peptides: The Future of Health and Wellness
    • Semax Peptide – A Glimpse into Nootropic Advancements
  • Personal Lubricants for Women – Liven Up Your Life!
  • Phentermine: Benefits, Usage, and Potential Side Effects
  • Privacy Policy
  • Private Health Insurance Plans
  • Rapamycin, the anti-aging marvel and its multidimensional health benefits
    • Rapamycin: The Anti-Aging Wonder Drug
  • Rhesus Negative
  • Self Employed Health Insurance
  • Semaglutide: A Safe and Effective Alternative to Surgical Weight Loss
    • Semaglutide and its Weight Loss Benefits
    • Semaglutide: A Revolutionary Treatment Explored
    • Semaglutide: Bridging Diabetes Treatment and Weight Loss While Managing Side Effects
    • Semaglutide: Revolutionizing Weight Loss and Diabetes Management
    • Semaglutide: Transforming Weight Management and Glycemic Control
  • Short Term Health Insurance Plans
  • Student Health Insurance Plans
  • Temporary Health Insurance
  • Terms of Use
  • Testosterone Replacement Therapy Insights
    • Exploring the HCG Diet: Unveiling a Unique Pathway Towards Weight Management
    • Testosterone for Females: Balancing Health & Wellness
      • Testosterone for Females: Exploration of Hormonal Balance and Health
    • Testosterone Replacement Therapy (TRT): A Comprehensive Guide
    • Unlocking the Pivotal Role of Testosterone in Holistic Wellbeing
  • Testosterone Therapy: Weighing the Benefits, Risks, and Identifying Symptoms
    • The Vital Role of Testosterone in Health & Well-being
  • The Basic Building Blocks For a Sustained, Healthy Diet
  • The Importance of Clinical Study Software
  • The Marvels and Misgivings of Rapamycin: A Glimpse into Anti-aging and Longevity Benefits
  • The Use of Post Cycle Therapy Supplements
  • Timeless Beauty Med Spa: Elevating Skincare in Dallas, Texas
    • Achieve Your Body Goals with Emsculpt Neo: Now Available at Timeless Beauty Med Spa in Dallas, Texas
    • The Ultimate Guide to Facials: A Path to Radiant Skin
  • Travel Health Insurance
  • Ultimate Guide for Anavar Cycles
  • Understanding Metformin: Benefits and Insights
    • Metformin: A Pillar of Hope in Weight Loss Journeys
    • Metformin: The Multifaceted Medication for Modern Health Challenges
  • Understanding Nandrolone: Benefits and Uses
    • Demystifying Nandrolone: Uses, Potential Benefits, and Considerations
    • Nandrolone for Joint Pain: Efficacy, Benefits, and Considerations
    • Nandrolone: From Muscle Building to Therapeutic Uses and Side Effects
  • Unleash your Potential with Nandrolone & Deca Durabolin
  • Unleashing Glutathione’s Power: The Key to Anti-Aging and Health
  • Unlocking Testosterone’s Power: A Comprehensive Guide to Better Health
  • Winstrol – Beyond the World of Bodybuilding
    • Unlocking the Potential of Winstrol: Dosage, Benefits, and Risks

Copyright © 2025 - Privacy Policy - Terms of Use - Disclaimer